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Uncovering The Origins Of Rare-Cell Phenomena 
Abstract 
Rapid advances in technologies have enabled scientists to measure the molecular composition of 
individual cells with increasing detail and throughput. As these technologies have become widely 
adopted, they have exposed widespread molecular variability even among cells previously thought to be 
identical. However, despite the excitement over these discoveries, for many scientists a fundamental 
question remains: what forms of variability matter for differences in single-cell behavior? Here we 
describe the development and application of two methodologies for connecting the molecular profile of a 
cell (cell state) with its future behavior (cell fate), with particular applications for rare biological 
phenomena. Our first approach combines the experimental design of Luria and Delbrück’s classic 
“fluctuation analysis” with modern RNA sequencing techniques to identify groups of genes that are 
coordinately expressed in rare cells and whose expression persists through multiple cell divisions. 
Applied to multiple cancer models, we identify and validate several such gene expression programs and 
furthermore, demonstrate that the rare cell subpopulations marked by these programs are far more likely 
to survive drug treatments. Our second methodology searches for functional forms of single-cell 
variability from the opposite direction, starting with the unique behavior and effectively going back in time 
to isolate the cells from which it originated. Combining transcribed single-cell barcodes with high-
sensitivity RNA FISH, this methodology is able to selectively recover cells as rare as 1:10,000 (from a 
population of millions) which can then be profiled using routine sequencing- or imaging-based assays. 
Using this approach in the context of therapy resistance in cancer, we uncover a variety of resistance 
outcomes that can be traced back, through weeks of selection and growth, to previously hidden axes of 
variability in the initial cell population before treatment. These findings begin to detail the complex 
mapping between rare-cell behaviors in cancer and the underlying molecular variability that enables these 
behaviors. Moreover, our work outlines a general strategy to uncover such mappings, with likely 
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UNCOVERING THE ORIGINS OF RARE-CELL PHENOMENA 
Benjamin Emert 
Arjun Raj 
Rapid advances in technologies have enabled scientists to measure the molecular composition of 
individual cells with increasing detail and throughput. As these technologies have become widely 
adopted, they have exposed widespread molecular variability even among cells previously 
thought to be identical. However, despite the excitement over these discoveries, for many 
scientists a fundamental question remains: what forms of variability matter for differences in 
single-cell behavior? Here we describe the development and application of two methodologies for 
connecting the molecular profile of a cell (cell state) with its future behavior (cell fate), with 
particular applications for rare biological phenomena. Our first approach combines the 
experimental design of Luria and Delbrück’s classic “fluctuation analysis” with modern RNA 
sequencing techniques to identify groups of genes that are coordinately expressed in rare cells 
and whose expression persists through multiple cell divisions. Applied to multiple cancer models, 
we identify and validate several such gene expression programs and furthermore, demonstrate 
that the rare cell subpopulations marked by these programs are far more likely to survive drug 
treatments. Our second methodology searches for functional forms of single-cell variability from 
the opposite direction, starting with the unique behavior and effectively going back in time to 
isolate the cells from which it originated. Combining transcribed single-cell barcodes with high-
sensitivity RNA FISH, this methodology is able to selectively recover cells as rare as 1:10,000 
(from a population of millions) which can then be profiled using routine sequencing- or imaging-
based assays. Using this approach in the context of therapy resistance in cancer, we uncover a 
variety of resistance outcomes that can be traced back, through weeks of selection and growth, to 
previously hidden axes of variability in the initial cell population before treatment. These findings 
begin to detail the complex mapping between rare-cell behaviors in cancer and the underlying 
molecular variability that enables these behaviors. Moreover, our work outlines a general strategy 
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A question that arises frequently throughout biology is how do seemingly identical cells 
give rise to biologically distinct behaviors? Such differences, for example, are manifest in the 
inefficient reprogramming of clonal fibroblasts into induced pluripotent stem cells (iPSCs) or in the 
emergence of drug-resistant cells in cancer 1–5. In recent years, rapid advances in technologies 
have enabled us to measure the molecular composition of individual cells with increasing detail 
and throughput, and through widespread adoption, these technologies have uncovered 
widespread molecular variability among single cells 6–16. Indeed, discovering variability among 
seemingly identical cells is now quite routine. However, widely available methods for single-cell 
profiling are inherently destructive and therefore connecting the observed molecular variability to 
differences in cell behavior often becomes a matter of guess and check. Besides inefficient, this 
approach leaves unanswered the general conceptual question of what forms of variability lead to 
what specific cellular outcomes.  
The central focus of my Thesis research has been to uncover forms of single-cell variability that 
lead to differences in cell fate, particularly for phenomena involving rare subpopulations of cells. 
In Chapter 2, I describe a close collaboration with Sydney Shaffer where we tested the 
hypothesis that coordinated fluctuations in gene expression that persist through cell division can 
be used to identify cell states associated with drug resistance in cancer. Note that in the context 
of this Thesis, “cell state” refers to a particular configuration of molecules within a cell at a specific 
position in space and time (discussed further in Section 1.2). In Chapter 3, I describe the 
development of a methodology to retrospectively and directly isolate rare cells based on their 
future behavior. Applying this methodology to the problem of targeted-therapy resistance in 
melanoma uncovered surprising details about the structure of rare cell states and their 
connections to distinct resistance outcomes. At the same time, the findings presented in these 
two chapters raise further questions about the mechanisms that generate rare cell states and the 
xv 
precise mapping of these states to particular cell behaviors. In Chapter 4 (Concluding Remarks), I 
discuss these lingering questions and propose future directions of research. 
Before discussing these projects, in Section 1.1, I outline a model of drug resistance in cancer 
that, while consistent with established mechanisms of resistance, provides a more likely 
explanation for recent observations in the field, including research described in this Thesis. 
Numerous members of the Raj lab have contributed to the conceptualization of this model, 
including Arjun Raj, Sydney Shaffer, Eduardo Torre, Margaret Dunagin, Stefan Torborg, Allison 
Cote, Yogesh Goyal, and Lea Schuh. Since much of the research that led us to this model is 
based on BRAF- and MEK-inhibitor resistance in melanoma, I will use examples from this system 
to describe key details. However, as will be discussed later, many of the principles of this model 
are relevant to other forms of cancer and all manner of single-cell phenomena (e.g. directed 
cellular reprogramming). I include this section early in this Thesis as I hope it will provide useful 
concepts and definitions for the Reader during the remaining text.   
Next, in Section 1.2, I describe state-of-the-art approaches for discovering molecular differences 
between single cells that lead to differences in their ultimate cell fate. This will include prior efforts 
using time-lapse microscopy to connect single-cell variability to differences in drug resistance in 
cancer as well as sequencing-based approaches to track single-cell transcriptomes during 
cellular differentiation and directed reprogramming. While these examples represent radically 
distinct biological phenomena, they share common findings which build upon the aforementioned 
model of drug resistance and provide key rationale for the hypotheses and strategies tested in 
subsequent chapters.  
1 
CHAPTER 1  
1.1 Non-genetic Mechanisms of Drug Resistance in Cancer 
Since the advent of modern cancer therapies, the effectiveness of these treatments has been 
hindered by the phenomena of therapy resistance 3,17,18. Even when treatments effectively 
eliminate the majority of cancer cells, there often exists a rare subset of cells that survive and 
resume unfettered proliferation. This phenomena has been attributed to the accumulation of 
random genetic mutations some of which enable a rare cell (and its progeny) to resist the effects 
of treatment 19,20. While individually these resistance mutations are exceedingly rare, according to 
this model, the increased proliferation and genomic instability of cancer cells provides ample 
opportunities for such mutations to arise 21–23.  
Support for the mutational model of resistance can be seen with the treatment of melanoma. 
Approximately 65% of cases of melanoma present with activation mutations in the mitogen-
activated protein kinase (MAPK) signaling pathway 24–27. A majority of these (~75%) are 
mutations affecting the BRAF kinase, mostly commonly a substitution of valine for glutamic acid 
at the 600th amino acid position (BRAFV600E). Expression of BRAFV600E leads to constitutive 
activation of downstream kinases (MEK and ERK) thereby promoting increased cell proliferation 
and decreased apoptosis (among various other hallmarks of cancer) 28–30. Drug that selectively 
inhibit  BRAFV600E elicits rapid tumor regression in ~50% of eligible patients, however in the 
majority of these cases, tumor progression resumes within a year 31,32. Addition of drug 
treatments that inhibit MEK can delay the time to progression, but even among patients with a 
complete clinical response, drug resistance often emerges 33–35. Consistent with the mutational 
model of drug resistance, DNA sequencing of relapsed tumors have identified a variety of 
mutations that bypass the effects of BRAF and MEK-inhibitor therapies and reestablish aberrant 
MAPK signaling, including BRAF amplification, loss of function mutations in NF1 and activating 
mutations in the pathway components MEK, NRAS, KRAS, and RAC1 among others 36–40.  
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However, there are examples of BRAF-inhibitor resistance in melanoma that are hard to reconcile 
with the mutational model alone. For example, by whole-exome sequencing, up to half of 
relapsed tumors studied lacked known or putative resistance causing mutations 37,41. 
Furthermore, in some cases of tumor recurrence following BRAF- and MEK-inhibitor therapies, 
patients have responded to the same drug treatments after an intermediate drug-free period 42–46. 
Consistent with those findings, patient-derived melanoma cells grown in culture or in xenografts 
have been found to transition between being drug-sensitive and drug-tolerant more rapidly than 
would be expected from de novo genetic mutations suggesting a role for alternative forms of 
molecular variability 5,47,48. Indeed, these phenotypic transitions (which share similarities with 
epithelial-mesenchymal transitions observed in other cancers 49,50) are associated with specific 
changes in gene expression even within isogenic populations of cells (derived from single-cell 
bottlenecked clones) 5,51. Notably, some of these gene expression differences (such as increased 
expression of the receptor tyrosine kinases EGFR, NGFR and AXL) predict clinical response to 
BRAF-inhibitor treatment and correspond to gene expression changes observed in relapsed 
tumors 48,52–55. These findings suggest that multiple forms of molecular variability, some of which 
are independent of genetic differences, can influence the fate of cancer cells exposed to anti-
cancer treatments.  
 
At first glance the noted transition between drug resistance and drug sensitive states seems at 
odds with the unwavering progression of relapsed tumors. Similarly, in culture, melanoma cells 
treated with BRAF-inhibitors for extended periods of time (several weeks or longer), continue 
proliferating in drug and do not seem to transition into a drug-sensitive state5,48. Specifically, 
Shaffer et al. found that if drug is removed from these BRAF inhibitor-resistant cultures for up to a 
month, and then reapplied, the cells continue growth unabated (unlike the initial drug-naive 
population in which most cells underwent cell-cycle arrest or apoptosis following drug treatment). 
These authors termed this process in which cells change from a reversible to an irreversible drug-
resistant state “reprogramming”. I note that whether the latter state is truly irreversible or very 
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slowly reversible is not clear, however the key observation is that the behavior of the cells have 
changed in response to drug treatment. Others have reported similar phenomena occurring in 
other cancers (e.g. non-small cell lung cancer) treated with other types of therapies (e.g EGFR 
inhibitors) 4,56,57.     
 
Perhaps unsurprisingly, drug-induced reprogramming is associated with profound molecular 
changes in cell state. For example, Shaffer et al. performed paired RNA sequencing and ATAC 
sequencing on melanoma cells treated with BRAF-inhibitor for up to 4 weeks and found gradual 
changes in expression of 1,000s of genes and in chromatin accessibility at more than 10,000 
loci5. Notably, when measured by RNA FISH, expression of some reprogramming-associated 
genes was undetectable across 10,000s of single-cells before drug treatment indicating that drug-
induced changes in gene expression are not simply a result of selection for particular cells. 
Working independently, other research groups reached similar conclusions based on single-cell 
RNA sequencing (scRNAseq) of melanoma xenografts treated with combination BRAF- and 
MEK-inhibitor therapy 58. These findings demonstrate that the phenotypic and molecular features 
of drug-resistant tumors may not perfectly reflect their cellular precursors, before treatment. In 
part, this motivates the methodologies developed as part of this Thesis to identify the initial, drug-
naive cancer cells that ultimately give rise to resistance.  
 
Collectively, these observations suggest the following model of cancer drug resistance: cancer 
cells transition between a variety of cell states some of which are “primed” to survive drug 
treatment. Drug treatment then elicits additional molecular changes in the primed cells that 
effectively “reprograms” these cells into irreversible, drug-resistant states. Importantly, the 
molecular differences that distinguish the primed and the final drug-resistant cells may include 




As mentioned in the Preface, I use “cell state” to mean a unique combination of molecules in a 
cell at a particular moment in time. This includes both molecules which we can measure, such as 
the collection of mRNA transcripts, as well as the many features which we cannot currently 
measure but may nonetheless influence cell behavior 59. While there may be an infinite number of 
possible cell states, for a given cell behavior, such as resistance to BRAF inhibitors, there is likely 
a restrictive set of permissive cell states and a limited number of features needed to identify these 
states 60 .  
 
In the context of this Thesis, a “primed state” refers to a set of cell states that lead to a certain 
fate upon a particular stimulus, for example proliferation and colony formation following BRAF-
inhibitor treatment. The characteristics of this set crucially depends on the choice of stimulus and 
fate. Stated differently, changing the stimulus (e.g. different drugs or dosages) or the choice of 
fate (e.g. resistant colonies with different growth rates and morphologies) may select for different 
primed states. At the same time, since most single-cell variability is likely inconsequential for a 
given cell fate, these primed states may be distinguished with a finite number of dimensions 60–62. 
A central focus of my research has been to identify such primed states and their variable 
dimensions in the context of cancer drug resistance.  
 
There are likely scenarios that cannot be described using the aforementioned model of priming 
and reprogramming or for which alternative explanations prove more useful. For example, there is 
substantial research highlighting a role for the tumor microenvironment in mediating drug 
resistance and one can imagine that such cell extrinsic factors may dominate intrinsic differences 
between cell states 63–66. However, it is worth noting that 1. there may be primed cell states which 
are more responsive to external factors required for a cell to become drug resistant and 2. such 
external factors must ultimately influence internal changes within cells that permit survival and 
thus the distinction may depend mostly on what can be measured. There are also scenarios in 
which, without external perturbations, a cell seems permanently destined for a particular fate, for 
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example with specification during development 67, and this seems inherently different from the 
transience of priming. Nonetheless, I believe that the remainder of this Thesis will provide 
compelling support for the utility of the priming model in describing non-genetic mechanisms of 
drug resistance in cancer.     
1.2 Approaches for connecting molecular variability among single cells to 
differences in cell fate.  
Observations that a single perturbation can elicit a range of distinct responses from 
seemingly identical cells have inspired numerous methodologies to identify the molecular origins 
of these distinct behaviors. In this section I will discuss two key methodologies: live-cell imaging 
of fluorescent reporters and single-cell RNA sequencing combined with clonal barcoding. 
Applications of these approaches to the phenomena of drug resistance, cellular reprogramming 
and differentiation have revealed key insights into the process of priming and reprogramming. 
However, these approaches also face significant limitations for studying rare cell phenomena and 
addressing these limitations are a major contribution of my Thesis research.  
 
An influential study by Spencer et al. exemplifies several strengths and limitations of the live cell 
imaging approach 68. These authors engineered clonal cell lines (HeLa and MCF10A) with 
fluorescent reporters of mitochondrial membrane permeabilization (MOMP) enabling them to 
monitor a critical step during apoptosis in live cells 69. These authors then tracked single-cells by 
live-cell imaging for 20 hours before and 8 hours after treatment with TRAIL, a protein ligand that 
induces the extrinsic apoptosis pathway. While across the population of cells the time to cell 
death varied from 45 minutes to > 8 hours (with some cells seeming to live indefinitely), this 
variable delay was highly correlated between recently divided sister cells (R2 = 0.75), implying 
that some set of heritable, molecular differences between cells predicts differences in fate. These 
molecular differences were not indefinitely heritable (as would be expected of genetic differences) 
since the correlation in time to death between sister cells decreased exponentially with increasing 
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intervals between cell division and drug treatment. Nor were these differences a reflection of cell 
cycle or position in the dish as these features were uncorrelated with time to death across the 
population.  
 
Using a second fluorescent reporter to simultaneously measure intrinsic caspase activity (and by 
proxy conversion of BID to tBID prior to MOMP) Spencer et al. find that variability in the rate of 
this step is also correlated between sister cells and is the primary determinant of variability in time 
to death. Notably, detailed modelling of TRAIL-mediated apoptosis suggested that the observed 
single-cell variability in key protein components of this pathway (i.e. XIAP, BAX, BCL2, CASP3, 
and BID) is sufficient to explain the population level variability in time to death, however, 
knowledge of levels of any one protein upstream of BID could not accurately predict single-cell 
differences in fate.  
 
While the study by Spencer et al. highlights the many detailed observations afforded by live-cell 
imaging, several limitations are worth noting. Engineering cells with fluorescent reporters, 
performing long-term live-cell imaging, and computationally tracking cell lineages are extremely 
challenging tasks for even the most equipped labs 70. In the best cases, this approach remains 
limited to tracking 100s-1000s of cells for up to a few days, a throughput and duration which may 
be insufficient for studying rare cell phenomena that take weeks or longer to manifest 71–74. 
Moreover, while fluorescent reporters can measure features of cell state not easily encoded into a 
sequencing assay, such as changes in protein localization 75 and kinase activity 76, it is typically 
infeasible to measure more than 2 or 3 fluorescent reporters simultaneously due to overlapping 
fluorescent spectra and compounding phototoxicity. As such, live-cell imaging is an impractical 
strategy for discovering markers of primed cell states, which may involve changes in expression 
of many unknown genes or other features 5. Instead, what is needed are more experimentally 
practical and high-throughput strategies that deeply characterizes molecular variability in single-




Recently, several groups have developed such a strategy by combining clonal barcoding with 
single-cell RNA sequencing 77–80. These barcodes take the form of semi-random nucleic acid 
sequences that are introduced into a cell’s genome and transcribed into RNA (often in the 3’ 
untranslated region of a marker gene such as GFP). As a cell divides, daughter cells inherit the 
same barcode which can be detected by scRNAseq along with the cells’ transcriptomes. By 
introducing a library of such barcodes (easily engineered to contain 100,000s to millions of unique 
sequences) into a population of cells and sampling a fraction of the population over time for 
scRNAseq, one can track the transcriptomes of 1000s of single cells. Critically, this approach 
relies on the assumption that related cells not only inherit the same barcode but also similar 
transcriptomes (and ideally other features of cell state that influence fate). Fortunately, this 
assumption can be directly tested within the same experiment and, as described below, is often 
valid.    
 
In a pioneering study,  Biddy et al. used this approach to track single-cell transcriptomes during 
directed reprogramming of mouse embryonic fibroblasts to endoderm progenitors driven by 
overexpression of HNF4A and FOXO1, a process thought to occur with ~1% efficiency 77. In a 
variation on the strategy described above, these authors barcoded the cells before 
reprogramming then again at day 3 and day 13 into their protocol, thereby combinatorially 
increasing the barcode diversity in the population and improving the resolution of their lineage 
reconstruction. In addition, the authors collected cells for scRNAseq every 3-7 days over the 
course of the 28-day reprogramming protocol, allowing the cells to undergo multiple cell divisions 
between collections. As a result, the authors could compare transcriptomes between related cells 
at the same time point and confirm that related cells are molecularly more similar than random 
pairs of cells grown under identical conditions. Notably, this molecular similarity translated into 
more similar reprogramming trajectories over time. By combining their lineage data with 
transcriptome-guided pseudotime ordering of cells, the authors find that cells choose between at 
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least two paths during reprogramming, one leading to successful conversion into induced 
endoderm progenitors and the other leading to temporary expression of some endoderm markers 
followed by a reinstatement of a fibroblast-like transcriptome. This choice appeared to be made 
by the earliest stages of reprogramming as clonal cells derived from the same initial fibroblast 
tended to follow the same path. During the late stages of reprogramming, the path to successful 
reprogramming was marked by lower expression of Mettl7a1 and adding Mettl7a1 knockdown to 
their reprogramming protocol increased the yield of induced endoderm progenitors. This study 
beautifully demonstrates that heritable molecular differences between single cells dictates 
differences in reprogramming outcomes. However, the initial characteristics of cells that 
successfully reprogram remain unknown, likely due to technical limitations in profiling such rare 
cell populations by scRNAseq (discussed further below).  
 
A subsequent study by Weinreb et al. used the approach of barcoding combined with scRNAseq 
to monitor the gene expression changes of individual hematopoietic stem cells (HSCs) as they 
differentiate into the various hematopoietic cell types, both in vitro and in transplantation 
experiments in vivo 78. As observed in the study described above, Weinreb et al. found that 
related progenitor cells share more similar transcriptomes as well as differentiation outcomes. 
However, going beyond the earlier work, Weinreb et al. connected clonal biases in differentiation 
outcomes to single-cell transcriptomes of the initial HSC progenitors. This information enabled the 
authors to ask to what extent these biases in fate are reflected in these transcriptomes (as 
measured by scRNAseq). Testing multiple algorithms with several choices of gene sets, the 
authors found that gene expression in the initial HSCs could at best predict the dominant fate of a 
clone with ~60% accuracy. This accuracy was notably lower than the ~70% concordance in fate 
between related cells differentiated in separate wells (or separate mice), suggesting that cell 
features hidden from scRNAseq influence fate biases in HSCs. Moreover, in a related analysis, 
the authors observe unexplained clonal biases in differentiation outcomes from transcriptionally 
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similar clusters of HSCs. These findings provide strong evidence for the existence and 
multivariate nature of primed cell states among hematopoietic stem cells. 
 
Although these single-cell RNA sequencing approaches provide a more high-throughput and 
comprehensive solution for connecting single-cell variability in cell state to fate, there remains 
substantial room for improvement. First, the cost (0.1-1.0$/cell at a minimum) and cell recovery 
rate (<50%) of current scRNAseq methods limits their feasibility for characterizing cells primed for 
very rare fates (such as drug resistance in cancer) without a strategy to a priori enrich for these 
populations. While Weinreb et al. clearly demonstrate that scRNAseq can uncover gene 
expression differences associated with priming, the majority of cell fates studied occur at 
relatively high frequencies (>1%), and, nonetheless, their findings relied on profiling of >300,000 
cells (likely aided by the creative ownership of the method used for scRNAseq 11). Second, as 
convincingly argued by Weinreb et al. and others, scRNAseq provides limited information about 
cell states, possibly for both technical and biological reasons, and there is a clear need for 
methods that can identify other features of cell states associated with priming. These include 
features that rely on non-sequencing-based techniques (such as microscopy) as well as dynamic 
properties of cell state (such as persistence through cell divisions). The next few sections will 
describe methods I developed with members of the Raj lab to address these needs. I will also 
describe how using these methods we discovered new mechanisms contributing to drug 
resistance and phenotypic diversity in cancer.
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CHAPTER 2: Memory sequencing reveals heritable single-cell gene expression 
programs associated with distinct cellular behaviors. 
 
2.1 Introduction 
Cellular memory in biology, meaning the persistence of a cellular or organismal state over time, 
occurs over a wide range of timescales and can be produced by a variety of mechanisms. 
Genetic differences are one form of memory 81, encoding variation between organisms on multi-
generational timescales. Within an organism, mechanisms involving the regulation of gene 
expression encode the differences between cell types in different tissues, with cells retaining 
memory of their state over a large number of cell divisions 82. In contrast, recent measurements 
suggest that the expression of many genes in single cells may have very little memory, displaying 
highly transient fluctuations in transcription. These rapid fluctuations have been referred to as 
gene expression “noise” and have generally been difficult to associate with physiological 
distinctions between single cells 59,71,83,84, although there are certainly specific examples in which 
such fluctuations can drive phenotype 72,85,86. 
 
Less well studied is memory on intermediate timescales; i.e., cellular states that may persist for 
several divisions, but are ultimately transient, and thus are not indefinitely heritable (distinguished 
from the short-lived fluctuations referred to as “noise”). Such timescales would be long enough to 
allow for coordinated fluctuations in the expression of many genes at once in individual cells, 
potentially resulting in biological activity within that cell that is distinct from the rest of the 
population. Yet it remains unclear how prevalent such longer-timescale fluctuations might be 
because finding the molecular markers of these longer fluctuations is difficult: current “snapshot” 
methods are unable to distinguish between fast and slow fluctuations because they lack any 
temporal component, while time lapse microscopy is laborious and difficult to scale to all genes 
87,88. Thus, we sought to develop a method that would enable us to find genes whose expression 
fluctuations would be maintained over several cell divisions. Ultimately, our goal was to use these 
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markers of slow fluctuations to identify functionally distinct subpopulations within otherwise 
indistinguishable cells. 
2.2 Genome-wide detection of heritable gene-expression states using MemorySeq 
The methodology we developed to distinguish heritable from non-heritable fluctuations in 
expression levels in single cells (MemorySeq) is based on the fluctuation analysis from Luria and 
Delbrück’s beautiful 1943 experiments on resistance to phage in bacteria, which they used to 
discriminate heritable from non-heritable mechanisms for resistance 89 (also used in cancer 
5,90,91). In our context of cellular memory, the experiment consisted of growing a number of 
“MemorySeq clones” (we aimed for 48 and ended up with 42-45 after losses from culture and 
library prep; see Appendix A.1 for details) of isogenic melanoma cells (WM989-A6) in individual 
wells, eventually growing them to around 100,000 cells per clone (Fig. 2.1A-B). If a fluctuating 
gene transitioned in and out of the “high” expression state relatively rapidly compared to the cell 
division rate, then a fairly constant proportion of those 100,000 cells would be in the high 
expression state for that gene (with some dispersion due to Poisson sampling). This constancy 
occurs because the cells do not remember the state through cell division. At the opposite 
extreme, if the high expression state was long-lived compared to the cell division time, then if a 
cell occasionally moves into the high expression state early in the family tree, all of its progeny 
will remain in the high expression state, leading to a very high proportion of the final 100,000 cells 
being in the high expression state. Thus, across multiple MemorySeq clones, we would find a 
high variance in the proportion of cells in the high expression state in the final population, where 
most clones would have low expression of that gene and a few clones would have high 
expression, depending on exactly how far up in the family trees the cells transitioned into the high 
expression state. To measure variability in the proportion of cells in the high expression state for 
any particular gene, we used bulk RNA sequencing to measure the transcription of all genes in 




Figure 2.1. MemorySeq identifies genes with high transcriptional memory. A. Rare-cell gene expression patterns, 
both with and without heritability. Histograms of single-cell expression levels are unable to discriminate between these two 
alternatives. B. Schematic of MemorySeq experiment. We started with a single melanoma cell (WM989-A6), grew it to 
~100 cells, then seeded 48 wells from those cells and allowed the cells to proliferate to around ~100,000 cells before 
subjecting the entire MemorySeq clone to RNA sequencing. In the case of non-heritable expression, the levels of 
expression would not vary dramatically between MemorySeq clones, whereas in the heritable case, some clones would 
exhibit much higher levels of expression when a cell moved into the high expression level state early in the family tree of 
the clone. To measure variability in expression from purely technical noise, we also performed control experiments by 
plating around ~100,000 cells directly into individual wells and performing RNA sequencing. C. Expression histograms 
across n=43 MemorySeq clones for genes identified as non-heritable (left) or heritable (right). D. Coefficient of variation 
versus mean expression levels for all 23,669 genes that we analyzed across all MemorySeq clones. Points labeled with 
blue dots (on MemorySeq clones plot) or pink dots (on Noise controls plot) passed the threshold for being identified as a 
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these clones (Fig. 2.1B). It was important to distinguish between biological variability between 
clones and variability due to sequencing, sampling, and technical errors. We therefore also grew 
a large population of cells that we split into 48 wells containing 100,000 cells each and subjected 
those cells to RNA sequencing and gene expression analysis (Fig. 2.1B right). 
 
We first applied MemorySeq to the melanoma cell line WM989-A6. We chose this cell line and 
culture system because we had already verified the presence of rare cells within the population 
marked by the expression of a particular subset of genes such as EGFR, NGFR and AXL. These 
rare cells were strongly associated with resistance to the targeted melanoma drug vemurafenib 
48, and the independent observation that sibling cells often expressed the same genes suggested 
that these genes displayed some degree of memory 5. Thus, in this system, we have already 
identified several genes that are both associated with a phenotype and appear to exhibit some 
degree of heritability. These genes naturally serve as positive controls for the MemorySeq 
methodology. 
 
Upon performing MemorySeq in this cell line, we first checked the distribution of expression levels 
across MemorySeq clones for a number of previously identified resistance-associated genes and 
non-resistance associated genes (Fig. 2.1C, Heritable genes) 5. As hoped, we found that the 
resistance marker genes displayed far greater variability across clones than the technical noise 
controls. Conversely, housekeeping genes and other genes that do not exhibit much cell-to-cell 
variability showed variance across clones that was much more similar to that of the technical 
noise controls (Fig. 2.1C, Non-heritable genes). Intriguingly, MYC, a proto-oncogene for which we 
have seen high levels of cell-to-cell variability, showed little increased variance across clones 
compared to controls, suggesting that its transcriptional memory was much lower than that 




Figure 2.2. MYC expresses in a highly variable but not heritable pattern. We measured expression of MYC in 
WM989-A6 cells grown on culture dishes for 10 days. A. Spatial position of each cell in culture with the top 2% of MYC 
expressing cells in red and the rest of cells labeled in gray. The degree of spatial clustering was minimal, reflecting the low 
heritability of the MYC-high expression state. B. Histogram of MYC mRNA levels across individual cells, showing the large 
amount of variability in MYC expression. The rightmost line (light blue) marks the top 1% of cells, the left line (dark blue) 
















Supplementary Figure 1. MYC expresses in a highly variable but not heritable pattern. We measured expression of MYC in WM989-A6 cells 
grown on culture dishes for 10 days. A. Spatial position of each cell in culture with the top 2% of MYC expressing cells in red  and the rest of cells labeled 
in gray. The degree of spatial clustering was minimal, reflecting the low heritability of the high MYC expression level cellular state. B. Histogram of MYC 
mRNA levels across individual cells, showing the large amount of variability in MYC expression. The rightmost line (light blue) marks the top 1% of cells, 




We observed similar behavior for CCNA2, a cell cycle gene whose expression would similarly be 
expected to vary from cell to cell but not exhibit much heritability due to cell cycle 
desynchronization93;Fig. 2.1C). 
 
Given that RNA sequencing provides expression levels across the transcriptome, MemorySeq is 
able to measure heritability in the expression of all genes at once. Thus, we analyzed expression 
variance across clones for all genes. We found that for many genes across a range of average 
transcription levels, variance across clones was much higher than technical noise controls, 
suggesting that those genes exhibited high levels of transcriptional memory (Fig. 2.1D). We found 
that genes with higher expression levels typically had systematically lower variance across 
clones. By explicitly fitting this relationship, we could identify genes as high memory based upon 
their large residuals from the fit. We generated a panel of high-memory genes with residuals in 
the 98th percentile or greater, and with a minimum expression level of 1.5 transcripts per million 
to eliminate spurious inclusion of lowly expressing genes, resulting in 227 genes identified as 
potentially having high heritability in WM989-A6 (alternative cutoffs and robustness analysis for 




Figure 2.3. MemorySeq data for WM989-A6 melanoma cells with distribution of the model residuals and 
robustness analysis. A. Histograms showing the overall distribution of the residuals for MemorySeq clones and Noise 
controls in WM989. To select heritable genes for subsequent analyses, we used a cutoff at the top 2% of the residuals. 
Cutoffs of 1% and 2% of the residuals are shown by the red and green lines, respectively, on both histograms. B. 
Robustness analysis showing the fraction of MemorySeq genes discovered by resampling the clones with replacement 
over 100 iterations. The plot shows the histogram of the fraction of genes overlapping with the core set of 227 through 
each iteration. Equivalent plots for residuals and robustness in WM983B, MDA-MB-231, and PC-9 are available on 
Dropbox (see Appendix A.1).  
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2.3 Validation of transcriptional memory using time-lapse microscopy. 
Our experimental design predicted that a gene whose expression exhibits high variability across 
MemorySeq clones would occasionally initiate high levels of expression that would persist across 
multiple cell divisions but would not persist indefinitely. We sought to directly confirm these 
expression characteristics by using time-lapse microscopy to trace the expression state of 
individual cells for three genes. For one gene (NGFR), we were able to genetically tag the gene 
using a split-fluorescent protein approach (see Appendix A.1) to fuse mNeonGreen2(11) to NGFR 
(producing the NGFR-mNG2 protein). We used that cell line to track NGFR levels by 
fluorescence microscopy over a period of 8.75 days (Fig. 2.4; see Fig. 2.5 for cell line validation; 
single allele tagged, which may affect the levels of variability as compared to total protein). The 
vast majority of cells displayed essentially no fluorescent signal, but as predicted, occasional rare 
cells within the population displayed high levels of fluorescence. We then tracked 222 cell 
lineages through several cell divisions (examples of positive cells in Fig. 2.4 A-B, link to movie in 
Appendix A.1.11). We observed that cells would occasionally initiate high levels of expression of 
NGFR-mNG2 (compare top branch vs. bottom branch), and once initiated, that high level of 
expression could be maintained through multiple cell divisions, thus confirming the presence of 
memory. Further demonstrating the transience of this high expression state, we also observed 
cells transitioning from the high state to low levels of expression, with an average time in the high 
state of 40 hours; however, a few cells showed longer fluctuations in NGFR levels ranging from 






Figure 2.4. Time-lapse microscopy verifies rare, high-expression states that persist for several cell divisions. We 
generated a cell line (WM989-A6-G3 C10-C2 clone E9) that expresses a large but incomplete (and thus nonfluorescent) 
portion of the mNeonGreen2 fluorescent protein with the remaining piece of mNeonGreen2 fused to NGFR at the 
endogenous locus. When the NGFR fusion protein expresses, the remaining portion of mNeonGreen2 binds to the NGFR 
fusion protein and becomes fluorescent. We then performed time-lapse microscopy imaging of the NGFR protein (nucleus 
labeled with H2b-iRFP670) at 6-hour intervals for 8.75 days. A. We tracked cells through several cell divisions, thus 
building cellular lineages, and quantified fluorescence intensity for each cell. The plot shows two branches from the same 
parent cell with fluorescence intensity of mNeonGreen2 over time. B. Series of fluorescent micrographs of the two cells 
highlighted in panel A. Images are subfield views taken from scans comprising several image tiles; boundaries in the 
image arise from edges between individual tiles. Scale bar is 8 µm long. C. Correlations between sibling cells, first 
cousins, and random pairs of cells (n = 486, 292, 905, respectively). 
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Figure 2.5. Validation of mNG2 fluorescence as a marker of NGFR expression. We sorted NGFR-mNG2 tagged 
WM989-A6-G3 cells then performed single-molecule RNA FISH to measure NGFR mRNA levels. A. Representative max 
merged image of NGFR-mNG2 cell line. Scale bars are 20 μm. B. Immunostaining of endogenous NGFR in untagged 
WM989-A6-G3 shows a similar fluorescence localization pattern as NGFR-mNG2. Scale bars are 10 μm. C. Scatterplot of 
data from 188 analyzed cells show that mNG2 fluorescence per cell area correlates with NGFR mRNA per cell area in 
single cells. D. We sorted bulk and mNG2-high (top 0.5-1%) WM989-A6-G3 then treated cells for 3 weeks with 1 μM 
vemurafenib. After fixation and staining nuclei with DAPI, we imaged plates and quantified drug resistant colonies using 
custom software (see Appendix A.1). The indicated number of cells correspond to cells within colonies. As with antibody 
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Figure 2.6. Fluctuations in NGFR levels can persist for at least 5.25 days. We performed time-lapse imaging of 
WM989-A6-G3 cells with NGFR tagged with mNeonGreen2 at the endogenous locus. We tracked cells through these 
images and quantified the mNeonGreen2 fluorescence signal to measure the length of time that cells reside in the NGFR-
high cell state. A. Plots of mNeonGreen2 fluorescence intensity over time for three example cells that enter the NGFR-
high state and remain high for 4.25 to 5.25 days, thereby demonstrating memory. These cells are from a lineage for which 
we manually curated data through 8.75 days. B. Cartoons depicting the two outcomes for NGFR-high cells. In scenario 1, 
cells pass the threshold and remain NGFR-high for a period of time (on time) and then fall below the threshold and are 
NGFR-low. In scenario 2, the cells become NGFR-high, but do not fall below the threshold during the length of this 
experiment (7 days). Given that these two scenarios are distinct we analyzed them separately. C. Histograms of the on 
time for all cells through 7 days of imaging (shorter data set than A, as we manually reviewed all cells up to this time 
point). We considered a range of thresholds (1500, 2000, 2500) for determining when individual cells are in the NGFR-
high cell state. The blue (both dark and light blue) show the raw data for the on time, while the gray shows the on times 
that result from using a moving average of the time trace using a 5-point median filter. At a threshold of 1500, the average 
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Figure 2.7. Comparison of fluorescence quantification for NGFR-mNG2 using nuclear and whole-cell 
segmentation. We developed a WM989 cell line with mNeonGreen2 at the endogenous NGFR locus. We performed 
time-lapse imaging of this cell line over 8.75 days. For analysis of this data, we wanted to determine if the nucleus area 
could be used for quantifying the mean fluorescence intensity from the NGFR-mNG2 tagged cell line. We tracked one cell 
through 8.75 days and performed manual segmentation of the whole cell at each time point. We then compared the mean 
fluorescence intensity from our manual segment to the mean fluorescence intensity observed over the nucleus as 
determined by an automatic segmentation algorithm (described in Appendix A.1). We found that these two approaches 
gave similar fluorescence intensity patterns over the 8.75 days. A. This plot shows the mean fluorescence intensity for 
mNeonGreen2 over time using the two different approaches. The blue line is the manual segmentation of the whole-cell 
and the yellow line is the automatic nuclear segmentation. B. Example images from each segmentation technique at time 







A B Example images at time = 5.75 daysComparing nuclear versus whole-cell segmentationfor quantifying NGFR-mNeonGreen2 fluorescence
6μm
Supplementary Figure 5. Comparison of fluorescence quantification for NGFR-mNG2 using nuclear and whole-cell segmentation. We 
developed a WM989 cell line with mNeonGre 2 at the endogenous NGFR l cus. We performed time-lapse imaging of this cell line over 8.75 days. For 
analysis of this data, we wanted to determine if the nucleus area could be used for quantifying the mean fluorescence intensity from the NGFR mNG2 
tagged cell line.  We tracked one cell through 8.75 days and performed manual segmentation of the whole-cell at each time point. We then compared 
the mean fluorescence intensity from our manual segment to the mean fluorescence intensity observed over the nucleus as determined by an automatic 
segmentation algorithm (described in the methods). We found that these two approaches gave similar fluorescence intensity patterns over the 8.75 
days. A. This plot shows the mean fluorescence intensity for mNeonGreen2 over time using the two different approaches. The blue line is the manual 
segmentation of the whole-cell and the yellow line is the automatic nuclear segmentation. B. Example images from each segmentation technique at time 
point 5.75 days. The scale bars are 6 μm.
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Another prediction of long-lived but imperfect memory is that sibling cells should show greater 
correlation in expression levels than cousins. Confirming this prediction, we observed that the 
correlation of expression between recently divided sibling cells was higher (R=0.58) than between 
cousins (R=0.43), although both values were higher than that between unrelated cells in the 
population (R=0.04) (Fig. 2.4C). Demonstrating the phenotypic significance of these fluctuations 
in expression levels, we further found that cells expressing high levels of NGFR-mNG2 at the 
time of vemurafenib addition were more likely to continue to proliferate (Fig. 2.8, links to time-
lapse movies available in Appendix A.1.11). 
 
We wanted to verify this same transient expression behavior for other genes, but it proved 
technically challenging to genetically tag genes such as AXL and EGFR. We thus used 
fluorescent antibodies to label AXL and EGFR, used FACS to isolate the high population, seeded 
that population on an imageable surface, and performed time-lapse microscopy on the 
transmitted light images in order to trace the lineage of these cells (Fig. 2.9). At the end of 8.67 
days, we fixed the cells and performed immunofluorescence in situ, followed by imaging to 
measure AXL and EGFR levels. We were able to track a total of 53 cells (26 for AXL, 27 for 
EGFR) (originating from 4; 2 each for AXL and EGFR), of which we could confidently re-identify 
29 after the second round of immunofluorescence. Of these, we observed that 15/15 and 6/14 of 
these cells starting from those that initially had high levels of AXL and EGFR (higher than all the 
negative cells; Fig. 2D), respectively, eventually turned off (<75th percentile) within the time 






Figure 2.8. NGFR-high cells survive vemurafenib treatment and continue to proliferate more than NGFR-low cells. 
We performed time-lapse imaging of WM989-A6-G3 cells in which endogenous NGFR protein is tagged with 
mNeonGreen2. We acquired images every 2 hours for 14.8 days and added 500 nM of vemurafenib starting after 6 days 
and 4 hours. Our analysis consisted of tracking lineages and then quantifying the green fluorescence signal from the 
NGFR-mNeonGreen2. This plot shows the fluorescence signal over time for four lineages in this data set. The y-axis is 
the median fluorescence over each cell segment minus the median fluorescence of the background for the image. The 
black dots are cell division, the red dots are cell death, and the green dots are when a cell disappears from the culture 


















































5 days 10 days 15 days
0 days 5 days 10 days 15 days
0 days 5 days 10 days 15 days

























Figure 2.9. Time-lapse imaging followed by immunofluorescence reveals reversibility of the AXL-high and EGFR-
high gene expression states. A. We stained cells with antibodies targeting AXL and EGFR, then sorted positive cells, 
plated them on a glass dish, and acquired tiled images of their immunofluorescence signal. Subsequently, we acquired 
transmitted light images every hour for 8.67 days to facilitate tracking of cell lineages, and then we performed 
immunofluorescence again to measure EGFR and AXL protein levels at the end of the tracking period. From the time-
lapse images, we tracked selected lineages that initially contained cells with high levels of EGFR and AXL. The red dots 
on the left images correspond to the red arrow on the histogram for an example initial cell subjected to tracking. Upon 
division, we colored the tracks of the sibling cells green and blue respectively. The EGFR and AXL levels for these cells in 
their final state is indicated by the green and blue arrows on the histograms on the right. B. Fields of view taken after 8.67 
days of imaging in both transmitted light and immunofluorescence targeting either AXL or EGFR. All tracked cells are 
labeled with red points. C. Histograms of average immunofluorescence signal intensity of all cells after the imaging period. 
Red arrows mark the intensity values for the cells labeled by dots in the images which were tracked through the 8.67 
days. All scale bars are 10 μm long.  
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(We also measured transcriptional memory of these genes (AXL, EGFR mRNA, Fig. 2.10; NGFR 
protein, Fig. 2.11) by using FACS to isolate highly expressing cells and measuring the degree to 
which the expression levels in these cells reverted towards the distribution from the original 
population, finding a variety of timescales ranging from 5 to 9 days. Note that we observed an 
initial increase in expression for some of these genes upon sorting, which may be due to the 
stress associated with flow sorting or paracrine signaling in the concentrated subpopulation.) 
2.4 Using single-molecule RNA FISH to observe rare-cell expression programs 
and infer transcriptional memory via spatial proximity.  
While time-lapse microscopy provided direct evidence of the long-lived fluctuations predicted by 
MemorySeq, it is difficult to perform for a panel of genes owing to the challenges associated with 
editing genes, especially those whose expression is very low in most cells. Thus, we sought 
another method to confirm these heritable fluctuations for a larger panel of genes. First, we 
performed experiments in fixed cells grown on culture dishes to measure heritability in gene 
expression by using spatial proximity as a proxy for relatedness. We seeded cells sparsely in 
culture dishes and then allowed them to grow for approximately 10 days, at which point we fixed 
the cells and subjected them to iterative single-molecule RNA FISH to measure the expression of 
19 genes with a range of MemorySeq values in individual cells while preserving their spatial 
context (Fig. 2.12; as in Ref. 5). (Genes with high MemorySeq signals also displayed rare-cell 
expression patterns as expected Fig. 2.13.) Our reasoning was that as cells divide, their spatial 
proximity would reflect their relatedness 88. In the case of a gene with non-heritable expression, 
one would expect to find no spatial correlation in which cells were deemed high expressing within 
the population. In contrast, for genes with heritable expression, one would expect to find the high 
expressing cells to appear in patches corresponding to related neighboring cells that share a 




Figure 2.10. RNA FISH time-course reveals transcriptional memory of AXL and EGFR expression. A. To estimate 
the transcriptional memory of EGFR and AXL in WM989 A6-G3, we sorted out high (top ~ 0.3% for EGFR and top ~ 0.5% 
for AXL) and low expressing cells then cultured these cells for up to 9 days before fixing and performing RNA FISH. B-C. 
We found persistence of elevated EGFR and AXL expression for up to 9 days in EGFR-high and AXL-high sorted cells, 
respectively. For AXL, we saw an initial increase in expression levels after sorting followed by a decrease towards 
baseline at Day 9, consistent with a long-lived but ultimately transient gene-expression state. The initial increase in AXL 
expression may be due to paracrine signaling or stress from sorting. D-E. Representative images showing clusters of 
EGFR-high and AXL-high expressing cells. Arrowhead point towards examples of transcription sites marked by 
colocalization of exon-targeting and intron-targeting RNA FISH probes. The presence of multiple transcription sites in 
these cells suggested that the observed gene-expression memory is due to persistence of active transcription rather than 
slower division or RNA degradation rates.  
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Figure 2.11. FACS Isolated NGFR-high WM989 A6-G3 cells maintain high NGFR levels over the course of 7 days 
in culture but partially revert towards baseline NGFR levels. A-B. We labeled W989 A6-G3 cells with a Phycoerythrin-
Cyanine7 (PE-Cy7) conjugated antibody targeting NGFR, then sorted equal numbers of cells from the indicated gates. 
After 7 days in culture, we re-stained the cells and measured fluorescence intensity by flow cytometry. At day 7, the 
distribution of NGFR-PE-Cy7 intensities is shifted higher for the NGFR-high samples relative to the NGFR-low samples, 
although the distributions are closer than at day 0. 
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Figure 2.12. Single-molecule RNA FISH verifies the quantitative nature of MemorySeq for measuring heritability in 
single cells. A. Schematic of spatial RNA FISH experiment. We plated WM989-A6 melanoma cells sparsely and allowed 
them to grow for 10 days. We then fixed the cells and performed iterative RNA FISH to measure expression of 19 genes. 
Closely related cells will remain in close proximity, thus heritable rare-cell expression would manifest as “patches” of ON 
cells, whereas non-heritable rare-cell expression would display a more salt-and-pepper pattern of expression. Right: RNA 
FISH micrographs for 4 genes, EGFR (heritable), NGFR (heritable), EEF2 (housekeeping) and GAPDH (housekeeping). 
B. Each spot is a cell from an RNA FISH image scan of 12,192 cells (subset of 2,103 cells shown). Cells above a 
threshold (6 for EGFR, 36 for NGFR and 320 for EEF2) were considered to be in the high expression state and colored 
green. C. Quantitative comparison of heritability as measured by MemorySeq (x-axis: skewness across MemorySeq 
clones) and spatial RNA FISH analysis (y-axis). We used the Fano factor measured for spatial bins of 20 nearest cells as 
a spatial clustering metric; randomly placed high-expression-state cells would display a Poisson distribution and thus give 
a Fano factor of 1. Cell populations with a Fano factor greater than 1 would display some degree of spatial clustering. Of 
note, this plot and the plot in panel D contain 18 of the 19 genes that we quantified with RNA FISH because 1 gene 
(CYR61) did not pass the minimum transcripts-per-million-cutoff for analysis. D. We plotted MemorySeq heritability versus 
the Gini coefficient (from RNA FISH), which measures expression inequality (range 0-1). E. Plot of coefficient of variation 
versus the log2 mean expression for all genes in WM989. The genes labeled in pink are the genes selected for RNA FISH 
in A-D. The points labeled with the green dots are genes that passed the threshold for selection as a heritable gene.   
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Figure 2.13. Histograms showing the distribution of expression levels in single cells as measured by RNA FISH. 
We plated WM989 cells sparsely on a dish and then allowed them to grow into clusters over 10 number of days. We 
performed RNA FISH for a panel of 19 genes and then quantified expression for each gene in single cells. The histograms 
show these expression levels for 12,192 cells total. One of two replicates is shown. Equivalent plots for replicates and 
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Supplem ntary Figure 10. Histograms showin  the distribut on of expression levels in single cells as measured by RNA FISH. We plated
WM989 cells sparsely on a dish and then allowed them to grow into clusters over 10 number of days. We performed RNA FISH for a panel of 19 genes 
and then quantified expression for each gene in single cells. The histograms show these expression levels for 12,192 cells total. One of two replicates 
is shown. Equivalent plots for replicates and other cell lines are available on the paper dropbox.
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We found that genes identified by MemorySeq as being highly heritable (e.g. EGFR, NGFR, 
NDRG1, SERPINE1) tended to show patch-like expression patterns across large numbers of 
cells, confirming that their expression was indeed heritable. In contrast, genes that MemorySeq 
would predict to not be heritable exhibited a more salt-and-pepper (variable but not heritable) 
expression pattern, as expected (Figs. 2.2 and 2.12). 
 
We wondered to what extent MemorySeq could measure differences in heritability of the high 
expression state for different genes. We therefore compared the degree of heritability from 
MemorySeq (given by the amount of skewness in the distribution of expression across 
MemorySeq clones) to the degree of heritability from spatial RNA FISH analysis (given by the 
amount of patchiness in the population). We found a strong correspondence between these two 
metrics (adjusted R2 = 0.6193), suggesting that MemorySeq can stratify genes by the gradations 
in the degree of heritability that they display (Figs. 2.12 and 2.14). 
 
The timescales of particular genes turning between high (ON) and low (OFF) expression states 
should in principle be quantitatively related to the measured variability across the MemorySeq 
clones, with high variability corresponding to slow switching and vice versa. We thus analyzed a 
stochastic model of cell proliferation and switching relating these two quantities (see A1.19 for 
further details; 94. Under the assumption that the ON state is relatively rare, this model yielded a 
direct relationship between the coefficient of variation measured by MemorySeq multiplied by the 
fraction of the time the cell is in the on state and the predicted memory (number of generations 
cells are on before turning off), with the only further parameter being the total number of divisions 
in the MemorySeq experiment. This equation predicted that over a relatively large range of 
reasonable parameters, (CV ~ 0.5-2, fraction of time on ~ 0.01), the predicted memory was 





Figure 2.14. Validation of MemorySeq using spatial single-cell gene expression analysis. We performed analysis of 
single-molecule RNA FISH for the indicated genes as per Fig. 2.12. Shown are two biological replicates (left and right). 
Within each replicate, we analyzed different cutoffs for cells to be considered to be in the high expression level state 
(either the top 1 percent of cells or the top 2 percent of cells). We also increased the bin size for each neighborhood for 
analysis, which is quantified as the number of neighboring cells included in each bin. We quantified the skewness across 
MemorySeq clones vs. the Spatial clustering metric, which is the Fano factor (variance/mean) in the number of positive 
cells per bin across all bins of indicated size. We found the correspondence decreased once the bin size reached 100, 
and that using the top 1 percent of cells also led to a tighter correlation. The decreased correlation at higher bin size likely 
reflects the fact that at larger bin sizes, more clusters would merge together, thus decreasing apparent Fano factor across 
bins. (To see this, take the limiting case of just two bins, in which the variance between the two would be relatively 
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Motivated by our previous work in this cell line, we also looked for correspondences between the 
degree of heritability and the rarity of gene expression as measured by the Gini coefficient, a 
metric for inequality 95,96. We observed that indeed the two metrics were correlated (adjusted R2 = 
0.4898) (Fig. 2.12), suggesting that heritable genes identified by MemorySeq are more likely to 
express only in rare cells. This correspondence may be due to the design of the MemorySeq 
experiment, in which skewness can reach potentially higher levels for rarer expressing genes 
than for less rarely expressing genes. 
2.5	Slowly	fluctuating,	rare-cell	gene-expression	states	are	associated	with	MEK-
inhibitor	resistance	in	melanoma.		
Having validated that MemorySeq was accurately identifying genes displaying transcriptional 
memory, we then asked what these genes were and what their expression in rare cells signified. 
The underlying hypothesis was that these slow fluctuations are more likely to be associated with 
distinct cellular behaviors in those cell subpopulations than fast fluctuations. Our reasoning was 
that a distinct cellular behavior would likely require a persistently different gene expression 
pattern, involving deviations in the expression of several genes simultaneously, as opposed to a 
transient (and, as we hypothesized, probably inconsequential) fluctuation. In this melanoma cell 
line, we have previously shown that rare cells have high levels of expression of certain genes 
associated with therapy resistance (including EGFR, NGFR, and AXL), and that these rare cells 
are much more likely to survive the initial application of drug to develop into resistant clusters. 
Thus, we first wondered whether the set of genes identified by MemorySeq that mark rare cells 
overlapped with the set of genes associated with resistance. We found that most MemorySeq 
heritable genes (162 out of 227) were also markers of resistance (as determined by Shaffer et al., 
Fig. 2.15). These results suggest that the genes identified by MemorySeq are expressed in cell 






Figure 2.15. Genes identified by MemorySeq are associated with BRAF- and MEK-inhibitor resistance. We 
wondered how the expression levels of genes identified by MemorySeq changed during the process of acquiring 
resistance (WM989-A6 cells) using data from Shaffer et al. 2017. A. Each column is a gene identified by MemorySeq as 
being heritable. Each row is a biological replicate, from bulk untreated cells, cells treated with vemurafenib for 48 hours (to 
account for drug-response effects) and the stably resistant cell lines. B. Venn diagrams showing which genes were 
associated with resistance together with being identified as heritable by MemorySeq. We ran the analysis at two different 
thresholds for fold change. Either way, we found that while a large fraction of heritable genes were also resistance-
associated genes (over 70% for a two-fold change cutoff), only a very small proportion of total resistance genes were 
identified by MemorySeq as being heritable, in agreement with the conclusions of Shaffer et al. 2017. C-D. Rare cells 
within clonal WM989-A6 populations marked by high levels of NGFR protein were sorted, cultured for 8-16 hours and then 
subjected to trametinib (MEK inhibitor) treatment at 10 nM for 3 weeks. Image shows the number of resistant colonies 














































































To verify the phenotypic differences of these cells, we used FACS to isolate cells by either high 
levels of NGFR or EGFR expression, and then we subjected them to a targeted inhibitor of MEK, 
trametinib, used to treat melanoma. On unsorted populations, upon treatment with this drug, a 
small percentage of cells will continue to grow and form colonies, mimicking the acquisition of 
drug resistance. In congruence with previous results, the EGFR/NGFR-high subpopulations 
resulted in far more resistant colonies after application of the drug, showing that this 
subpopulation is highly enriched for pre-resistant cells (Fig. 2.15). This result demonstrated that 
MemorySeq revealed the same subset of cells that we had previously determined to be highly 
enriched for drug resistant cells. 
2.6 MemorySeq identifies de novo gene-expression programs associated with 
chemotherapy resistance in breast cancer.  
Our results thus far highlight MemorySeq’s ability to prospectively reveal functionally distinct 
subpopulations within clonal populations of apparently homogeneous cells. In the case of the 
WM989-A6 melanoma cell line, we had already established the existence of such a 
subpopulation, but for most cell lines, there is little to no information about single-cell fluctuations 
that exhibit memory and thus may also be associated with distinct phenotypes. We thus set about 
testing MemorySeq in another cell line, MDA-MB-231-D4, which is a clonal derivative of a triple 
negative breast cancer cell line (does not express HER2, estrogen receptor nor progesterone 
receptor; Fig. 2.16). Paclitaxel is a drug used to treat such breast cancers, but while it is able to 
kill most MDA-MB-231-D4 cells, some cells in the population are still able to survive the drug, 
thus leading to drug resistance (Fig. 2.16). However, prospective markers to isolate the 
subpopulation of cells that are resistant to drug have remained elusive 97, and we hypothesized 





To test this hypothesis, we performed MemorySeq on the MDA-MB-231-D4 cell line by growing 
each of 48 subclones to around 100,000 cells, after which we performed RNA sequencing and 
quantification as described for WM989-A6. As with the melanoma cell lines, MemorySeq revealed 
a large number of genes in the MDA-MB-231-D4 cell line with putative heritable expression 
patterns (230 genes, Fig. 2.16). The range of variability in expression levels for all genes across 
the MemorySeq clones (most genes having low variability, but a few showing high variability) was 
comparable to that identified by MemorySeq for the WM989-A6 cell line. Interestingly, however, 
the overlap between the gene sets was relatively small (Fig. 2.16), suggesting that different cell 
lines may have distinct sets of “memory genes” and that there is no universal “memory gene” 
expression program (with a potential exception noted below). As with WM989, we confirmed both 
the rarity and heritability of the expression pattern by using RNA FISH on cells initially seeded 
sparsely and then allowed to grow in place for 10 days, as done for the melanoma lines (Fig. 
2.16, compare to Fig. 2.12). 
 
Given the existence of these rare, slowly fluctuating subpopulations in the MDA-MB-231-D4 cells, 
we next asked whether these newly identified subpopulations were associated with phenotypic 
differences such as differential sensitivity to paclitaxel. Amongst the genes identified by 
MemorySeq was CA9, a surface marker known to be negatively associated with breast cancer 
chemosensitivity 98,99, but for which there was no reason to suspect that its expression at the 
single-cell level would be indicative of which cells specifically survived upon drug treatment. We 
thus immunolabeled the MDA-MB-231-D4 cells using antibodies targeting CA9 and then used 
FACS to isolate a rare population of CA9-high cells (2-4% percent, along with CA9-low and -
mixed subpopulations), after which we added paclitaxel to both and grew the cells for 5 days (Fig. 
2.16). We found that, when treated with 1 nM paclitaxel, the CA9-high cells were more likely to be 
resistant than either the CA9-low or -mixed subpopulations. (Furthermore, the sorted 
subpopulations reverted to the population average, demonstrating that the CA9-high state is 
ultimately transient; 2.17.) These results, in a cancer cell line of a completely different type 
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involving a drug with a completely different mechanism of action, demonstrate that MemorySeq is 
able to identify de novo heritable, rare-cell expression states, and that these rare cells are 





Figure 2.16. MemorySeq reveals a rare subpopulation of MDA-MD-231-D4 cells associated with drug resistance. 
A. Most MDA-MD-231-D4 cells die upon treatment with paclitaxel for 5 days, but a small subpopulation of cells (cell 
marked with “?”) survive and become resistant (red cell). B. We performed MemorySeq analysis on MDA-MD-231-D4 
cells (n=39 clones, left; n=46 control clones, right). The blue colored dots correspond to genes that we statistically 
identified as being highly heritable by fitting a Poisson regression model and selecting genes with residuals in the top 2%, 
as was done with WM989. C. We stained cells with antibody targeting the CA9 surface marker and then sorted out the top 
2-4% of cells, the lowest 2-4% of cells, and the total “mix” population into chamber wells, after which we applied paclitaxel 
1 day after sorting for 5 days. Transmitted light micrographs show the number of cells remaining after drug treatment for 
the different populations. D. We plotted heritability index from MemorySeq (skewness across individual MemorySeq 
clones) vs. Gini coefficient as computed from single-molecule RNA FISH across two biological replicates. The general 
correspondence between the two variables, as was seen for WM989-A6 cells, suggests that MemorySeq also identifies 
genes that are expressed in rare cells. E. We found that most heritable genes identified by MemorySeq were distinct 
between cell lines, perhaps reflecting the potential for cell-type specific heritable rare cell expression programs. There was 
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Figure 2.17. Isolated CA9-high MDA-MB-231 cells revert towards baseline CA9 levels over the course of 5 days in 
culture. A-B. We labeled MDA-MB-231 cells with a phycoerythrin (PE) conjugated CA9 antibody, then sorted equal 
numbers of cells from the top ~0.5-2% and bottom ~5-10% gates. After 5 days in culture, we re-stained the cells and 
measured fluorescence intensity by flow cytometry. For technical reasons, the day 5 measurement for replicate 2 was 
obtained on a separate flow cytometer from the day 0 sort. At day 5, the distribution of CA9-PE intensities in the CA9-high 
samples were shifted towards higher overall expression than the CA9-low samples, albeit with much more overlap than in 







2.7 MemorySeq identifies groups of genes which co-fluctuate in rare cells.  
Behavioral differences such as drug resistance are typically associated with the differential 
expression of many genes at once. We thus further hypothesized that the long timescale of these 
single-cell fluctuations could allow for significant co-fluctuation; that is, if a cell expresses a high 
level of one high-memory gene for a sufficiently long time period, it could also have a higher 
probability of expressing another slowly fluctuating gene simultaneously. Indeed, should such a 
phenomenon be prevalent, it would allow us to organize these high memory genes into 
characteristic modules of genes that co-fluctuate in single cells. 
 
To isolate such modules, we calculated the correlation coefficient between the expression of all 
pairs of heritable genes across the MemorySeq clones derived from WM989-A6. We reasoned 
that if a particular clone had a high abundance of a particular transcript, then the abundance of 
transcripts of co-fluctuating genes would also be high in that particular clone. We saw large 
blocks of genes whose expression appeared to correlate strongly with each other, suggesting that 
they co-fluctuate at the single-cell level (Fig. 2.18). To validate that the programs so identified by 
MemorySeq corresponded to single-cell correlations, we compared the correlations between 
MemorySeq and RNA FISH in single cells on a panel of genes across two separate clusters. We 
found a general correspondence between these two assays, suggesting that MemorySeq is able 
to identify groups of genes de novo that co-fluctuate in rare-cell expression programs (Fig. 2.18). 
(The expression of some genes appeared to mismatch between MemorySeq and single cell RNA 
FISH, potentially due to mutually exclusive expression patterns in rare cells or due to short-lived 
transition states.) We observed similar clustering in another melanoma cell line (WM983B-E9) 
and MDA-MB-231-D4, although the specific genes were typically different (Fig. 2.19) We also 
performed MemorySeq on the lung cancer cell line PC-9, which showed a total of 240 heritable 
genes, including 8 genes that were heritable in all of the other cell lines on which we performed 





Figure 2.18. MemorySeq enables the identification of coordinated rare-cell expression programs. A. We measured 
correlations between genes across MemorySeq clones derived from WM989-A6 melanoma cells. Shown is an example 
correlation between MMP1 and SERPINB2 across 43 MemorySeq clones. B. Correlations between all pairs of genes 
exhibiting heritability as determined by the threshold described in Appendix A.1.2. C. Comparison of coherence between 
MemorySeq bulk RNA-seq analysis and single-cell correlations as measured by single-molecule RNA FISH. We 
performed RNA FISH on 20 genes in WM989-A6 cells, keeping for further analysis genes whose RNA FISH Gini 
coefficient was greater than 0.6 (13 genes remaining). The correlation between bulk MemorySeq RNA-seq levels is on the 
left, RNA FISH on the right. Callout shows raw RNA FISH counts for 12,192 cells between MMP1 and SERPINB2 in 
single cells. D. For the co-expression of all pairs of genes shown above, we plotted the Pearson correlation measured in 
single cells by RNA FISH against the Pearson correlation measured across MemorySeq clones. For this comparison, the 






Bulk RNA seq correlations
(MemorySeq)
Correlations between clones in MemorySeq
SERPINB2 21.9 9.3 0.20.3
MMP1 169.4 123.1 5.81.8
EGFR 3.2 2.5 0.20.3
NGFR 148.1 99.5 49.61.1
...all heritable
genes















































































































































































Figure 2.19. MemorySeq identifies modules of co-fluctuating genes. A-C. Correlation heatmap for all pairs of 
heritable genes in WM983B-E9, MDA-MB-231-D4 and PC-9. Color indicates the Pearson correlation coefficient. D. List of 
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The appearance of distinct clusters of slowly co-fluctuating genes led us to use community 
detection algorithms for network data to demarcate these groups of genes for further analysis. 
We used a weighted version of k-clique community detection 100–102 to identify such groups of 
genes (Fig. 2.20) (see Appendix A.1.18 for more information). We chose k-clique community 
detection because it allows for nodes to be in multiple communities at once, echoing the ability of 
a protein to simultaneously play multiple roles within the cell. In WM989-A6 cells, one large 
community of genes overlapped very strongly with the vemurafenib pre-resistance marker gene 
set that we identified earlier 55. We verified this correspondence by comparing the transcriptomes 
of sorted subpopulations of EGFR-high cells to the clusters of genes identified by MemorySeq, 
showing that the expression levels of genes specifically in this cluster correlated well with that of 
genes that correlated with EGFR expression (Fig. 2.20). (All networks shown in figures were 
visualized with Gephi 103.) 
 
We also found other communities within the set of heritable genes in WM989-A6 cells, suggesting 
the existence of multiple independent heritable gene expression programs. One prominent one 
included DDX58 (RIG-I), IFIT1, PMAIP1, and OASL, which may be related to type 1 interferon 
signaling 104, and was notable because it also appeared to some extent in MDA-MB-231-D4 and 
WM983B-E9 (Fig. 2.16). We verified that this cluster expressed in a distinct rare-cell 
subpopulation from that containing EGFR and AXL by performing RNA FISH for PMAIP1, 
DDX58, AXL, and EGFR simultaneously. This analysis showed that PMAIP1 and DDX58 
expression exhibited very strongly correlated rare-cell expression, but neither correlated to much 
extent with either AXL or EGFR expression, and both genes’ expression also exhibited memory 
(Fig. 2.21). This cluster appeared relatively distinct from the primary community associated with 
drug resistance and EGFR expression, and indeed, did not show any association with the EGFR-
high transcriptome (Figs. 2.20 and 2.21). Another community in WM989-A6 cells was somewhat 
less coherent and included genes such as VGF. VGF expression also showed strong heritability 
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(Fig. 2.12) but its expression levels appeared not to correlate with the other pre-resistance genes 





Figure 2.20. Community identification in MemorySeq. A. Community detection within the network defined by the 
correlation matrix of co-expression patterns among heritable genes in WM989-A6. Gray circles indicate genes that did not 
comprise a network community. Green and Red indicate the two communities detected; KEGG pathway and GO 
Biological Process analysis results shown for both communities. B. Comparison of rare-cell expression programs 
identified by MemorySeq and those identified by sorting EGFR-high (top) or NGFR (bottom) high cells (using fluorescent 
antibody labeling followed by RNA-seq on the high versus mix populations). 
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Figure 2.21. Validation of single-cell gene expression coordination and spatial clustering of DDX58 and PMAIP1 
in WM989 A6-G3 cells. MemorySeq identified DDX58 and PMAIP1 as members of a correlated network of genes distinct 
from the network containing AXL, EGFR, WNT5A and other resistance markers. A-D. Using RNA FISH, we find that 
DDX58 and PMAIP1 expression is correlated in single-cells but both genes are far less correlated with the expression of 
AXL, EGFR or WNT5A. Shown are representative images (maximum Z-projection) of a group of cells co-expressing high 
levels of DDX58 and PMAIP1 and the measured Pearson correlation values across 362 cells. E. As described in the main 
text, we use spatial clustering of gene expression in single cells as a metric for transcriptional memory. To assay spatial 
clustering for DDX58 and PMAIP1, we sparsely plated WM989-A6-G3 melanoma then cultured the cells for 11 days 
before fixing and performing RNA FISH. We quantified the significance of spatial clustering by calculating the Fano factor 
of the number of high expressing cells across windows of 20, 50, 100 and 200 nearest cells (see Appendix A.1.13 for 
















































































































































































































































































































2.8 Slowly fluctuating MemorySeq genes are coordinately regulated in trans and 
associated with repressive patterns of histone modifications.   
The fact that multiple genes appeared to coordinate their expression across multiple 
chromosomes suggested that the mechanism for maintaining memory occurs in trans, i.e., 
through the regulatory milieu rather than just a short but intense pulse of transcription from a 
single allele that is maintained through cell division. Labeling sites of nascent transcription for 
EGFR and AXL revealed that transcriptional activity also occurred in patches (as opposed to just 
transcript abundance), further suggesting that memory of the high expression state was due to 
sustained transcriptional activity as opposed to a single sporadic, large, transient burst of 
transcription in a precursor cell 105; Fig. 2.10). Moreover, we often observed multiple active 
transcription sites active within a single cell, confirming that the fluctuations in expression were 
not the result of a fluctuation at just one allele (Fig. 2.21). We also performed allele-specific 
expression analysis from the RNA sequencing data across MemorySeq clones to confirm these 
results across a broader swath of MemorySeq genes. We found that fluctuations appeared to 
occur across both alleles simultaneously, further suggesting that fluctuations are driven by 
transactivation rather than pulses at a single allele of a given gene (Fig. 2.21). 
 
We sought to identify regulatory factors that may be responsible for the unique behavior of 
MemorySeq genes. We first utilized ATAC-seq profiling on WM989-A6 cells to reveal regions of 
DNA with increased chromatin accessibility in the vicinity of the genes identified by MemorySeq 5. 
We searched these regions for sequence motifs matching known transcription factor binding sites 
and found enrichment for motifs corresponding to SOX10 and the FOS/JUN and NFAT families of 
transcription factors compared to accessible regions surrounding randomly chosen expression-
matched control genes (Fig. 2.22). To validate these associations, we knocked out a total of 6 
transcription factors from these families and performed RNA-seq to measure changes in 
expression 106. As suggested by our ATAC-seq analysis, knockout of 4 of these factors showed 
strong effects on MemorySeq gene transcription (FOSL1, JUNB, NFAT5, SOX10) and 2 showed 
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small effects (JUN, NFAC2; Fig. 2.22). The manner by which such factors may act to change the 
expression of these genes is unknown, but we did look for specific signatures of histone marks 
around MemorySeq genes. We observed depletion of H3K27 acetylation (H3K27ac) marks 
typically associated with active transcription and gain of H3K27 trimethylation (H3K27me3) marks 
typically associated with repression (again, compared to expression-matched control genes). 
These associations suggest that the fluctuations may result from an inability to sustain ongoing 





Figure 2.22. MemorySeq gene fluctuations are driven by transcription from multiple alleles. A. We asked to what 
extent the fluctuations in gene expression observed using MemorySeq are due to high levels of transcription from a single 
allele (i.e. driven by a local factor) versus high levels of transcription from multiple alleles (i.e. driven by a trans-acting 
factor). For MemorySeq genes containing heterozygous variants, we could distinguish these two possible modes of 
regulation with our RNA sequencing data by counting reads aligning to each allele. In the case of fluctuations driven by a 
single allele, we expected that high expression in particular clones (e.g. clone #1) to be driven by transcription from one of 
multiple alleles (and likely different alleles in different clones). In contrast, for regulation by a common transactivator, we 
expected that in these particular clones, expression from both alleles would be higher than the majority of other clones. 
We note that for polyploid loci (common in cancer cell lines), this approach based on RNA sequencing may assign reads 
coming from different gene copies to the same allele if they carry identical variants (Dashed lines show the expectation for 
balanced expression from indicated ratio of alleles.) B. We identified heterozygous variants in 202 MemorySeq genes for 
allele specific expression analysis (54 in WM989, 79 in WM983B and 69 in MDA-MB-231; see Appendix A.1.16). For each 
gene, we selected the variant with the greatest number of aligned reads across all clones then filtered variants with ≥50 
reads in at least one MemorySeq clone. Plotted are the normalized, allele specific read counts across MemorySeq clones. 
C. Single-cell model for MemorySeq gene expression fluctuations driven by transcription from a single allele versus 
multiples alleles. D. Images of RNA FISH for AXL and EGFR RNA using both intron and exon probes labeled with 
distinguishable fluorescent dyes. Co-localization of RNA FISH signals demonstrates multiple transcription sites in single 
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Figure 2.23. Identification of candidate transcription factors regulating MemorySeq genes in WM989 A6-G3. A. 
Comparison of WM989-A6 ATAC sequencing peaks across MemorySeq genes (± 10,000 bp) to peaks across 100 
separate expression-matched gene sets identified 148 transcription factors enriched in at least one comparison (adjusted 
p-value ≤ 0.025). Plot shows the number of comparisons enriched for each motif. Motifs with corresponding transcription 
factor knockout data in F are colored red. B. Log2 fold change in gene expression of MemorySeq genes (blue), a 
randomly sampled, control gene set (purple), and all genes included in the MemorySeq analysis (gray; mean RPM ≥ 1 
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Figure 2.24. MemorySeq genes have lower levels of activating chromatin marks than expression matched 
controls. To determine whether specific chromatin features are associated with MemorySeq genes we analyzed H3K27 
acetylation and tri-methylation (H3K27me3) ChIP sequencing data from 11 different melanoma cell lines. For each of 
these samples, we calculated read coverage surrounding the transcription start site (+/- 2,000 bp) for MemorySeq genes 
and 100 randomly sampled, expression matched gene sets (sampling was performed separately for each cell line using 
paired RNA sequencing data; see Appendix A.1 for details). A-B. Heatmaps show the ChIP sequencing coverage for one 
melanoma cell line (SKMEL5) across MemorySeq genes and an expression matched, control gene set ordered by 
expression level. Compared with the expression matched controls, MemorySeq genes show lower levels of H3K27ac and 
modestly higher levels of H3K27me3. C-D. We observed a similar pattern in all 11 melanoma cell lines analyzed, 
summarized here by the average ChIP sequencing coverage across MemorySeq genes (red line) and expression 
matched controls (black line indicates mean of 100 gene sets and grey area indicates range). E. We repeated this 
analysis for multiple chromatin marks in MDA-MB-231 cells. Similar to the melanoma cell lines above, we observed lower 
levels of active chromatin marks (H3K27ac, H3K4me3, H3K9ac, K3K79me2) and slightly elevated levels of repressive 
marks (H3K27me3) surrounding transcription start sites of MemorySeq genes compared to expression matched control 
gene sets.  
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2.9 Discussion  
In sum, we believe MemorySeq is a simple but powerful method for identifying rare, heritable 
expression patterns in cells. We have shown here that such rare, heritable expression programs 
may be related to non-genetic mechanisms of therapy resistance in cancer 4,47,68,107. However, 
they may also be important in other contexts in which rare cells behave differently than the rest of 
the population, both in cancer (such as metastasis), but also in otherwise healthy tissues or in 
cellular reprogramming contexts like the induction of iPS cells 2. 
 
The mechanisms underlying these fluctuations remain mysterious. We identified some 
transcription factors that can affect expression of these genes and found patterns of histone 
acetylation that are associated with these genes as well. Further work will be required to test 
other potential models of gene regulation that could lead to fluctuations, such as methylation 
patterns or other regulatory mechanisms that may operate on the relevant timescales. Other 
potential mechanisms include autocrine or paracrine signaling, by which cells are able to sustain 
longer fluctuations by signaling feedback to themselves or nearby relatives. 
 
It is also interesting that MemorySeq is quantitative in the sense that it is not just able to report 
that a gene’s expression is heritable, but is also able to provide a relative sense of how heritable 
that expression is, meaning how many cell divisions are required before cells begin to forget the 
rare-cell expression state. By revealing such intermediate timescales of fluctuation, the results of 
MemorySeq suggest that the classic use of the concept of somatic epigenetics (non-genetic 





CHAPTER 3: Variability within rare cell states enables multiple paths towards drug 
resistance 
3.1 Introduction 
Individual cells—even those of ostensibly the same cell type—can differ from each other in a 
number of ways. Some of these differences can result in a “primed” cellular state that can, in a 
particular context, ultimately lead to biologically distinct behaviors 59,83. This cellular priming 
underlies a number of important single cell phenomena. For instance, when anti-cancer 
therapeutics are applied to clonally derived cancer cells, most of the cells die; however, a small 
number of cells survive and proliferate, and these cells drive therapy resistance 4,47,108. Yet, while 
this phenomenon implies the existence of rare, primed cells in the initial population, it remains 
unclear what distinguishes these cells at the molecular level from the rest of the population. 
 
We and others have shown that rare cells within an isogenic population can exhibit fluctuations in 
expression of several genes simultaneously, which predict rare-cell phenotypes and persist 
through multiple cell divisions 108,109. What remains largely unknown, outside of a few cases 5,68,72, 
is precisely how this variability maps to distinct cellular outcomes following a treatment. As a 
result, several questions remain unanswered. Is molecular variability in the initial state of cells 
inconsequential because all cells ultimately funnel into the same cell fate? Can different cell fates 
arise from otherwise indistinguishable initial molecular states? Or can most differences in ultimate 
fate be traced back to measurable differences in the initial states of cells? What is the structure of 
this initial variability? These questions remain largely unanswered because of our limited ability to 
longitudinally track and profile cells (especially rare ones) from initial state to final fate. 
Longitudinal profiling by time-lapse microscopy is generally limited in its ability to interrogate large 
numbers of molecular features simultaneously 71,72. Barcoding, in which cells are labeled by 
unique and sometimes mutable nucleic acid sequences 110–115, allows one to track and profile 
single cells by sequencing or imaging based readouts 77–79,116. However, a key challenge for both 
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of these methodologies is the detection of rare cells (1:1000 or even more rare), for which neither 
time-lapse nor single-cell RNA sequencing is particularly effective (new techniques aim to 
circumvent these limitations 117–120. Yet, many biological phenomena, such as therapy resistance 
in cancer cells, occur in subpopulations that are at least that rare. 
 
Here, we explicitly connect drug-resistant cell fates in melanoma to specific molecular features in 
rare subsets of cells in the drug-naive population. These connections revealed a rich mapping 
between previously-hidden single-cell variability and a number of latent cellular behaviors. Our 
results suggest the existence of a large number of rare subpopulations within seemingly 
homogenous cells, each with potentially distinct biological behaviors, and set out a path to 
discover biologically consequential axes of variability. 
3.2 Developing Rewind, a methodology for isolating primed cells that give rise to 
rare biological phenomena. 
Therapy resistance in cancer provides an excellent system in which to map out the connections 
between rare cell states and fates. In this context, fates refer to cells that proliferate when treated 
with targeted therapies, and the states are the molecular profiles of drug-naive cells that will 
ultimately lead to these resistant fates. These variable profiles can appear even in clonally-
derived lines and have a non-genetic basis 4,5,47,108. We here have focused on BRAFV600E-mutated 
melanoma, in which we have previously demonstrated that there is a rare, transient 
subpopulation composed of cells (~1:2000) that are primed to survive treatment to the targeted 
therapy vemurafenib 106,109. These rare, primed cells often express higher levels of certain 
receptor tyrosine kinases (such as EGFR, NGFR and AXL) and lower levels of melanocyte-
determining transcription factors (SOX10 and MITF) than the rest of the cells in the population. 
However, these markers are highly imperfect, with many positive cells being non-resistant and 
many negative cells being resistant, leaving open the question as to what markers specifically 




The primary technical challenge for studying rare cell processes like drug resistance is the rarity 
of the cells of interest. Current techniques for retrospective identification require profiling of the 
entire initial population and then post-facto determining which profiles correspond to cells of 
interest 77,78. We developed an alternative methodology, dubbed Rewind, to retrospectively 
isolate or identify rare cell populations of interest for downstream characterization. Rewind works 
by using a lentiviral library of transcribed barcodes, in which the barcode sequence is 
incorporated into the 3’ untranslated region of green fluorescent protein (GFP) mRNA. (Fig. 3.1). 
After labeling cells with these barcodes, we allowed the cells to divide for a few divisions and then 
separated the population into two equal groups (“twins”) such that most barcoded lineages 
(>90%) were present in each group (see A.2.4 for discussion and empirical simulations). One 
group we fix in time as a “Carbon Copy” of the cells in their initial state, and to the other, we apply 
the treatment to see which cells undergo the rare behavior of interest (e.g., becoming resistant to 
drug). After selecting the cells that undergo the rare behavior, we sequence their DNA to identify 
their barcodes, and then we use those barcodes to identify their “twins” in the Carbon Copy by 
fluorescently labelling the RNA transcribed from those specific barcodes using RNA in situ 
hybridization techniques (see appendix A.2 for details and Fig. 3.2 for validation). We verified that 
the barcode library was sufficiently diverse to label 100,000s of cells with over 99% receiving 
unique barcodes, thus minimizing spurious identification (Fig. 3.3). Once isolated, we can 
molecularly profile the Carbon Copy twins to determine what is different about their initial state 
that led to their distinct fate. Altogether, the Rewind methodology enables retrospectively 




Figure 3.1. Retrospectively isolating rare primed cells based on their unique future behavior using Rewind. 
Schematic of Rewind approach for isolating the initial primed WM989 A6-G3 melanoma cells that ultimately give rise to 
vemurafenib resistant colonies. For the experiment shown, we transduced ~ 200,000 WM989 A6-G3 cells at an MOI ~ 1.0 
with our Rewind barcode library. After 11 days (~4 population doublings) we divided the culture in two, fixing half in 
suspension as a Carbon Copy and treating the other half with 1 μM vemurafenib to select for resistant cells. After 3 weeks 
in vemurafenib, we extracted genomic DNA from the resistant cells that remain and identified their Rewind barcodes by 
targeted sequencing. We then designed RNA FISH probes targeting 60 of these barcodes and used these probes to 
specifically label cells primed to become resistant from our Carbon Copy. We then sorted these cells out from the 





















































Figure 3.2. Detection and isolation of rare cells expressing Rewind barcodes using RNA FISH. A-B. We sought to 
isolate 100s of primed cells for downstream assays such as RNA sequencing and RNA FISH. In order to capture these 
many cells using Rewind, we needed to probe for multiple barcodes simultaneously while maintaining a low false positive 
rate due to non-specific signal. To test the accuracy of our barcode RNA FISH protocol, we combined GFP- WM989 A6-
G3 cells (~98% of cells) with a GFP+ WM989 A6-G3 subclone carrying a single, known Rewind barcode (~2% of cells) 
then hybridized 4 probes targeting the known barcode along with 240 “off-target” probes (designed to target barcodes 
sequenced in other experiments). In parallel, we hybridized a second mix of cells with only the off-target probes. After 
hybridization and RNA FISH amplification (see Appendix A.2 for details), we ran these samples on a FACS instrument 
and used GFP fluorescence as ground truth for estimating the sensitivity and specificity of our barcode RNA FISH signal 
(indicated below the FACS plots). To isolate rarer subpopulations with Rewind (i.e. primed cells from our Carbon Copy), 
we used a more conservative Alexa647 gate in order to further minimize false positives. C. To assess the accuracy of 
Rewind for in situ, imaging-based applications, we mixed together and plated GFP- WM989 A6-G3 cells (~99% of cells) 
with a GFP+ WM989 A6-G3 subclone carrying a single, known Rewind barcode (~1% of cells). We then cultured the cells 








































































































































for 4 days before fixing the cells and performing barcode RNA FISH (HCR protocol) using 4 probes targeting the known 
barcode and 120 probes targeting random off-target barcodes. We then imaged the entire well with a tiled scan at 20x 
magnification and identified all barcode FISH+ cells (Alexa647+) followed by all GFP+ cells (true positives) using custom 
software. D. We plotted the position of each cell analyzed in C. and color-coded each point by its assigned GFP and 
barcode FISH status. The red square corresponds to the position of the micrographs shown in E. The number of cells with 
each label are indicated in parentheses in the legend. E. Example 20x micrographs showing barcode RNA FISH signal 






3.3 The Primed Cell State Leading to Vemurafenib Resistance is Maintained 
Through Several Cell Divisions. 
A critical feature of these rare primed cell states is that they are transient, meaning that cells can 
fluctuate both into and out of the primed state 5,109. An important biological question that is 
relevant to the ability of Rewind to profile primed cells is whether these cells maintain 
(“remember”) their primed state through several cell divisions. (Memory would be required for the 
profile of cells isolated from the Carbon Copy to reflect those of their twins that received treatment 
with vemurafenib.) To empirically test for the existence of such memory, we let a barcoded 
WM989 A6-G3 culture double 4-5 times, split the culture in two, and then separately treated both 
halves of the population with vemurafenib. We found a large overlap in the barcodes between the 
two halves, demonstrating that the primed state is maintained for several divisions and that there 
is sufficient memory in the system for Rewind to effectively profile the primed state (Fig. 3.4).  
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Figure 3.3. The Rewind barcode library can uniquely label 100,000s of cells with transcribed barcodes that can be 
identified via sequencing. A. Critical for Rewind is the ability to uniquely label enough cells with our transcribed 
barcodes to observe rare phenomena such as drug resistance (frequency < 1:1000). To test this empirically, we 
separately transduced 2 groups of 150,000 cells at an MOI of ~1.5, cultured the cells for ~ 1 day then extracted genomic 
DNA (gDNA) and sequenced their barcodes. Consistent with the starting cell number and MOI, we observed between 
210,000 and 253,000 barcodes in the two samples (≥2 UMIs per million; see Appendix A.2 for description of barcode 
count normalization) with fewer than 3,500 (~0.75%) shared between the two groups. B-C. To ensure that we can 
uniquely distinguish barcodes despite errors during library preparation and sequencing, we estimated the observed 
barcode diversity in the data from A. We randomly sampled 1,000 barcode sequences and calculated the average and 
minimum sequence distance (both Hamming and Levenshtein sequence distances) for all 499,500 pairs of barcodes. We 
repeated this process 500 times and plotted the average and standard deviation of the observed sequence distances. D. 
We tested the reproducibility of our barcode sequencing protocol by preparing separate libraries with unique indexes 
using the same starting gDNA. As shown in the scatter plots we see a high correspondence in barcode abundances 
(UMIs per million) between these replicate libraries, even when using different amounts of gDNA (two separate 
experiments). Plotted are all barcode sequences with at least 50 reads per million in at least one of the two samples. We 
believe these data also suggest that our barcode sequencing protocol is quantitative, however we acknowledge the 
possibility that differences between barcode sequences could systematically bias library preparation or PCR. Our 
validation of barcode RNA FISH probes designed to target more abundant versus less abundant resistant cells (Fig. 3.13) 
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Figure 3.4. Barcode sequencing of “twin” cultures treated with vemurafenib suggests that the primed cell state is 
maintained through several cell divisions. A. Schematic of the cellular barcoding approach used to test whether the 
primed cell state is “remembered” through cell division. We transduced ~150,000-200,000 WM989 A6-G3 cells with our 
Rewind barcode library and allowed the cells to divide for 11-12 days (~4-5 cell divisions). We then split the culture in two 
and treated both halves with 1 μM vemurafenib for 3 weeks. Finally, we sequenced the barcodes in genomic DNA 
extracted from each culture then ranked the barcodes by abundance to identify those likely derived from resistant colonies 
(expected 100-400 unique barcodes from resistant colonies). In the absence of memory of the primed cell state, we 
expected to find unique sets of barcodes emerging in the two parallel cultures. In the presence of partial or complete 
memory, we expected to find some overlap in the barcodes identified in each culture. B. Heatmap shows the proportion of 
barcodes shared between the parallel cultures at different rank thresholds. For our Rewind experiments, we selected the 
top 100-200 barcodes for RNA FISH probe design. C. We sought to rule out the possibility that differences in division rate 
between cells before adding vemurafenib could skew the distribution of barcodes enough to generate the observed 
barcode overlap by chance alone. To this end, we sequenced barcoded cells after 11 days of growth (before vemurafenib 
treatment) to estimate the change in the barcode distribution due to differences in cell growth. We then simulated the split 
and vemurafenib treatment in A. by randomly sampling 2 groups of 200 cells each from the observed barcode distribution 
and calculating the proportion of shared barcodes. The histogram shows the results of repeating this simulation 10,000 









































0.5 0.6 0.7 0.8 0.9 1.0
Fraction of 
shared barcodes






















































Heritability split replicate 1










































Model 1: Cell state leading
to resistance is remebered 
across cell division
Model 2: Cell state leading

















3.4 Rewind combined with RNA sequencing uncovers markers of primed cell 
states.  
We then applied the Rewind approach to isolate the rare WM989 A6-G3 cells primed for 
vemurafenib resistance by FACS, after which we profiled these primed drug-naive cells by RNA 
sequencing (RNA-seq) (Fig. 3.5). Upon sequencing barcodes from cDNA, we found that ~48% of 
reads in the sorted primed subpopulation contained probe-targeted barcodes matching those 
identified in vemurafenib resistant colonies (vs. 0% in the non-primed subpopulation), reflecting 
an estimated ~1,600-fold enrichment over the baseline frequency of these barcodes in the 
Carbon Copy (~0.03%; Fig. 3.5C). (We suspect the proportion of on-target cells isolated here is 
lower than in our pilot experiments (Fig. 3.2) due to the lower prevalence of the targeted cells.) 
Having confirmed that FACS enriched for primed cells, we then looked for differentially expressed 
genes compared to non-primed cells. Consistent with previous research from our lab and others, 
we found that primed cells sorted from the Carbon Copy expressed greater than 2-fold higher 
levels of the receptor tyrosine kinases AXL, EGFR and NGFR as well as lower levels of the 
melanocyte transcription factors SOX10 and MITF (Fig. 3.5D)5,52. Beyond these known markers, 
the transcriptome profile provided by Rewind enabled us to identify nearly 200 new marker genes 
whose expression was significantly altered in primed cells. Among these genes, we found a 
significant enrichment for genes associated with cell adhesion, extracellular matrix (ECM) 
organization and cell migration (Fig. 3.5). Longitudinal tracking of primed cells revealed that the 
expression of most priming marker genes either stayed the same or increased during the 
acquisition of stable resistance over 3 weeks in vemurafenib treatment, while an additional 
~2,800 genes showed a greater than 2-fold change in expression during this period (Fig. 3.6). 
Thus, most of the genes that are upregulated in resistant cells are not the genes whose 






Figure 3.5. RNA sequencing of primed WM989 A6-G3 isolated using Rewind identifies markers of vemurafenib 
resistance. A. Example FACS data for a Rewind experiment in WM989 A6-G3. B. Shown is the mean expression level 
(TPM) for protein coding genes in primed cells (y-axis) and log2 fold change in expression comparing primed cells to non-
primed cells. We estimated log2 fold change values using DESeq2. Colors indicate differentially expressed genes related 
to ECM Organization and Cell Migration (red), MAPK and PI3K/Akt signaling pathways (blue) and previously identified 
resistance markers (purple; Shaffer et al. 2017). Genes were assigned to categories based on a consensus of KEGG 
pathway and GO enrichment analyses (see Appendix A.2. for details). C. To assess the sensitivity and specificity of the 
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Rewind experiment in A., we performed targeted sequencing to identify barcodes from cDNA generated during RNA-seq 
library preparation. Bar graphs show the abundance (y-axis) and rank (x-axis) of each sequenced barcode (≥ 5 
normalized reads). Red bars correspond to barcodes targeted by our probe set and gray bars correspond to “off-target” 
barcode sequences. Inset shows the percent of barcode sequencing reads that match a probe-targeted barcode. These 
data correspond to 1 of 2 replicates. C. Bar graph indicates the average log2 fold change in expression in primed cells 
compared to non-primed cells for genes previously implicated in vemurafenib resistance (Shaffer et al. 2017). Points 
indicate individual replicates. D. We found an enrichment for genes associated with ECM organization and cell migration 
among differentially expressed genes comparing primed cells to non-primed cells. Bar graph corresponds to the average 
log2 fold change in expression in primed versus non-primed cells with individual replicates indicated as points. We bolded 
the gene, ITGA3, that we validated as a predictive marker of vemurafenib resistance (Figure 3.7). We did not detect 
expression of ITGA11 in non-primed cells in 1 of 2 replicates (it was detected in primed cells) and the presented data 




Figure 3.6. Most priming markers remain transcriptionally altered after 3-weeks of vemurafenib treatment, and an 
additional ~3000 genes become differentially expressed. A. When performing Rewind in WM989 A6-G3, we collected 
~10% of vemurafenib-resistant cells (treated for 3 weeks with drug) for transcriptome profiling alongside cells sorted from 
our Carbon Copy. Profiling these cells enabled us to ask how gene expression changed in primed cells after vemurafenib 
treatment during their transition into resistant cells. B. To address this question, we compared the expression of priming 
markers in non-primed cells (left), primed cells (middle) and vemurafenib resistant cells (right). We defined priming 
markers as genes differentially expressed (p-adjusted ≤ 0.1 and abs(log2 fold change) ≥1) in drug-naive primed cells 
versus non-primed. C. We found more than 3,000 genes differentially expressed comparing resistant cells to drug-naive 
non-primed cells of which the ~200 priming markers represented a small subset. We performed pathway and gene-
ontology analyses on the genes differentially expressed only in resistant cells and highlight several recurring annotations.   
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Many of these markers have not previously been implicated in cellular priming for vemurafenib 
resistance and hence represent potentially novel single cell biomarkers of resistance. An example 
was ITGA3, which was the most differentially expressed cell surface marker identified by Rewind. 
To verify that it marked primed cells, we prospectively sorted drug-naive WM989 A6-G3 cells 
expressing high levels of ITGA3. These cells gave rise to 10-fold more resistant colonies upon 
exposure to vemurafenib, confirming that ITGA3 is a marker (Fig. 3.7). We also used Rewind to 
identify markers in another melanoma line, WM983b E9-C6, in which markers of the cells primed 
for resistance were unknown, revealing and validating that AXL was a marker (Fig. 3.8). 
Together, these results demonstrate that there are large sets of genes that exhibit rare-cell 




Figure 3.7. ITGA3 is a prospective marker of vemurafenib resistance in WM989 A6-G3 cells. We stained cells with a 
fluorescently labelled antibody targeting ITGA3, then sorted equal numbers of the brightest ~0.5% (ITGA3-High) and 
remaining ~99% (ITGA3-Low) cells. We plated these cells into separate wells and treated them with 1 μM vemurafenib for 
approximately 18 days. We then fixed the cells, stained nuclei with DAPI and imaged the entire wells to quantify the 
number of resistant colonies. Whole-well scans after vemurafenib treatment are shown on the right with resistant colonies 
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Figure 3.8. Performing Rewind on WM983b E9-C6 identifies AXL as a marker of primed cells giving rise to 
vemurafenib resistance. A. Starting with ~400,000 cells transduced at an MOI ~ 1.0, we repeated the “heritability split” 
experiment in WM983b E9-C6 to determine if the initial primed cell state giving rise to vemurafenib resistance was 
maintained through several cell divisions. The Venn diagram and heatmap show the proportion of barcodes shared 
between the parallel cultures at different rank thresholds. B. To estimate the probability of seeing the observed fraction of 
shared barcodes due to chance, we simulated the experiment using data from WM93b E9-C6 cells transduced as in A 
then cultured for 7 days before sequencing. The histogram shows the results of repeating this simulation 10,000 times 
(gray bars) with the red line indicating the observed proportion of shared barcodes from A. C. Using Rewind we isolated 
primed WM983b E9-C6 cells from Carbon Copies fixed prior to vemurafenib treatment (n = 2 biological replicates). We 
then performed RNA sequencing on sorted cells. We used DESeq2 to identify differentially expressed genes (p-adjusted ≤ 
0.1 and abs(log2 fold change) ≥1) in primed cells versus non-primed cells (red points). Compared to similar experiments in 
WM989 A6-G3, fewer genes passed our significance cutoff which may reflect the shorter memory of the primed cells state 
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but showed ≥ 2-fold higher expression in primed cells in 2 out of 2 replicates. D. We sorted drug-naive cells expressing 
high levels of AXL and low levels of AXL then compared their response to vemurafenib treatment. We treated the cells 
with 1 μM vemurafenib for 3 weeks then imaged the wells to quantify the number of resistant colonies.   
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3.5 Single-cell differences between rare primed cells predict quantitative differences in 
resistance outcomes 
Yet, while isolating rare cells that express high levels of these markers enriched for cells that 
could become drug resistant, we also observed that the majority of cells that expressed any one 
marker still died when faced with drug. Thus, there was no one factor whose expression precisely 
marked the cells that were primed for drug resistance. These facts suggest that the cellular 
fluctuations that lead to a cell becoming primed for drug resistance may be complex, and 
potentially marked by the fluctuations of several genes in tandem. Indeed, our lack of knowledge 
of the precise nature of the mapping between fluctuations and outcomes leaves open a rich set of 
possibilities. In principle, rare-cell fluctuations of genes associated with a particular behavior need 
not be independent of each other but may take on many correlation structures and sub-
structures, with sets of genes potentially co-fluctuating or anti-fluctuating to demarcate specific 
subpopulations within the overall rare-cell population. A parallel question is whether these 
different subpopulations all funnel to the same drug-resistant outcome: it is possible that these 
new axes of variability may represent fluctuations that lead primed cells to adopt phenotypically 
distinct cellular fates after, say, the addition of drug. Rewind allowed us to look for these new sub-
populations. 
 
We first attempted to resolve the question of why most cells that expressed any one particular 
marker actually did not become resistant to drug. We hypothesized that simultaneous co-
expression of multiple markers may more accurately and specifically identify the exact cells that 
are primed to be resistant. To look for evidence of such structured fluctuations, we used Rewind 
in combination with RNA imaging to transcriptionally profile primed cells with single molecule 
resolution (Fig. 3.9A). In this manner, we located 162 primed cells in situ within a total of 
~750,000 cells scanned in our Carbon Copy, which we then probed for expression of 9 genes by 
single-molecule RNA FISH. These cells showed substantially higher expression of AXL, EGFR, 
NGFR, WNT5A, ITGA3, MMP1, and FN1 and lower expression of SOX10 and MITF than 
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randomly selected cells, consistent with our earlier results from RNA-seq (Fig. 3.9C and Fig. 
3.10A). Moreover, cells primed for resistance were far more likely to co-express any pair of 
markers (odds ratios ranging from ~1.5 to ≥58; Fig. 3.10C), and ~87% percent of cells expressed 
high levels of ≥4 of 7 marker genes simultaneously, in stark contrast to cells not expressing 
resistant barcodes (Fig. 3.10B). This apparent coordination suggests that the cell-to-cell 
differences that lead to distinct cell fates following drug treatment are a consequence of the 
coordinated fluctuations of several factors simultaneously, as opposed to sporadic fluctuations of 






Figure 3.9. Measuring single-cell gene expression in rare primed cells using Rewind. A. We performed Rewind with 
image-based profiling to identify WM989 A6-G3 cells primed to become vemurafenib resistant in situ and measure gene 
expression in individual cells using single-molecule RNA FISH. B-C. To identify these rare primed cells, we first imaged 
Carbon Copies at 20x magnification and identified primed cells labeled with our barcode RNA FISH probes using a 
combination of automated image analysis and manual image review. Once identified, we returned to these cells for re-
imaging at high magnification (60x) and quantification of marker gene expression using single-molecule RNA FISH. We 
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Figure 3.10. A coordinated primed cell state characterized by high expression of multiple markers gives rise to 
vemurafenib resistance in WM989 A6-G3. Quantification of single-cell gene expression in primed and non-primed cell 
populations (from Fig. 3.9). Each point corresponds to an individual cell. We set thresholds for high marker expression 
based on the observed expression distribution in non-primed cells (dotted horizontal lines). Error bars indicate 25th and 
75th percentiles of distributions. B. Frequency of cells expressing high levels (beyond the thresholds shown in A.) of 1, 2, 
...7 markers (out of a total of 7 measured) simultaneously in primed and non-primed cell populations. C-D. For all pair of 
markers, we calculated odds ratios for co-expression (at levels greater than the threshold shown in A.) and Pearson 











































































































































































A possible mechanism for how these primed cells survive drug is that the observed increases in 
expression of multiple receptor tyrosine kinases and their cognate ligands lead to differences in 
MAPK pathway activation. To address this hypothesis, we measured dual phosphorylated ERK 
(pERK) levels in primed and non-primed cells by immunofluorescence (Fig. 3.11). We found 
similar levels of pERK in primed non-primed cells in Carbon Copies fixed before vemurafenib 
treatment. However, in Carbon Copies that underwent vemurafenib treatment for 24 hours, we 
found that primed cells had residual levels of pERK that were on average 40% higher than the 
rest of the population, with some primed cells having levels nearly 5-fold higher than non-primed 
cells (within the range of untreated cells). We also observed that within individual clusters of 
closely related primed cells, not all cells contained higher levels of pERK, which may reflect 
pulsatile changes in pERK as documented elsewhere 73. In contrast, single-cell levels of total 
ERK levels were modestly lower in primed cells compared to non-primed cells, both before and 
after vemurafenib treatment. These results suggest that primed cells are able to maintain residual 
MAPK signaling following vemurafenib treatment that may allow them to continue proliferating in 






Figure 3.11. Resistance to vemurafenib is associated with increased levels of phosphorylated ERK 24 hours after 
treatment but not prior to treatment.  A. We used Rewind to quantify dual-phospho-ERK (p44/p42, pERK) levels in 
primed cells before and 24 hours after vemurafenib treatment. To quantify pERK levels over time, we plated two Carbon 
Copies and fixed one 24 hours after vemurafenib treatment and the other prior to treatment. B. Barcode RNA FISH and 
ERK immunofluorescence images of primed cells identified in Carbon Copies fixed before vemurafenib treatment (left) 
and 24 hours after treatment (right). C. Quantification of average pERK immunofluorescence intensity in primed cells and 
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While these results showed an overall coordination between the different marker genes in primed 
cells, there were considerable differences in the degree of co-expression between these marker 
genes in single cells (Fig. 3.10C). These differences suggest the possibility that the expression of 
specific subsets of genes may delineate specific subpopulations within the overall rare primed 
population that could in principle have different fates. Evidence for different fates comes from 
inspection: it was visually clear that different colonies of vemurafenib-resistant cells can show 
dramatic differences in basic properties like the number of cells in the colony. We wondered 
whether tracing back these differences in fate with Rewind could reveal the molecular profiles that 
distinguish subsets of the initial primed cell subpopulation with distinct potential. We applied 
Rewind in the WM989 A6-G3 cell line as before but used the number of barcode reads in the 
resistant population as a proxy for the number of resistant cells carrying a given barcode (Figs. 
3.12 and 3.13). We then designed RNA FISH probes that distinguished 30 of the most abundant 
barcodes (i.e., “highly resistant”, meaning many resistant cells) from 30 barcodes in the next tier 
of abundance (i.e., “less resistant”). We used these probes to identify their twin cells in a Carbon 
Copy fixed prior to vemurafenib treatment (Figs. 3.13 and 3.14). 
 
To find transcriptional profiles that predict whether cells are primed to become either highly 
resistant or less resistant, we measured transcript abundances in individual primed cells by RNA 
FISH for 9 genes, including 7 priming markers, MITF and SOX10 (Figs. 3.13 and 3.14). We used 
the dimensional reduction technique UMAP to visualize differences between cells based on 
expression levels and then marked individual cells in this visualization based on their ultimate fate 
as determined by the barcode RNA FISH signal (primed to become highly vs. less resistant vs. 
non-primed). We found that non-primed cells clearly separated from all the primed cells, and that 
within the primed cells, the highly resistant primed cells grouped together, while the less resistant 
cells formed two distinct groups (Fig. 3.14A). These groupings were also apparent in hierarchical 
clustering of the single-cell gene expression data, with cluster assignment of each cell roughly 
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corresponding to its resistance fate, suggesting a clear distinction between the groupings (Fig. 
3.15A-B) 
 
We then asked how expression levels of particular genes corresponded to these groupings. As 
expected, most (>80%) of the primed cells had markedly decreased levels of both SOX10 and 
MITF (Figs. 3.14 and 3.15). We also found that almost all primed cells had increased levels of 
FN1 (>98%), thus suggesting that FN1 is a “pan” marker of cells primed for vemurafenib 
resistance (Figs. 3.14 and 3.15). Co-expression of AXL, ITGA3, and EGFR marked cells primed 
to become highly resistant, but individually these genes were also expressed in subsets of cells 
primed to become less resistant (Figs. 3.14B and 3.15A). These subsets could also be 
distinguished by expression of WNT5A, MMP1, NGFR with one group (group A) expressing the 
highest levels of WNT5A and MMP1 and the other (group B) expressing the highest levels of 
NGFR (NGFR also had intermediate levels of expression in the cells primed to be highly 
resistant; Figs. 3.14B and 3.15A). In addition, quantitative comparison of expression levels 
between pairs of markers showed that the expression of, for example, AXL vs. MMP1 fell along 
two separate axes of variability (Fig. 3.14C). Together, these analyses suggest that multiple 
classes of primed cells with different expression patterns give rise to resistant colonies with 
different phenotypes. 
 
Although our labeling scheme did not discriminate between different primed cells that ended up 
with the same fate, in these imaging data, we were able to use spatial proximity of barcode-
positive cells to infer that neighboring barcode-positive cells were likely derived from the same 
initial cell and therefore belong to a unique subclone (Fig. 3.15C). We could then use the single-
cell gene expression levels to further determine which primed cell class these cells belonged to, 
and ask whether there were any signs of switching between primed cell classes (including 
reversion to the non-primed state). In nearly half of the subclones (11 out of 24), all cells fell into a 
single primed-cell class (Fig. 3.15D). Moreover, for most (7 out of 13 remaining) subclones 
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containing a mix of cell states, only 1 cell within the subclone was classified as a separate class. 
These data suggest that primed cells can transition between states, and these transitions occur 
on a relatively slow time-scale (potentially once per 4 days or ~2-3 cell divisions; slow compared 
to most expression fluctuations), consistent with recent work quantifying the transcriptional 
memory of several primed-cell marker genes 109.   
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Figure 3.12. Related primed cells have similar resistance outcomes. As in Fig. 3.4 We transduced ~150,000-200,000 
WM989 A6-G3 cells with our Rewind barcode library and allowed the cells to divide for 11-12 days (~4-5 cell divisions). 
We then split the culture in two and treated both halves with 1 μM vemurafenib for 3 weeks. Finally we sequenced the 
barcodes in genomic DNA extracted from each. We compared the abundance of barcodes from parallel cultures by 
plotting all barcodes with at least 100 UMIs per million in at least one sample (see Appendix A.2.8 for description of 
normalization).To better visualize lower abundance barcodes, we binned the barcodes by count and colored each bin by 
its number of unique barcodes. Based on the observed correlation in barcode abundance between parallel cultures, we 
reasoned that differences in the number of cells that make up a vemurafenib resistant clone (which varies by more than 
an order of magnitude) are at least partially pre-determined in the initial primed population 3 weeks earlier.  





















































































































Figure 3.13. Experimental design and validation of Rewind experiment to distinguish subpopulations of primed 
cells. A. We performed Rewind in WM989 A6-G3 cells and identified barcode sequences enriched in resistant colonies 
following vemurafenib treatment. We ranked these barcodes by abundance as a proxy for ranking the number of resistant 
cells carrying each specific barcode. We then designed separate RNA FISH probe sets targeting barcodes from the ~ 50 
most abundant resistant clones (“highly resistant cells”) and barcodes targeting the next ~ 50 resistant clones (“less 
resistant cells”). Each probe set contained probes targeting 30 distinct barcodes. B. We used these separate probe sets 
to identify corresponding primed cells in the Carbon Copy fixed prior to vemurafenib treatment then performed sequential 
rounds of RNA FISH to measure single-cell expression of 9 genes. C-D. We used the same probe sets designed in A. to 
label resistant colonies derived from the same population of cells. We then quantified the number of resistant cells 
labelled with each probe set.  
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Figure 3.14. Differences in resistance outcomes can be traced back to single-cell gene expression variability 
among the initial primed cells. We used Rewind to label primed cells based on their resistance outcome then performed 
RNA FISH to measure single-cell gene expression of 9 marker genes (see Fig. 3.13 for experimental design). A. We used 
the UMAP algorithm to visualize the relationship in gene expression between primed cells (n = 132)  and non-primed cells 
(n = 124), then colored each cell by its predicted fate based on its barcode. To orient the reader, we circled the largest 
group of primed cells that give rise to highly resistant colonies in orange, and the two separate groups of primed cells that 
give rise to less resistant colonies in green. B. Maintaining the organization provided by UMAP, we colored each cell by its 
expression of each of the 9 genes measured. C. Scatterplots show the single cell expression for pairs of markers that 
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Figure 3.15. Rewind uncovers multiple, slowly-transitioning primed cell states. A. Dendrogram shows the results of 
hierarchical clustering of the single-cell gene expression data for primed cells from Fig. 3.14. The branch colors indicate 
the 4 clusters of primed cells. Below the dendrogram, we used points to label the subclone (top row) and resistance fate 
(bottom row) of each primed cell (terminal branch). Below these points, we plotted the expression of each marker gene in 
each primed cell. The color of each bar indicates the resistance fate of the corresponding primed cell. B. We calculated 
the mutual information between the gene expression cluster labels and resistance fate labels for primed cells. We then 
permuted the cluster labels 10,000 times and recalculated the mutual information each time. Plotted is the distribution of 
mutual information values for the permuted data (gray bars) and the value for the observed data (red line). C. Stitched, 
whole-well, 20x scan of a Carbon Copy with DAPI signal pseudocolored in blue. The colored squares outline image tiles 
containing at least 1 barcode-FISH-positive, primed cell. To identify subclones of closely-related primed cells, we grouped 
primed cells located within a distance of 2 mm (see Appendix A.2.16 for further details). The color of each square 
indicates a separate subclone with the number of primed cells within the subclone shown in parentheses. D. Venn 
diagram indicates the number of subclones containing primed cells belonging to a single cluster from C (edges) or a mix 
of clusters (overlaps). For the Venn diagram on the right, subclones were defined as mixed only if at least 2 primed cells 
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3.6 Rewind uncovers a distinct subpopulation of primed cells that require DOT1L 
inhibition to become vemurafenib resistant.  
These results show that primed cells consist of a complex set of subpopulations that can map to 
a variety of cell fates. A critical point is that the mapping and hence subpopulations were revealed 
by the addition of a particular drug. It is possible that there are additional subpopulations present 
in cells that would normally not survive drug treatment. Further, it may be that the molecular 
differences that characterize these subpopulations could allow otherwise drug-susceptible cells to 
become primed for drug resistance in different conditions. Evidence for such a possibility comes 
from the existence of factors that, when perturbed in drug-naive cells, can reduce or increase the 
frequency of resistant colony formation, implying an increase or decrease in the number of 
primed cells within the population 106. Amongst these is DOT1L, a H3K79 methylase whose 
inhibition leads to a 3-fold increase in the number of resistant colonies that form upon addition of 
vemurafenib 106. While DOT1L inhibition removes some type of barrier that allows more cells to 
be primed, this barrier is not removed in all cells because not all cells are able to form resistant 
colonies. Thus, an important question is what distinguishes the small subset of the cells that 
become primed for resistance upon DOT1L inhibition from the majority of cells that remain non-
resistant to drug. (Barcoding analysis revealed that DOT1L inhibition indeed permits a new 
subset of cells to enter a primed state rather than affecting proliferation or reversion of primed 






Figure 3.16. Models of how DOT1L inhibition may increase vemurafenib resistance.  We hypothesized that DOT1L 
inhibition increases the frequency of resistant colonies by either 1. selectively increasing the proliferation of these primed 
cells, 2. decreasing their transition out of the primed state, or 3. enabling a new subpopulation of cells to survive 
vemurafenib treatment. We reasoned that we could distinguish these possibilities by splitting barcoded cells into parallel 
cultures, treating one with DOT1L inhibitor and the other with vehicle control, then treating both with 1 μm vemurafenib 
and comparing the barcodes in cells that survive. If either increased primed cell proliferation or decreased reversion were 
the sole factors leading to an increase in vemurafenib resistance, then we expected to find mostly the same barcode 
sequences in resistant colonies from the parallel cultures (with a small number of distinct barcodes similar to what we 
observed in Fig. 3.4). In contrast, if DOT1L inhibition permitted a new subset of cells to survive vemurafenib treatment, 
then we expected to find their distinct barcodes in the additional resistant colonies that emerge with DOTL inhibitor pre-
treatment. Rightmost Venn diagrams show the observed overlap in barcode sequences in resistant cells from cultures 
pretreated with DOT1L inhibitor (red) or vehicle control (black). The presence of distinct barcodes DOT1L inhibitor 
pretreatment suggests that DOT1L inhibition increases the frequency of resistance, in part, by enabling a new 
subpopulation of cells to proliferate in vemurafenib. To select barcodes from resistant colonies, we used the normalized 
read count for the 500th most abundant barcode in the vehicle control pretreated samples as a threshold. This threshold 
undercounts the number of resistant colony barcodes in DOT1L inhibitor pretreated cultures since these cultures have a 
greater number of distinct barcodes which reduces the relative abundance of each individual barcode. Therefore, the 
number of distinct barcodes in resistant colonies forming after DOT1L inhibition is likely greater than what is shown.   
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Using Rewind, we sought to reveal the molecular profile specific to the subpopulation of cells that 
required DOT1L inhibition to survive vemurafenib treatment. To this end, we designed multiple 
RNA FISH probe sets to separately label the cells that required DOT1L inhibition to become 
resistant and cells that become resistant irrespective of DOT1L inhibitor treatment (Fig. 3.17). 
(We expect these probe sets to label fewer than 1:10,000 cells.) We then used these probes to 
sort corresponding cells from Carbon Copies fixed prior to vemurafenib treatment (Fig. 3.18).  
RNA sequencing of the sorted subpopulations revealed a few dozen genes differentially 
expressed between cells that required DOT1L inhibition to survive vemurafenib treatment and 
non-primed cells (Fig. 3.18). Interestingly, we observed differences in expression even in the 
absence of DOT1L inhibition, suggesting that these genes marked a subpopulation that exists 
independent of the inhibition of DOT1L, but nevertheless requires DOT1L inhibition in order to 
become resistant (Fig. 3.18E-F). While most differentially expressed genes were also expressed 
in “conventionally primed” cells, there were a few genes whose expression was somewhat 
specific to cells that were primed for resistance only when DOT1L was inhibited (Fig. 3.18). Of 
these, we selected the gene DEPTOR, whose expression we sought to characterize in single 
cells in our Carbon Copy by RNA FISH (Figs. 3.18H and 3.19). (We also chose another gene, 
MGP, whose expression was similarly highly elevated, but only in one replicate.)  
 
For single cell analysis, we performed RNA FISH on the Carbon Copies (half treated with DOT1L 
inhibitor and half treated with vehicle control) for 10 total genes: 6 priming markers, SOX10, 
MITF, DEPTOR, and MGP. We scanned through ~2 million cells to find those expressing the 
targeted barcodes, identifying 850 such cells. Using UMAP, we first visualized the expression 
profiles of cells from the vehicle control treated Carbon Copy, overlaying the information provided 
by barcode RNA FISH to label cells by their fates (Fig. 3.19B). We found that the primed cells that 
did not require DOT1L inhibition to become resistant separated into a distinct grouping that, as 
before, expressed the previously identified markers such as AXL and EGFR (Fig. 3.19B). We 
initially expected the expression of these genes to also be elevated in the cells that required 
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DOT1L inhibition to become resistant, but perhaps to a lesser extent, reflecting a “subthreshold” 
state that was unable to survive vemurafenib treatment alone. Contrary to this expectation, the 
expression profiles of this new subpopulation were far more similar to the general population of 
cells that were not primed for resistance in either condition (Fig. 3.19B). While in the UMAP 
projection, many of these cells were grouped together with the non-primed cells, there was a 
distinct grouping nearby that consisted almost exclusively of cells that were primed for resistance 
only upon DOT1L inhibition. These cells specifically expressed high levels of DEPTOR, along 
with slightly elevated levels of EGFR and lower levels of MITF but showed no differences in the 
expression levels of the other genes measured compared with non-primed cells (Fig. 3.19B-C). 
(Cells requiring DOT1L inhibition for priming were also enriched for MGP in a separate replicate 
experiment.) Taken together, the identification of a unique molecular state marked by DEPTOR 
expression in the overall absence of established priming markers highlights the existence of a 
qualitatively distinct rare cell state that can lead to drug resistance when a DOT1L inhibitor is 
given prior to vemurafenib. It is noteworthy that many of the primed cells which require DOT1L 
inhibition to become vemurafenib resistant expressed neither DEPTOR nor established markers 
(e.g. AXL, NGFR, ITGA3 etc.) and further work is needed to identify features that better 







Figure 3.17. Experimental approach for identifying the subpopulation of primed cells that require DOT1L 
inhibition to become vemurafenib resistant.  A. We transduced approximately 400,000 WM989 A6-G3 cells at an MOI 
~ 1.0 then allowed the cells to divide for 6 days before splitting the culture into two groups. We treated one group with 4 
μM DOT1L inhibitor (pinometostat) and the other with vehicle control (DMSO) for another 6 days. We then split each 
group again, fixing half as our “Carbon Copies” and treating the other half with 1 μM vemurafenib for ~2.5 weeks. After 
vemurafenib treatment, we extracted genomic DNA from the remaining cells for barcode sequencing. B. For each barcode 
identified by sequencing, we plotted its abundance in resistant cells pre-treated with DOT1L inhibitor versus its abundance 
in resistant cells pre-treated with vehicle control. This comparison revealed a subset of barcodes with a greater relative 
abundance in resistant cells pre-treated with DOT1L inhibitor (blue points). We used these barcodes to design RNA FISH 
probes targeting cells that required DOT1L inhibition to become vemurafenib resistant. A separate set of barcodes were 
highly abundant in resistant cells both with or without DOT1L inhibition (orange points), suggesting that these cells were 
destined to become resistant whether or not they were pre-treated with DOT1L inhibitor. We used these barcodes to 
design RNA FISH probes targeting primed cells not requiring DOT1L inhibition to become resistant. Dashed, diagonal line 
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Figure 3.18. Primed cells that require DOT1L inhibition to become vemurafenib resistant express a subset of 
conventional priming markers as well as a few additional, unique markers. A. We labeled and sorted cells requiring 
DOT1L inhibition to become vemurafenib resistant (blue), primed cells not requiring DOT1L inhibition (orange), and non-
primed cells (gray) from Carbon Copies for RNA sequencing. We separately sorted cells from Carbon Copies treated with 
DOT1L inhibitor and Carbon Copies treated with vehicle control. B-D. Venn diagrams show the overlap in differentially-
expressed genes (p-adjusted ≤ 0.1 and abs(log2 fold change) ≥ 1) identified in each subpopulation of primed cells (orange 
and blue) compared to non-primed cells. B. and C. show separate analyses for cells isolated from DMSO control and 
DOT1L-inhibitor treated Carbon Copies, respectively, and D. shows the results of a combined analysis with DOT1L-
inhibitor treatment modeled as a covariate. E-F. For all differentially expressed genes identified in each subpopulation of 
primed cells, we plotted the observed log2 fold change with DOT1L-inhibitor treatment (y-axes) vs. with DMSO treatment 
(x-axes). This analysis revealed that most gene expression differences between primed and non-primed cells exist 
independently of DOT1L-inhibitor treatment. G. To identify markers of cells that require DOT1L inhibition to become 
resistant, we used DESeq2 to compare their gene expression to non-primed cells (x-axis) and primed cells not requiring 
DOT1L inhibition (y-axis). In this analysis, we included cells sorted from all Carbon Copies (treated with DOT1L inhibitor 
or vehicle control) from 2 biological replicates and included DOT1L inhibitor treatment as a covariate in estimating log2 fold 
changes. Red points correspond to genes differentially expressed in one or both comparisons. H. Expression of DEPTOR 
in transcripts per million in the subpopulations isolated in A. Points indicate TPM values for each experimental replicate.  
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Figure 3.19. At the single-cell level, most primed cells that require DOT1L inhibition to become vemurafenib 
resistant appear transcriptionally distinct from conventional primed cells. A We used the same probe sets as in Fig. 
3.18 to identify cells in situ in Carbon Copies fixed prior to vemurafenib treatment, then measured single cell expression of 
DEPTOR, MGP, SOX10, MITF, and 6 priming markers by RNA FISH. B. Using these data, we applied the UMAP 
algorithm to visualize the relationship in gene expression between single cells from the vehicle control treated Carbon 
Copy (n=423). In the upper left plot, points are colored according to the fate of each cell as determined by its barcode, 
and the number of cells corresponding to each fate are labelled separately above the two largest groupings. For the 
remaining plots, points are colored by the expression level of the indicated gene in that cell. C. Shown is the expression of 
DEPTOR in the indicated cell populations identified in the Carbon Copies treated with vehicle control. Each point 
corresponds to an individual cell. Above each boxplot is the proportion of cells with levels of DEPTOR RNA above the 
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While the cells that require DOT1L inhibition to become vemurafenib resistant expressed distinct 
markers initially, we wondered whether DOT1L inhibition pushed these cells towards a molecular 
state more similar to the conventional primed cell state (i.e. high levels of AXL, EGFR, NGFR, 
etc.; Fig. 3.20). To this end, we compared the transcript levels as measured by RNA sequencing 
from cells sorted from Carbon Copies treated either with DOT1L inhibitor or vehicle control (Fig. 
3.21). As expected, with vehicle control, cells that require DOT1L inhibition to become 
vemurafenib resistant clustered separately from primed cells that do not require DOT1L inhibition 
(Fig. 3.21). With DOT1L inhibition, these two populations appeared modestly more similar 
transcriptionally, however they remained predominantly distinct (Fig. 3.21). RNA FISH on cells 
that require DOT1L inhibition to become resistant revealed that DOT1L inhibition did not increase 
expression of established priming markers, and if anything, modestly decreased their expression 
(Fig. 3.22). Overall, these gene expression differences between primed subpopulations both 
before and after DOT1L inhibition suggest that DOT1L inhibition does not simply convert cells into 
the previously established primed cell state capable of surviving vemurafenib treatment, but 





Figure 3.20. Models of how DOT1L inhibition could enable a new subpopulation of cells to become vemurafenib 
resistant. We asked whether DOT1L inhibition enables a new subpopulation of cells to survive vemurafenib treatment by 
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Figure 3.21. By RNA sequencing, separate primed subpopulations remain distinct following DOT1L inhibition. A. 
We used Rewind to isolate and perform RNA sequencing on cells requiring DOT1L inhibition to survive vemurafenib 
treatment (blue), cells not requiring DOT1L inhibition (orange), and non-primed cells (gray) sorted from both Carbon 
Copies treated with DOT1L inhibitor (red outline) and Carbon Copies treated with vehicle control (gray outline) (2 
replicates each sorted for RNA sequencing). B. Heatmap displays expression of established priming markers across 
sorted subpopulations from control and DOT1L-inhibitor pre-treated Carbon Copies. Dendrogram shows hierarchical 
clustering of samples by expression values. We defined priming markers as protein-coding genes differentially expressed 
(p-adjusted ≤ 0.1 and abs(log2 fold change) ≥ 1) in primed cells not requiring DOT1L inhibition compared to non-primed 
cells, both isolated from the Carbon Copy treated with vehicle control. C. Using expression of priming markers as in B., we 
performed principal component analysis on primed and non-primed cell populations. Red outline indicates samples sorted 
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Figure 3.22. By RNA FISH, separate primed subpopulations remain distinct following DOT1L inhibition. A-B. We 
used the same probes as in Fig. 3.19 to identify cell populations in situ in Carbon Copies treated with DOT1L inhibitor or 
vehicle control. We then used RNA FISH to measure single cell expression of 10 priming markers and visualized the 
relationship in gene expression between single cells using the UMAP algorithm with the first 6 principal components. This 
analysis included expression data from 850 single cells. Points are colored according to the fate of each cell as 
determined by its barcode. C. Plotted are single cell expression data for 6 priming markers, MITF and SOX10 in cells that 
require DOT1L inhibition to become vemurafenib resistant. Each point corresponds to an individual cell. Below each 
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We have here revealed the existence of a rich set of rare subpopulations within seemingly 
homogenous cells, several of which can lead to phenotypically distinct fates. Despite the 
population having a clonal origin and being grown in homogeneous cell culture conditions, these 
subpopulations spontaneously emerge via transient cell-state fluctuations that can persist for 
several cell divisions. It remains unclear how precisely these subpopulations arise, although, 
intriguingly, it may arise from network interactions between multiple regulatory factors 121. It is 
also unclear how these states revert to the population baseline. We here observe states 
persisting for over 5-6 generations, whereas previous reports based on sorting by single markers 
suggested reversion on shorter timescales. It is possible that the more purely primed population 
identified by Rewind can persist longer than the more impure populations which may contain 
transient intermediates. 
 
For the variability that is associated with priming, it is tempting to imagine single axes of variability 
for both state and fate, in which cells that have fluctuated further up a putative primed state 
hierarchy lead to different degrees of resistance. However, our results show that even for the 
simple case of heterogeneity in the size of resistant clones, expression of the rare cell markers 
AXL/ITGA3/EGFR and WNT5A/MMP1/NGFR varied along at least two axes prior to the addition 
of drug, with each axis being associated with either the low-abundance or high-abundance 
clones. Further use of tools like Rewind, potentially in combination with transcriptome-scale RNA 
FISH or single-cell RNA sequencing, may help to fully reveal the structure of these fluctuations 
and consequent subpopulations. Resistant cell fates likely have similarly complex modes of 
variability, and our results suggest that these modes likely have origins in molecular variability in 
the initial cell state. The nature of these mappings may help guide therapy, and it may be 
important to consider the multiple different initial primed cellular states that give rise to resistant 




A critical consideration in developing Rewind was minimizing contamination from “off-target” non-
primed cells. These cells could in principle come from probes falsely generating signal in non-
primed cells or technical limitations of FACS. These contaminating cells can dramatically dilute 
measurements of gene expression specific to the targeted, rare subpopulations. We found that 
barcode detection by FACS was far more prone to contamination than barcode detection by 
imaging, which had very high precision (estimated to be ~97%; Fig. 3.2); indeed, we believe it is 
for this reason that we observe larger magnitude differences by RNA FISH than by RNA 
sequencing of sorted populations, particularly for markers down-regulated in primed cells such as 
SOX10 and MITF. Yet, despite these concerns, we discovered and validated the priming markers 
ITGA3 and AXL, while also identifying previously known markers such as NGFR and EGFR. We 
also found that experiment-to-experiment technical variability was relatively minimal: by imaging, 
we did not see much difference in off-target signal across different probe sets (with rare 
exceptions of "dirty” probes), and barcode sequencing of cDNA from sorted subpopulations 
labelled with different probe sets suggested similar levels of enrichment. 
 
The global transcriptional profiles afforded by RNA sequencing of rare primed cells allowed us to 
ask what pathways might be active in these cells beyond the ones like growth factor receptor 
signaling that have already been associated with vemurafenib resistance in melanoma 
5,54,55,106,122. One of the strongest signatures was the upregulation of cell adhesion proteins and 
structural components of the extracellular matrix. Such signatures suggest the possibility that 
control of cell state and behavior may have both a component that is autonomous to the cell itself 
and a component that is instructed by the extracellular matrix. Future research may help reveal if 
and how the extracellular matrix is able to influence primed cellular states, and consequently, 
therapy resistance.  
 
There were also several other expression signatures active in distinct subpopulations of cells. For 
instance, DEPTOR expression marked one set of primed cells. While DEPTOR may not have any 
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functional role in priming, it is known that DEPTOR inhibits mTOR signaling, which may relieve 
negative feedback on PI3K/Akt signaling, and, in turn, bypass the inhibition of BRAF signaling 123 
. Further work is needed to establish such potential mechanisms. 
 
The processes involved in the acquisition of stable drug resistance act both on short timescales 
(such as signaling) and on longer timescales (transcription). For instance, vemurafenib acts by 
inhibiting MAPK signaling, but the vemurafenib treatment itself relieves negative feedback on 
growth factor receptor signalling and allows ERK reactivation via BRAFV600E-independent routes 
73,124. Single cell analysis of ERK signaling has shown that individual cells vary dramatically in 
ERK activity following vemurafenib treatment with rare cells reactivating ERK to levels 
comparable to untreated cells. Rewind allowed us to connect these near-term single-cell signaling 
dynamics in rare cells to both their initial transcriptional state and their ultimate resistant fate. 
These connections revealed that the primed melanoma cells that go on to survive vemurafenib 
treatment had both higher levels of phosphorylated ERK soon after treatment and expressed 
multiple receptor tyrosine kinases along with their cognate ligands. It is possible that this unique 
gene expression program enabled autonomous ERK reactivation. 
 
We chose to focus on the priming of melanoma cells towards different fates following targeted 
therapy treatment. However, there are several examples in which non-genetic differences can 
lead rare cells to undergo important transformations, including the induction of pluripotency in 
otherwise terminally differentiated cells and transdifferentiation of one cell type into another 1. 
Application of techniques like Rewind in these contexts may reveal universal characteristics of 





CHAPTER 4: Concluding Remarks. 
Chapters 2 and 3 describe two methodologies, MemorySeq and Rewind, for characterizing 
primed cell states that give rise to rare cell phenomena. Both of these methodologies rely on 
persistence of these states through several rounds of cell division. While it appears that most 
genes do not exhibit such prolonged transcriptional memory (Fig. 2.1 and 71, there is growing 
evidence from diverse model systems that cell states giving rise to particular cell fates are 
maintained for extended periods of time 77,78,88,125,126 (although notable exceptions exist 
68,80,116,127). These findings raise the question of whether such prolonged memory is somehow 
required for these cells to give rise to these particular fates or, alternatively, whether the evidence 
of memory is merely a reflection of more extreme fluctuations in cell state that simply take more 
time to reverse? In either case, it is tempting to speculate that such persistent fluctuations may 
have evolved as a mechanism to increase phenotypic diversity without relying on the slow pace 
of genetic change 128–131. Moreover, this process may be exploited by cancer cells and underlie 
their deftness at colonizing diverse tissue environments and surviving medical therapies132. 
 
The mechanisms that enable the persistence of these rare cell states have yet to be fully 
unraveled. While genes identified by MemorySeq that exhibit transcriptional memory are 
surrounded by particular patterns of histone modifications, it is unclear whether these patterns are 
a cause or consequence of the defining differences in gene expression at these loci. Regions of 
accessible chromatin flanking these loci are also enriched with motifs bound by particular 
transcription factors (i.e. SOX10, FOS/JUN and NFAT family), however knockout of these factors 
individually has a relatively modest effect on expression of MemorySeq genes by bulk RNA 
sequencing. Further single-cell experiments and modelling are needed to determine whether 
these modest effects can be explained by changes in transcriptional memory per se.  
 
Another proposed mechanism for slowly fluctuating changes in gene expression involves 
alterations in DNA methylation133. In a parallel and independent study, Meir et al. explored this 
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proposed mechanism after developing an approach nearly identical to MemorySeq and 
identifying several gene sets showing coordinated and heritable changes in expression in clonal 
cell lines (including some genes also identified in our study)134. Interestingly, after knocking out 
two key DNA methyltransferases (DNMT1 and DNMT3B) in one of cell lines studied, the authors 
still found heritable changes in expression of many of these same genes sets, suggesting that 
maintenance of DNA methylation is not essential for these cell state fluctuations. 
  
It is also worth considering whether these rare cell fluctuations could be explained by well-
established properties of transcription and generic configurations of gene regulatory networks 
(GRN). Indeed, through modeling, Schuh et al found that with a variety of GRNs, across a range 
of network sizes, transcriptional bursting could generate rare coordinated gene expression states 
with striking similarity to those observed in Shaffer et al. 2017 and in Chapters 2 and 3 above 
5,121. In simulations, these states were more likely to occur with weakly connected networks and 
with a constrained set of parameters controlling bursting rates and inter-node interactions, which 
may suggest why only a subset of genes seem to exhibit this rare, coordinated expression 
behavior. As the study by Schuh et al. did not seek to identify long-lived versions of this behavior, 
further research is needed to determine whether similar models could generate the slowly 
fluctuating, rare cell states identified by MemorySeq. If so, there still would be the need to identify 
which genes constitute the core of the GRN and which lie on the periphery without influence on 
the maintenance of cell state.  
 
In all cell lines studied, MemorySeq identified multiple distinct sets of genes co-fluctuating in 
separate clonal cell populations. When tested, these gene sets could be used to identify rare 
cancer cells with enhanced capacity to survive drug treatments. However, similar prospective 
experiments were not feasible for many of the identified gene sets and it is unknown whether 
these genes mark cells that can also survive drug treatment or display other rare behaviors. Even 
if these cells could be isolated it would be unclear what behaviors to test. What may be needed is 
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a strategy for high-throughput, multiplexed behavioral testing of cells or, as coined by Dr. Sydney 
Shaffer, a sort of “cellular Olympics”. Such a strategy could be combined with MemorySeq (and 
related methodologies) to generate a broader mapping between the molecular state of rare cells 
and their unique behaviors.  
 
As mentioned in the Introduction, there may be intrinsic features of primed cell states that 
influence cell fate yet are not reflected in gene expression (at least as measured by scRNAseq). 
In principle, these may include features that cannot be measured by single-cell sequencing or 
even by sequencing technologies at all (such as imaging-based cell features). Therefore, an 
obvious future direction is to combine MemorySeq and Rewind with additional assays for 
measuring features of cell state beyond gene expression. As already demonstrated by the 
imaging data in Chapter 3, measuring these additional features may be more feasible using 
Rewind or Memory compared to scRNAseq-based strategies for discovering primed cell states.  
 
A central finding in chapter 3 is that seemingly subtle differences between rare cell fates (i.e. 
number of resistant cells) or between drug treatments are a result of selection for distinct primed 
states within an isogenic population of cells. Evidence for this can be first seen in experiments 
where we grew barcoded melanoma cells for a few cell divisions then divided the cells into two 
separate cultures and exposed both to a BRAF inhibitor for several weeks to select for rare 
(<1:1000) drug resistant cells. Upon DNA sequencing of barcodes from the surviving cells, we 
found that not only were the same barcodes detected in both cultures, but the abundance of 
these barcodes were strongly correlated between the separate culture, suggesting that heritable 
differences between rare cells in the initial population are responsible for both qualitative (death 
vs. resistance) and quantitative differences in cell fate. Moreover, when the parallel cultures are 
exposed to different combinations of drugs (BRAF-inhibitor with vs. without DOT1L-inhibitor pre-
treatment) we found a subset of barcodes which rose to high abundance in one but not the other 
culture, also suggesting the existence of multiple initial primed subpopulations. Using Rewind to 
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isolate these subpopulations, we then identified gene expression markers associated with the 
distinct primed states (Figs. 3.18 and 3.19), thereby uncovering finer details of the mapping 
between rare cell states and drug resistance. 
 
There are, however, lingering questions about these multiple primed states. In our data, it is clear 
that these states cannot be distinguished entirely by expression of markers we measured by RNA 
FISH. This may reflect the choice of markers, the choice of thresholds used to select barcodes 
that correspond to different fates, fundamental limits on the ability of gene expression to 
distinguish these states, and various technical factors. A possible solution (currently being 
spearheaded by Naveen Jain) is to isolate primed cells using Rewind then deeply profile 
individual cells using single-cell sequencing (e.g. scRNAseq, CITE-seq135, scATACseq12,136) or 
highly-multiplexed in situ based methods (e.g. seqFISH15, FISSEQ137, and cyclic-IF138). This 
strategy may find features which better resolve boundaries between primed states or uncover 
axes of variation that map to a continuum of cell fates.  
 
Another lingering question is what are the transition routes between primed states as well as 
between primed and unprimed states? One could imagine how knowledge of these routes could 
inform therapeutic strategies aimed at reducing tumor heterogeneity and improving treatments 
responses106. Since monitoring the expression of multiple marker genes in rare cells by live-cell 
imaging is not simple, alternative strategies for charting cell state transition routes may be 
needed. One such strategy may be to estimate RNA velocity based on measurements of intron 
fragments or nascent RNA, either by scRNAseq139 or RNA FISH105,140. Another approach may be 
to combine the static Rewind barcodes with additional, mutable barcodes (much like the 
impressive design of macsGESTALT141) to construct more complete cell phylogenies which can 
be overlaid with single-cell measurements of both gene expression and cell fate. It is also worth 
highlighting a clever methodology developed by several groups that uses CRISPR/Cas9 to 
activate a fluorescent protein in rare subpopulations of cells identifiable by a unique sgRNA 
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sequence or binding site117,118,120. Since these subpopulations can then be isolated alive, it may 
be feasible to track changes in their cell state directly. However, since these methods currently 
require transfection with unique sgRNAs or reporter plasmids, improvements to these strategies 
would be needed to isolate more than a couple clonal subpopulations. 
 
While my research has primarily focused on drug resistance in cancer, I believe it is likely that the 
tools developed and principles of cellular priming uncovered will be relevant for all manner of 
phenomena in Biology. Already members of the Raj lab, including Connie Jiang and Naveen Jain, 
have begun applying these tools in new and exciting ways to address fundamental questions 
regarding cardiomyocyte differentiation and iPSC reprogramming. Indeed, it is because of its 



















APPENDIX A: Experimental and Computational Methods. 
A.1 Material and Methods for Chapter 2 (MemorySeq) 
A.1.1 Cell lines and culture 
We used 4 cell lines in our study: WM989-A6, which is a subclone of the melanoma line WM989 
(Wistar Institute, a kind gift of Meenhard Herlyn142); WM983B-E9, a subclone of WM983B (a kind 
gift of Meenhard Herlyn, Wistar Institute); MDA-MB-231-D4, a subclone of MDA-MB-231 (ATCC 
HTB-26) and PC-9-D11, a subclone of PC-9 (a kind gift from Matthew Lazzara, University of 
Virginia). We verified all cell lines by DNA fingerprinting: WM989-A6 and WM983B-E9 were 
performed at the Wistar Institute by DNA STR Microsatellite testing and MDA-MB-231 and PC-9 
were performed by ATCC human STR profiling cell line authentication services. We cultured the 
melanoma cell lines in TU2% (containing 80% MCDB 153, 10% Leibovitz’s L-15, 2% FBS, 2.4 
mM CaCl2 and 50 U/mL penicillin, and 50 μg/mL streptomycin), the MDA-MB-231 cell lines in 
DMEM10% (DMEM with Glutamax, 10% FBS and 50 U/mL penicillin, and 50 μg/mL 
streptomycin) and the PC-9 cell lines in RPMI10% (RPMI 1640, 10% FBS, 2 mM Glutamax, and 
50 U/mL penicillin, and 50 μg/mL streptomycin) . 
 
A.1.2 MemorySeq Protocol 
Our experiment roughly followed the design of Luria and Delbrück’s original fluctuation analysis, 
but with RNA sequencing as the terminal readout instead of the number of resistant colonies. 
From the parental cell line (WM989-A6, WM983B-E9, MDA-MB-231-D4), we isolated a single 
cell, let it proliferate until reaching roughly 100-200 cells, then plated these cells into a 96 well 
plate at a dilution in which we expected roughly 0.5 cells per well. From these wells, we isolated 
~100 clones for further expansion, excluding wells that were seeded with more than 1 cell. Of the 
100 starting clones, we aimed for 48 clones from each cell line for downstream analysis. We grew 
the clones until they reached a minimum of around 100,000 cells, with some reaching as high as 
roughly 200,000 cells. At that point, we used miRNAeasy RNA extraction kit to isolate RNA from 
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each clone, followed by library preparation using the NEBNext Poly(A) Magnetic Isolation Module 
and NEBNext Ultra RNA sequencing library prep kit for Illumina. At the time of RNA isolation for 
the clones, we also isolated 48 separate samples of 100,000 cells from the parental line and 
prepared these samples for RNA sequencing as controls. For each cell line, we sequenced a total 
of 96 samples, including 48 clones and 48 controls from a mixture of the parental cell line. We 
sequenced to a depth of at least 500,000 reads per RNA sequencing library (with a typical depth 
of around 4 million reads) on a NextSeq500 (Illumina). While we targeted 48 clones and 48 
controls for each cell line, we had a few samples with poor RNA quality and occasionally lost 
samples when preparing the libraries. Therefore, after culturing, extracting RNA, and preparing 
libraries, we ended up with 39-46 clones total for each cell line for our analysis (43 clones for 
WM989, 46 clones for WM983B, 39 clones for MDA-MB-231, and 42 clones for PC-9). We 
aligned the reads using STAR and enumerated uniquely mapped read counts per gene using 
HTseq 143–146; pipeline available at https://github.com/arjunrajlaboratory/RajLabSeqTools). 
 
For computational analysis of the Luria-Delbruck RNA sequencing data, we calculated the 
transcripts per million of every gene in each sample. We then calculated metrics of the variation 
across the different 48 clonal samples, including the coefficient of variation, skewness, and 
kurtosis. We also compared these metrics in the clonal samples to those observed in the mixed 
controls. We found that the relationship between the coefficient of variation and the transcripts 
per million for every gene could be fit by a Poisson regression model. We fit this model for each 
cell line and then defined the panel of heritable genes as those with residuals greater than the 
98th percentile. We also set a minimum level of expression for heritable genes as 1.5 transcripts 
per million for WM989 and MDA-MB-231 and 1.5 transcripts per million for WM983B. This 
approach yielded 227 heritable genes in WM989, 230 heritable genes in WM983B, 230 heritable 
genes in MDA-MB-231, and 240 heritable genes in PC-9. We generated correlation matrices from 
the pairwise Pearson correlation coefficients for heritable genes across all clones. We calculated 
the Cook’s distance for the pairwise correlations to determine sensitivity to outliers. For a few 
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pairs, the correlation coefficient was deemed sensitive to the presence of outliers. This sensitivity 
is to be expected because of the experimental design; as per Luria and Delbrück’s fluctuation 
analysis, there will be rare outlier cultures. Given that we did not observe such outlier cultures in 
our technical controls, we believe that these outlier cultures reflect true biological variability. 




A.1.3 Generation of NGFR-mNG2 reporter cell line 
To create the NGFR-mNG2(11) WM989-A6-G3 cell line, we used the split mNeonGreen2(mNG2) 
system described in 147. In brief, we first transduced WM989-A6-G3 with 10/11ths of mNG2, 
which is non-fluorescent without the remaining 1/11th of the protein. We then electroporated cells 
with Cas9 RNP containing a guide RNA specific to the C-terminus of NGFR and a single-
stranded DNA template encoding the remaining 1/11th of the protein flanked by sequences 
homologous to the targeted locus (sequences available on Dropbox at 
https://www.dropbox.com/sh/pqjropgxr1u5xd3/AACEgMjetkmINp_l0Df8ujSUa?dl=0). We then 
isolated fluorescent cells by FACS and generated clonal cell lines by serial dilution. To verify in-
frame integration of the mNG2(11) construct, we PCR amplified the C-terminus NGFR locus from 
cell lysates and cloned the amplicon into a recipient plasmid. Half of the resulting plasmids 
contained the in-frame mNG2(11) sequence and the remaining half contained the unedited NGFR 
sequence without substitutions, insertions or deletions. Sanger sequencing traces are located 
here: https://www.dropbox.com/sh/65rvfs3pka5zii4/AAAwBZOynkB4rU9NJvCo_RJha?dl=0. We 
further confirmed that mNG2 fluorescence correlates with NGFR mRNA abundance at the single-
cell level by single-molecule RNA FISH and validated that the NGFR-mNG2(11) WM989-A6-G3 
cell line recapitulates phenomenology described in Shaffer et al. (2017), showing increased 
resistance to vemurafenib in the mNG2-high cells (Fig. 2.5; experiments described in RNA FISH, 
FACS, and drug treatment methods below). We also demonstrated that the localization of the 
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protein was identical to that of the endogenous protein by comparing the NGFR-mNG2  
fluorescence to that of the signal produced by immunofluorescent labeling of NGFR (Fig. 2.5). To 
facilitate cell tracking in the time-lapse images, we transduced cells lines in which we tagged 
NGFR with mNG2(11) with lentivirus encoding H2B-iRFP670 which localizes to the nucleus, thus 
enabling us to track cell nuclei. Following transduction, we derived clonal cell lines by serial 
dilution before imaging. All plasmid sequences are available here: 
https://www.dropbox.com/sh/wpgyfup6gwiyaeb/AAC0gRgg0dmBJoUlypvSDWnIa?dl=0. 
 
To validate that cells with high levels of NGFR-mNG2 (as measured by fluorescence) were more 
resistant to vemurafenib, we trypsinized and pelleted the NGFR-mNG2(11) WM989-A6-G3 cell 
line, washed cells once with PBS containing 2 mM EDTA, then resuspended in PBS containing 2 
mM EDTA and 100 ng/mL propidium iodide or 200 ng/mL 7-AAD and proceeded with sorting. 
Using a MoFlo Astrios (Beckman Coulter) or FACSJazz (BD Biosciences), we isolated the top 
0.5-1% of mNG2 fluorescent cells and equal numbers of the bulk population gated only for live 
cells. We then treated these samples with vemurafenib as described in the drug treatment 
methods below. All flow cytometry data is available on Dropbox here: 
https://www.dropbox.com/sh/9bq1eg0k5o0q452/AACunY5g1xtp5lxSIox1OqOka?dl=0. 
 
A.1.4 Fluorescence-Activated Cell Sorting (FACS) 
We stained WM989-A6-G3 melanoma cells for fluorescence-activated cell sorting using 
antibodies for EGFR and NGFR. We note that while we stained for both proteins, we did not 
isolate enough EGFR-high cells for testing trametinib resistance in all three replicates. First, for 
EGFR staining, we trypsinized 40-50 million cells, washed once with 0.1% BSA-PBS, and 
incubated for 1 hour at 4ºC with 1:200 mouse anti-EGFR antibody in 0.1% BSA-PBS. Next, we 
washed with 0.1% BSA-PBS and then incubated for 30 minutes at 4ºC with 1:500 donkey anti-
mouse IgG labeled with AlexaFluor 488 (Alexa488). We washed the samples again with 0.1% 
BSA-PBS and then incubated for 10 minutes at 4ºC with 1:250 anti-NGFR antibody conjugated 
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directly to PE-Cy7 in 0.5% BSA-PBS with 2 mM EDTA. Finally, we washed the samples with 
0.5% BSA-PBS containing 2 mM EDTA, then resuspended in 1% BSA-PBS containing 100ng/mL 
propidium iodide or 200 ng/mL 7-AAD and proceeded with sorting using a MoFlo Astrios 
(Beckman Coulter) or FACSJazz (BD Biosciences). To aid with gating, we incubated control 
samples without the anti-EGFR primary antibody and with a PE/Cy7 mouse IgG1 isotype control. 
After gating for live cells, we collected either the top 0.02-0.2% EGFR-high cells or the top 0.5% 
NGFR-high cells. We also collected equal numbers of the bulk population by using the same 
gating for live cells, but without gating on either the EGFR or NGFR stains. 
 
To monitor the dynamics of AXL expression, we stained WM989-A6-G3 melanoma cells for 
fluorescence-activated cell sorting by trypsinizing 40-50 million cells, washing once with 1% BSA-
PBS, and incubating for 30 minutes at 4ºC with 1:50 goat anti-AXL antibody in 1% BSA-PBS. 
Next, we washed the cells twice with 1% BSA-PBS and then incubated for 30 minutes at 4ºC with 
1:85 bovine anti-goat IgG labeled with AlexaFluor 647 (Alexa647). Finally, we washed the 
samples with 1% BSA-PBS, then resuspended in 1% BSA-PBS containing 100ng/mL propidium 
iodide or 50ng/mL DAPI and proceeded with sorting. After gating for live cells, we collected the 
top 0.5-1% AXL-high cells and equal numbers of the lowest 80%-95% AXL-low cells, then plated 
cells onto glass-bottom chamber plates. After 1, 3, 6 or 9 days in culture, we fixed the sorted cells 
for RNA FISH as described below. To account for cell growth and changes in cell density, we 
plated fewer cells for later time points. We performed a similar set of experiments for EGFR and 
NGFR using the staining procedure described above. For NGFR, we re-stained the sorted 
population after 7 days in culture (following the same procedure described above) and assessed 
NGFR intensity by flow cytometry using the same instrument as the initial sort.  
 
To monitor the dynamics of CA9 expression in MDA-MB-231 cells, we trypsinized cells, washed 
once with 0.1% BSA-PBS then stained with anti-CA9 antibody conjugated to phycoerythrin (PE) 
at a dilution of 1:11 in 0.1% BSA-PBS for 30 minutes at 4ºC. After staining we washed the cells 
106 
 
twice with 0.1% and resuspended in 0.1% BSA-PBS containing 200ng/mL 7-AAD and proceeded 
with sorting. After gating for live cells, we sorted the top 0.5%-2% CA9-high and the bottom 5-
10% CA9-low cells. For 2 of 3 replicates, we stained the sorted cells with 2.5-5 µM 
CellTraceViolet in PBS at 37ºC for 20 minutes, followed by 2 washes with media. We then culture 
the cells for 5 days before re-staining the cells and measuring CA9-PE and CellTraceViolet 
intensities by flow cytometry.  
 
For testing the response of CA9-high cells to paclitaxel, we stained MDA-MB-231 cells as 
described above then sorted the top 2-3% of CA9-high, the bottom 2-3% CA9-low, and a mixed 
population using only the live cell gates (CA9-mix). After allowing the sorted cells to adhere 
overnight, we began treatment with 1 nM paclitaxel as described below.  We performed single-
molecule RNA FISH for CA9 RNA confirming that sorting with CA9 antibody enriched for CA9-
high expressing cells.  
 
A.1.5 Live-cell immunofluorescence 
We stained and sorted AXL-high and EGFR-high cells as described above, then proceeded with 
live-cell imaging on a Nikon Ti-E inverted microscope enclosed in a temperature-controlled and 
humidified chamber at 5% CO2. We acquired an initial set of images measuring Alexa488 and 
Alexa647 fluorescence to verify that the cells indeed had high protein levels, then proceeded to 
scan the slide (20x magnification) in brightfield every hour for 8 days and 16 hours. We then 
incubated the live cells with 1:80 goat anti-AXL antibody or 1:200 mouse anti-EGFR antibody in 
TU2% for 1 hour at 4ºC followed by two washes with TU2%, secondary incubation with 1:250 
bovine anti-goat Alexa647 or 1:250 donkey anti-mouse Alexa488, and two final washes with 
TU2%. After this re-staining, we imaged these live cells for Alexa488 and Alexa647 fluorescence 
at 20x magnification and quantified fluorescence intensity using rajlabimagetools available: 





A.1.6 Drug treatment experiments 
We made stock solutions of 4 mM trametinib, 4 mM vemurafenib, and 4 mM paclitaxel. For drug 
treatment experiments, we diluted the stock solutions in culture medium to a final concentration of 
10 nM for trametinib, 1 µM for vemurafenib, and 1 nM for paclitaxel. For trametinib treatment 
experiments, we sorted WM989-A6 subclone G3 by NGFR levels as described in A.1.4 and then 
cultured them for 2-3 weeks. For vemurafenib experiments, we cultured the FACS sorted NGFR-
mNG2 WM989-A6-G3 in vemurafenib for 21 days. For paclitaxel experiments, we cultured CA9 
FACS sorted MDA-MB-231 cells in paclitaxel for 5 days. At the end of all drug treatment 
regimens, we fixed each sample in 4% formaldehyde for 10 minutes, permeabilized the sample in 
70% ethanol, and then performed cell quantification. 
 
A.1.7 Time-lapse imaging 
We acquired time-lapse images of the NGFR-mNG2 WM989-A6-G3 cell line using two different 
imaging platforms. First, for data of the WM989 NGFR-mNG2 cell line growing without drug, we 
used a Nikon Ti-E microscope encased in a plexiglass chamber ventilated with heated air and 
CO2. We took images at 60x magnification of mNG2 fluorescence every 6 hours and images of 
the iRFP nuclear reporter (H2B-iRFP670) every hour for 8.75 days. We chose these time 
intervals based on pilot experiments we performed to minimize overt signs of phototoxicity (cell 
death, growth inhibition, nuclear morphology changes) and enable the tracking of cell lineages. 
Second, for data in which we cultured these cells and then treated with vemurafenib, we used an 
IncuCyte S3 Live Cell Imaging Analysis System (Sartorius). We cultured the NGFR-mNG2 cell 
line on a 96-well plate inside the IncuCyte, which is fully contained within an incubator for long-
term culture and time-lapse microscopy. With this system, we acquired images in green, red, and 
brightfield using a 10X objective at intervals of 2 hours over a total of 14.8 days. We added 500 
nM of vemurafenib after 6 days and 4 hours in culture, and then changed the media with 
vemurafenib every 3 days. We used these two different imaging platforms for their distinct 
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advantages. The high magnification Nikon system allowed for the most accurate quantification of 
the mNeonGreen2 signal, allowing us to measure the length of time of the NGFR fluctuations. 
Meanwhile, the IncuCyte is a more stable environment for time-lapse imaging that therefore 
induced less stress on the cells, and thus we used this platform for the longer experiments, 
particularly involving the additional stress of drug treatment. 
 
A.1.8 RNA FISH 
We designed custom oligonucleotide probe sets complementary to our genes of interest using 
custom probe design software written in MATLAB (code freely available for non-commercial use 
here https://flintbox.com/public/project/50547/) and ordered them with an amine group on the 3’ 
end from Biosearch Technologies (probe sequences available in Table S2). We pooled 15-32 
oligonucleotides targeting each gene and coupled each set of probes to either Cy3, AlexaFluor 
594 (Alexa594), Atto647N or Atto700. We performed single-molecule RNA FISH for multiple 
cycles of hybridization as described previously5. We fixed cells in 4% formaldehyde solution for 
10 minutes at room temperature, permeabilized in 70% ethanol, and stored samples at 4C. For 
hybridization, we first washed samples with washing buffer containing 10% formamide and 2X 
SSC. We then applied hybridization buffer containing custom RNA FISH probes and 10% 
formamide, 2X SSC, and 10% dextran sulfate. We hybridized samples overnight at 37ºC and 
then performed two cycles of 30-minute washes at 37ºC with washing buffer. For imaging, we first 
DAPI stained the cells and then transferred them to 2X SSC.  
 
A.1.9 RNA FISH imaging 
We imaged RNA FISH samples on an inverted Nikon TI-E microscope with a 60x Plan-Apo or a 
100x Plan-Apo using filter sets for DAPI, Cy3, Atto647N, Alexa594, and Atto700. We took images 
in either z-stacks of 30 planes at 0.3µm intervals using custom journals built in Metamorph or tiled 
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grids of single-plane images using Metamorph Scan Slide Application. We used a Nikon Perfect 
Focus system to maintain focus across the imaging area. 
 
A.1.10 Cell quantification 
We quantified cell numbers for drug treatment experiments by fixing the cells, staining with DAPI, 
then imaging across the majority of the well via image scanning at 20x magnification. After 
scanning, we computationally stitched the images together, after which we used custom software 
written in MATLAB to identify nuclei, which is publicly available here: 
https://github.com/arjunrajlaboratory/colonycounting_v2.  
 
A.1.11 Time-lapse analysis 
For tracking cell lineages and quantifying fluorescence signal of the NGFR-mNG2 WM989-A6-G3 
cell line, we developed a set of publicly available tools for tracking cells in time-lapse images 
(https://github.com/arjunrajlaboratory/timelapseGUI). First, this pipeline uses an automated 
algorithm for nuclear segmentation to identify all the cells in each image. We then used a 
combination of automatic assignment of parents along with human-supervised annotation to fix 
errors to obtain lineage information. Next, we quantify the fluorescence signal from the NGFR-
mNG2 by using the nuclear segment from each cell and calculating mean and median 
fluorescence intensity across these segments (Fig. 2.7). Of note, for the time-lapses of AXL-high 
and EGFR-high sorted cells that lacked the H2B-iRFP670 nuclear marker, we had to manually 
mark all the cells that we wanted to analyze because the lack of nuclear markers precluded 
automatic segmentation. This same method of analysis was applied to all data acquired on the 
IncuCyte platform. Our subsequent analysis consisted of building a custom data structure in 
MATLAB to contain each lineage and a series of plotting functions to allow us to plot the 
fluorescence intensity from an entire lineage (or part of a lineage) over the length of these 
experiments. For the lineages derived from AXL-high and EGFR-high sorted cells, the final 
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frames were manually registered to images acquired after repeated immunofluorescence staining 
of live cells. The code for all the downstream processing is available on Dropbox at 
https://www.dropbox.com/sh/q2kbatojibljg8j/AABiFvNvsQm288tC3n-4qn5Za?dl=0 and 
https://www.dropbox.com/sh/zrc0g9vtxewcctl/AABVYCaXHYyvWFPOx4ipXLJGa?dl=0. 
Additionally, time-lapse movies referenced in Chapter 2 are available on Dropbox at 
https://www.dropbox.com/sh/98z2p5v0djwwd28/AABEWzFW97R533z5c8HJHSpQa?dl=0 
 
A.1.12 RNA FISH image analysis 
For analysis of gridded image scans, we used custom MATLAB software designed for the 
analysis in5. This pipeline consists of first segmenting the nuclei of individual cells using DAPI 
images. Next, the software calculates regional maxima for all RNA FISH dyes and then the user 
specifies a global threshold for calling individual spots. Through a GUI interface the user then 
reviews the high expressing cells and uses editing tools to remove artifacts or autofluorescent 
debris. Lastly, we constructed tables containing RNA FISH spot counts for each gene in individual 
cells.  
 
For image z-stacks, we used custom MATLAB software to count spots for each cell. Briefly, this 
image analysis pipeline includes manual segmentation of cell boundaries, thresholding of each 
channel in each cell to identify individual spots, and then extraction of spot counts for each gene 
in each cell. The software for analysis of RNA FISH images is available on Github at 
https://github.com/arjunrajlaboratory/rajlabimagetools. After extracting spot counts from either 
data format, we performed the remainder of the analysis of mRNA distributions in R. We 
calculated Gini coefficients (as described in Ref. 95) for each gene using the “ineq” package. The 





A.1.13 Spatial analysis 
We used spatial single-cell analysis to enable us to independently measure the heritability of high 
expression states. We sparsely plated cells (WM989-A6, MDA-MB-231-D4, WM983B) on a 2-well 
chambered coverglass, and then we allowed the cells to grow for 10 days (sometimes fewer days 
for MDA-MB-231-D4 if the cells grew faster), at which point we performed iterative RNA FISH, 
image analysis, and thresholding for high expression as described above. Intuitively, the stronger 
the heritability (i.e., over several generations), the larger the clusters of high-expressing cells we 
would find. To quantify clustering, we created, for each cell in the dataset, a “bucket” consisting of 
the 20 (or 50, 100, 200) closest cells and then kept track of the number of high-expressing cells in 
that bucket. We then computed the variance and the mean of this number across all buckets, 
allowing us to then calculate the heritability index, which is the Fano factor (defined as the 
variance divided by the mean). In the case of complete spatial randomness, the distribution would 
be Poisson, and the heritability index would be 1. To verify this null distribution, we permuted the 
label of cells as jackpots or non-jackpots uniformly at random 1000 times and re-computed the 
heritability index for each permutation. This approach allowed us to compute 95% confidence 
intervals for the null distribution given our particular spatial configuration of cells; the data for null 
distributions is not shown, but is available online here: 
https://www.dropbox.com/sh/m1rdxjrfeo6be3m/AADphkUBGT0zgppppssP_LbSa?dl=0. 
 
A.1.14 ATAC sequencing analysis 
Using previously published ATAC sequencing data from EGFR-high sorted WM989 A6 cells, we 
identified peaks within each of the 227 WM989 MemorySeq genes (including 10 kb upstream and 
10 kb downstream)5. We included peaks present in 2 of 2 biological replicates and merged 
overlapping regions with a point-source peak to peak distance of less than 500 bp. For 
comparison, we used these same data to identify peaks within TPM-matched, control gene sets. 
We generated these control gene sets by taking the expression of each MemorySeq gene 
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(average TPM across MemorySeq clones) and randomly sampling a gene with similar expression 
levels (+/- 20%). We included MemorySeq genes in the sampling set and sampled without 
replacement to obtain gene sets with equal numbers of unique genes. We repeated this sampling 
procedure 100 times to generate 100 TPM-matched, control gene sets.   
We then used the Analysis of Motif Enrichment (AME) tool from the MEME suite to identify 
enriched motifs underlying peaks near MemorySeq genes compared to each of the control gene 
sets148. For AME, we used the average odds score and Fisher’s exact test to measure motif 
enrichment and the HOCOMOCO Human v11 CORE database match enriched motifs to 
transcription factors149. We then summarized and plotted results using R (v3.6). All datasets are 
available at https://www.dropbox.com/work/Papers/cancerpaper_public/data/ATACseq and all 
scripts are available at https://www.dropbox.com/work/Papers/memoryseq/code/ATACanalysis.  
 
A.1.15 RNA sequencing analysis of WM989-A6-G3 knockouts 
We accessed RNA sequencing count data for 266 CRISPR/Cas9 knockouts of WM989-A6-G3 
106. These data included knockouts for 84 genes (2-6 replicates using distinct sgRNAs for each) 
and 10 control samples transduced with non-targeting sgRNAs. For each gene we used DESeq2 
to calculate log2 fold change in expression compared to the non-targeting control samples 150. 
The RNA-seq count data can be found 
https://www.dropbox.com/sh/zold8icu30h6njc/AAC4BJOIz-uWGU0DU5SOcDzYa?dl=0 and 
scripts used for analysis can be found 
https://www.dropbox.com/sh/wtbk6j0umxgovwi/AABbzGg7sIuqh2I_umU4nRpSa?dl=0 and 
https://www.dropbox.com/s/7ly259ou1fm8lsk/plotKOenrichment.R?dl=0. 
A.1.16 Allele-specific expression (ASE) analysis 
To identify variants in MemorySeq data we first aligned the RNA sequencing reads to hg38 
(reference available at 
https://www.dropbox.com/sh/dpxfu9vowd9rgxw/AABUd3d1_Eg3VgWEtCU45CCja?dl=0) using 
STAR (v2.7.1a), then filtered unique alignments, and marked duplicate alignments143. Next, we 
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combined alignments from all MemorySeq clones and used freebayes (v1.3.2) to identify biallelic 
variants with hg38 as the reference151. We repeated this procedure separately for the 48 control 
clones (see A.1.2 above and Fig. 2.1). Using bcftools, we filtered heterozygous variants with a 
minimum quality score of 30 and minimum depth of 5 reads then took the intersection of variants 
identified in both MemorySeq clones and control clones to remove mutations present in a small 
subset of clones152. All scripts for this analysis are available at 
https://github.com/arjunrajlaboratory/memSeqASEanalysis and the final list of variants is available 
on Dropbox at 
https://www.dropbox.com/sh/yinthy6f2u7pwwu/AACqf_4WSFow6njp8xzzTRYca?dl=0 (under {cell 
line}/freebayes/{cell line}.singleRG.freebayes.intersect.Q30.DP5.het/0002.vcf.gz).  With these 
lists of variants, we used phASER to count uniquely mapped, allele specific reads for each 
individual clone153. We then summarized and plotted these data using custom R scripts available 
at https://www.dropbox.com/sh/l607yt9vu4dlr3n/AAAofMByQ4KYTdQWm6zlxj_Va?dl=0. 
 
A.1.17 ChIP sequencing analysis.  
We downloaded H3K27 acetylation (H3K27Ac) and tri-methylation (H3K27me3) ChIP-sequencing 
coverage data and matched RNA sequencing data from 11 melanoma cell lines from 154. With the 
RNA-sequencing data, we generated TPM-matched control gene sets by randomly sampling 
genes whose expression matched each MemorySeq gene (+/- 20%). MemorySeq genes were 
included in the sampling set and we sampled without replacement to obtain gene sets with equal 
numbers of unique genes. For both WM989 and WM983b MemorySeq genes we separately 
generated 100 control gene sets using each of the 11 melanoma samples. For each of the ChIP 
sequencing datasets, we then used deepTools to calculate the ChIP sequencing coverage 
flanking the transcription start site (+/- 2,000 bp in 10 bp bins) for MemorySeq genes and TPM-




For MDA-MB231 cells, we downloaded H3K4 trimethylation (H3K4me3), H3K9 acetylation 
(H3K9Ac), H3K79 dimethylation (H3K79me2), H3K27Ac and H3K27me3 ChIP sequencing 
coverage data and matched RNA sequencing data from 156,157. As described for the MemorySeq 
analysis, we aligned the RNA sequencing data to hg19 using STAR and counted alignments 
using HTSeq. We generated TPM-matched control gene sets and calculated ChIP-sequencing 
coverage flanking the transcription start sites of MemorySeq and control gene sets as described 
above. We then summarized and plotted these data using R. All datasets are available at 
https://www.dropbox.com/sh/mjw5n5zeau9lpwb/AAD6uCZ4fFU8c36izOJ35B9aa?dl=0 and 




We used the RefSeq hg19 annotations for determining transcription start sites rather than the 
Ensembl annotations used for RNA sequencing as we observed better aligned coverage profiles 
across genes using RefSeq annotations. However, ~7% of MemorySeq genes (11/227 for 
WM989, 16/230 for WM983b and 15/230 for MDA-MB231) were not uniquely identified in the 
RefSeq annotation and were excluded from this analysis, including the initial sampling procedure. 
We observed lower levels of activating chromatin marks and slightly elevated levels of repressive 
marks near MemorySeq genes using either RefSeq or Ensembl transcription start site 
annotations. Both reference files are available at 
https://www.dropbox.com/sh/sf93jf48p7u1q0e/AABt6Od4AeOMABFb6pl9f881a?dl=0. 
A.1.18 Network community identification 
For each pair of significantly heritable genes (from gene lists described in the MemorySeq RNA 
sequencing analysis in A.1.2), we calculated the Pearson correlation coefficient between their 
expression across clones. This procedure resulted in a symmetric weighted matrix of size 227 
genes x 227 genes in WM989 (and 230 genes x 230 genes in WM983B, as well as MDA-MB-
231-D4). We represent these matrices as undirected weighted networks with nodes 
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corresponding to genes, and with the weight of edges between nodes corresponding to the value 
of the correlation coefficient. Within this network, we sought tightly connected groups of nodes 
within this network known as network communities. We performed k-clique community detection 
100–102 with k=4 on binarized networks created by thresholding the original weighted network at 
decreasing values 158,159. More specifically, a k-clique is a collection of k nodes that are all-to-all 
connected, and a k-clique community is a collection of k-cliques that are connected through 
adjacent k-cliques (two k-cliques are adjacent if they share k-1 nodes). Repeatedly thresholding 
the network at decreasing values of the edge weight creates a sequence of binary graphs, each 
of which is included in the next. Since the addition of edges to a binary graph can only enlarge or 
merge k-clique communities, we can track communities from one binary network to the next in a 
well-defined manner. This mapping allows us to both observe which nodes were included in the 
community at slightly lower threshold values and to qualitatively assign statistical significance to 
communities based on the range of threshold values for which they stay isolated from the rest of 
the network. 
 
A.1.19 Inferring timescale of expression heritability from MemorySeq 
We modelled gene expression as a binary switch, where individual cells were either in a high 
(ON) or low (OFF) expression state. We assumed that cells proliferated exponentially at a rate 𝑘! 
(i.e. a generation time of 1/𝑘!), and that each MemorySeq clone began as a single cell, ultimately 
growing into the final population. We made two simplifying assumptions: i) The proliferation rate 
of a cell was the same irrespective of its ON/OFF state; and ii) The population remained in the 
exponential growth phase during the timespan of the experiment. Further, cells in the OFF state 
turned ON with rate 𝑘"#, and reverted back to the OFF state with rate 𝑘"$$. We defined 𝑓 =
𝑘"#/(𝑘"# + 𝑘"$$) as the fraction of ON cells in the original population, and further assumed (as 
indicated by our experimental data) that the ON state was rare, i.e., 𝑓 ≪ 1.  
To model Luria and Delbrück’s fluctuation analysis, we sampled a single cell from the original 
population, which was ON with probability 𝑓, and OFF with probability 1 − 𝑓. Starting with this 
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initial condition, we defined the random variables 𝒙(𝒕)and 𝒚(𝒕) to be the number of cells in the ON 
and OFF states, respectively, at time 𝑡. The time evolution of integer-valued random processes 
𝒙(𝒕)and 𝒚(𝒕)is governed by proliferation (with probabilities 𝑘!𝑥𝑑𝑡 and 𝑘!𝑦𝑑𝑡) and switching 
between the ON and OFF states (with probabilities 𝑘"$$𝑥𝑑𝑡  and 𝑘"#𝑦𝑑𝑡). The ratio 𝒙(𝑡)/(𝒙(𝒕)  + 
𝒚(𝒕)) represented the fraction of ON cells at time t, and our goal was to quantify fluctuations in 
this ratio across MemorySeq clones. To do this, we derived the time evolution of the first two 
statistical moments of 𝒙(𝒕)and 𝒚(𝒕) 94. Assuming 𝑓≪ 1, the coefficient of variation squared (𝐶𝑉%) 





, where 𝑇 =
𝑡𝑘! is the duration of the experiment (normalized to the generation time), and 𝑇"# = 𝑘!/𝑘"$$ is the 
time spent in the ON state (normalized to the generation time). This equation quantifies the noise 
measured in MemorySeq, and as expected, 𝐶𝑉% is a monotonically increasing function of𝑇"#; i.e., 
slower switching results in higher variation across MemorySeq clones. It turns out that the 
product 𝐶𝑉% × 𝑓 is independent of 𝑓, and it is convenient to look at this product as a function of 
𝑇"#. Given a priori knowledge of 𝑓 and a measurement of the noise level 𝐶𝑉%, 𝑇"# can be 
estimated via an inverse transformation of equation (1). In our experiments, 𝑓 was typically 
around 1% or less, as measured using RNA FISH, and each MemorySeq clone started as a 
single cell and grew to around 105 cells, for which the number of doublings T = 17. Using these 
values, we estimated 𝑇"# of 5-10 cell divisions for several MemorySeq genes based on the 
observed CV values across MemorySeq clones. Further discussion of this model can be found at 
https://www.dropbox.com/s/n34mz3ctk1w5xu8/SupplementalNote1.pdf?dl=0.    
A.1.20 Statistical Analysis 
For each experiment, the sample sizes, number of replicates, and randomization procedure 
(when relevant) are indicated in the main text and figure legends. Statistical tests for calculating 




A.1.21 Data and Code Availability 
Sequencing data generated as part of this study are available on GEO under the accession 
number GSE151375. In addition, the data and code used for this study are available on Dropbox 









A.2 Material and Methods for Chapter 3 (Rewind) 
 
A.2.1 Rewind Barcode Library Construction  
Starting with the LRG2.1T plasmid kindly provided by Dr. Junwei Shi, we derived a lentivirus 
vector backbone for Rewind by removing the U6 promoter and sgRNA scaffold then inserting a 
spacer sequence flanked by EcoRV restriction sites after the stop codon of GFP. For the barcode 
insert, we ordered PAGE purified ultramer oligonucleotides (IDT) containing “WSN” repeated for 
100 nucleotides (W=A or T, S = G or C, N = Any) flanked by 30 nucleotides homologous to the 
vector insertion site for Gibson Assembly (see 
https://www.dropbox.com/s/9ec5hk3tzbmea6x/RewindSupplementaryTables_v2.xlsx?dl=0 for 
barcode insert sequence). We then digested the vector backbone overnight with EcoRV (NEB), 
gel purified the linearized vector. We combined 100ng of linearized vector, 1.08 μL barcode oligo 
insert (100 nM in nuclease-free water), 10 μL Gibson assembly master mix (NEB E2611) and 
nuclease free water to a final volume of 20 μL then incubated the reaction at 50ºC for 1 hour. We 
next column purified the assembled plasmid using Monarch  DNA cleanup columns (NEB) 
according to the manufacturer’s protocol then electroporated 2 μL of the column purified plasmid 
into Endura Electrocompetent E. coli cells (Lucigen) using a GenePulserXCell (Biorad) with the 
following settings: 25msec pulse length, 10 μF capacitance, 600Ω resistance, and 1800V voltage. 
We performed 6 electroporations using the same plasmid in parallel. Immediately after 
electroporation, we added 1mL of pre-warmed (37ºC) recovery media to each electroporation 
cuvette then transferred the liquid to 1.5mL Eppendorf tubes and placed these tubes on a shaker 
at 225rpm and 37ºC for 1 hour. After this recovery, we took 10 μL of the culture for plating serial 
dilutions and transferred the rest to 150-200mL of 1X LB Broth containing 100 μg/mL ampicillin. 
We incubated these cultures on a shaker at 225rpm and 32ºC for 12-14 hours then pelleted the 
cultures by centrifugation and isolated plasmid using the EndoFree plasmid maxiprep kit (Qiagen) 
according to the manufacturer’s protocol. In some instances, pellets were frozen at -20ºC for 
several days before plasmid isolation. To estimate transformation efficiency, we counted colonies 
on the plated serial dilutions and verified barcode insertion by PCR from 20-30 colonies per plate. 
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We pooled the plasmids from the 6 separate cultures in equal amounts by weight before 
packaging into lentivirus. This protocol is also available online at  
https://www.protocols.io/view/barcode-plasmid-library-cloning-4hggt3w       
 
A.2.2 Cell lines and culture  
We derived the WM989 A6-G3 melanoma cell line by twice single-cell bottlenecking the WM989 
melanoma cell line kindly provided by Dr. Meenhard Herlyn142. Similarly, we derived WM983b E9-
C6 by twice single-cell bottlenecking the WM983b melanoma cell line also provided by Dr. 
Meenhard Herlyn. We verified the identity of these cell lines by DNA STR Microsatellite 
fingerprinting at the Wistar Institute. 
 
We cultured both melanoma cell lines in TU2% media consisting of 80% MCDB 153, 10% 
Leibovitz’s L-15, 2% FBS, 2.4 mM CaCl2, 50 U/mL penicillin, and 50 μg/mL streptomycin and 
passaged cells using 0.05% trypsin-EDTA. For harvesting drug-treated resistant cells we used 
0.1% Trypsin-EDTA. For lentivirus packaging, we cultured HEK293FT cells in DMEM containing 
10% FBS 50 U/mL penicillin and 50 μg/mL streptomycin and passaged cells using  0.05% 
Trypsin-EDTA. 
 
A.2.3 Lentivirus packaging and transduction 
Prior to plasmid transfection, HEK293FT cells were grown to ~90% confluency in 6-well plates in 
DMEM containing 10% FBS without antibiotics. For each 6-well plate, we added 80 μL PEI to 0.5 
mL Opti-MEM (ThermoFisher 31985062) and separately, combined 7.5 μg pPAX2, with 5 μg 
VSVG and 7.71 μg of the barcode plasmid library in 0.5 mL Opti-MEM then incubated the 
solutions at room temperature for 5 minutes. We then mixed the 2 solutions together with 
vortexing and incubated the combined solution at room temperature for 15 minutes. We added 
184 μL of the plasmid-PEI solution dropwise to each well of the 6-well plate. After 6-8 hours, we 
aspirated the media from the cells, washed the cells once with 1X DPBS, then added fresh 
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culture media (DMEM containing 10% FBS and antibiotics). The following morning, after 
confirming that the majority of cells were GFP positive, we aspirated the media, washed the cells 
once with 1X DPBS then added 1 mL of TU2% to each well. Approximately 12 hours later, we 
transferred the virus laden media to a falcon tube and added another 1 mL of TU2% to each well. 
We collected virus laden media twice more over the next ~16 hours and during this time, stored 
the collected media at 4ºC. After the final collection, we filtered the virus laden media through a 
0.22 μm PES filter then stored 1-2 mL aliquots at -80ºC.   
 
To transduce WM989 A6-G3 and WM983b E9-C6 cells we added freshly thawed (on ice) virus 
laden media and polybrene (final concentration 4 μg/mL) to dissociated cells, then plated the cells 
onto 6-well plates (100,000 cells in 2mL per well) and centrifuged the plate at 1,750 rpm (517 x g) 
for 25 minutes. We incubated the cells with virus for 6-8 hours then removed the media, washed 
the cells once with 1X DPBS and added 3mL of TU2% to each well. The following day, we 
passaged the cells to 10cm dishes (1 x 6-well plate into 3 x 10 cm dishes). For WM989 A6-G3, 
we split barcoded cells into Carbon Copy and separate vemurafenib treatment groups 11 days 
after transduction for sort experiments or 10 days after transduction for in situ experiments unless 
otherwise specified. For WM983b E9-C6, we split barcoded cells into Carbon Copy and separate 
vemurafenib treatment groups 7 days after transduction for sort experiments unless otherwise 
specified. We cultured in situ Carbon Copies for 4 days before fixation in order to more easily 
identify clusters of cells expressing targeted barcodes.  
 
A.2.4 Simulations of experimental conditions used for Rewind 
As described above, we expanded barcoded cells for at least 4 population doublings before 
splitting-off the Carbon Copy and drug-treatment groups for Rewind. As such, there were on 
average ~16 closely-related cells for each barcoded clone before the split. For a 50:50 split, the 
probability that at least 1 of 16 cells ends up in both groups is ~99.997%, or in other words, less 
than 0.002 % of clones are expected to be “missing” from either group. However, given the 
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unavoidable variability in cell growth, it is likely that some clones will have divided fewer than 4 
times, and these clones are more likely to be entirely missing from the Carbon Copy. (We note 
that we do not care about clones that are missing from the drug treatment group since they will 
not become resistant colonies and their barcodes will not be selected for probe design). To 
empirically estimate the proportion of clones present in our Carbon Copy, we sequenced barcode 
gDNA from barcoded WM989 A6-G3 after ~4 population doublings, then computationally “split” 
the sequenced barcodes into 2 halves, after first weighting each barcode by its read count and 
scaling the average read count to 16. Finally, we calculated the proportion of barcodes present in 
both halves. Simulating this procedure 10,000 times, we found that ~92.3-92.6% of barcodes 
were present in both halves and <4% of barcodes were “missing” from the simulated Carbon 
Copy.  
 
We also note that to eliminate spurious barcodes arising due to PCR or sequencing errors, we 
merged highly similar barcode sequences as described further below (see A.2.9 Computational 
analyses of barcode sequencing data) and filtered barcodes with fewer than 5 unique reads. 
The simulations were robust to a range of read count thresholds ≥ 2.  
 
We used the same barcode sequencing data to simulate the “heritability-split-experiment” for Fig. 
3.3. In this case, we randomly sampled 200 barcodes twice (without replacement and weighting 
each barcode by its read count), then calculated the proportion of barcodes shared between the 
two samples. We performed the same simulation for WM983b E9-C6 using sequencing data from 
barcoded WM983b E9-C6 grown for ~4 population doublings. 
 
A.2.5 Fluorescence-Activated Cell Sorting (FACS)  
To isolate ITGA3-High WM989 A6-G3, we first trypsinized and pelleted 8 confluent 10cm plates, 
washed once with 1 x DPBS containing 0.1% BSA (0.1% BSA-PBS), and then split the cells into 
two equal pellets. We resuspended each pellet in 0.4 mL 0.1% BSA-PBS containing 1:200 anti-
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ITGA3 antibody (DSHB clone P1B5 stock concentration 354 μg/mL) then incubated on ice for 1 
hour. After primary incubation, we pelleted the cells, washed twice with ~5 mL 0.1% BSA-PBS 
then resuspended cells in 0.16 mL 0.1% BSA-PBS containing 1:500 anti-mouse FAb2 secondary 
antibody conjugated to AlexaFluor488 (Cell Signaling #4408) and incubated on ice for 30 
minutes. Finally, we pelleted the cells, washed twice with 0.1% BSA-PBS, then resuspended the 
pellet in 0.1% BSA-PBS  containing 100 ng/mL DAPI and proceeded with FACS on a MoFlo 
Astrios (Beckman Coulter). After gating for singlets and live cells, we collected 15,000 events 
from the brightest 0.3-0.4% ITGA3-High gate and equal numbers from the dimmest ~99% ITGA3-
Low gate. We plated two thirds of the sorted cells onto 2-well glass bottom chamber plate (Nunc 
Lab-Tek 155380) for treating with vemurafenib (see below) and the rest on a separate 2-well 
glass bottom chamber plate for verifying ITGA3 expression by RNA FISH.  
 
We followed a similar procedure for isolating AXL-High WM983b E9-C6 starting with 10 10cm 
dishes split into two equal cell pellets, performing all incubations and washes with 1%BSA-PBS 
and staining with 1:50 primary antibody (goat anti-human AXL AF154 from Novus Biologicals) 
and 1:60 secondary antibody (bovine anti-goat conjugated to AlexaFluor647; Jackson 
ImmunoResearch 805-605-180). After gating for singlets and live cells, we collected 20,000 
events from the brightest ~0.3% AXL-High gate and equal numbers from the dimmest ~20% AXL-
Low gate, then plated cells onto 2-well glass bottom plates (10,000 per well) for vemurafenib 
treatment or RNA FISH as above. 
 
A.2.6 Drug treatment experiments 
We prepared stock solutions of 4 mM vemurafenib (PLX4032, SelleckChem S1267), 10 mM 
pinometostat (SelleckChem S7062), 100 μM trametinib (SelleckChem S2673), and 10 mM 
Dabrafenib (SelleckChem S2807). We prepared all stock solutions in DMSO and divided into 
small aliquots stored at -20ºC to minimize freeze-thaw cycles. For drug treatment experiments, 
we diluted the stock solutions in culture medium to a final concentration of 1 µM for vemurafenib, 
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4 µM for pinometostat, 10 nM for trametinib, and 1 µM for dabrafenib unless otherwise specified.  
For Rewind experiments in WM989 A6-G3, we treated cells for 3 weeks replacing media 
containing drug every 3-4 days. Following vemurafenib treatment, we trypsinized and collected all 
remaining cells, washed cells once with 1X DPBS, then pelleted and froze 90% of the cells at -
20ºC until gDNA extraction and barcode sequencing as described below. We fixed the remaining 
10% of vemurafenib resistant cells for barcode RNA FISH, FACS and RNA sequencing as 
described below and in Fig. 3.6. For DOT1L inhibitor pre-treatment, we treated cells with 4 µM 
pinometostat for 6 days, replacing media on day 3 and again when splitting off the Carbon Copy 
on day 5. Following the ITGA3 sort, we fixed WM989 A6-G3 cells after 18 days of vemurafenib 
treatment in order to more easily quantify numbers of colonies. For Rewind experiments in 
WM983b E9-C6, we treated cells for 4 weeks replacing media containing 1 µM of vemurafenib 
every 3-4 days. Cells surviving drug treatment were harvested and frozen as described above.  
 
A.2.7 Cell quantification  
Following drug treatment experiments, we fixed cells by incubation for 10 minutes in 3.7% 
formaldehyde (Sigma F1635) diluted in 1X PBS, followed by two washes with 1X PBS then 
overnight permeabilization at 4ºC with 70% ethanol. We stained nuclei by incubation in 2X SSC 
containing 50 ng/mL DAPI then imaged the majority of each well via a tiling scan at 20X 
magnification. To quantify cell and colony numbers, we used custom MATLAB software to stitch 
the tiled images, identify nuclei and manually circle individual resistant colonies. Software and 






A.2.8 Barcode library preparation and sequencing 
We isolated genomic DNA (gDNA) from barcoded cells using the QIAmp DNA Mini Kit (Qiagen 
51304) according to the manufacturer’s protocol. We performed targeted amplification of the 
integrated barcode vector using custom primers containing Illumina adapter sequences, unique 
sample indexes, variable length staggered bases, and 6 random nucleotides (“UMI”; NHNNNN) 
which, despite not uniquely tagging barcode DNA molecules, appeared to modestly increase 
reproducibility between replicate libraries and normalize read counts (see 
https://www.dropbox.com/s/9ec5hk3tzbmea6x/RewindSupplementaryTables_v2.xlsx?dl=0 for a 
complete list of primers). For each sample, we performed multiple PCR reactions (using 20-40% 
of the total isolated gDNA) each consisting of 1 μg of gDNA,  500 nM primers, 25 μL NEBNext Q5 
HotStart HiFi PCR master mix and nuclease free water to a final volume of 50 μL. We ran the 
reactions on a thermal cycler with the following settings: 98ºC for 30 seconds, followed by N 
cycles of 98ºC  for 10 seconds then 65ºC for 40 seconds, and finally 65ºC for 5 minutes. After the 
PCR, we purified libraries using 35 μL (0.7X) Ampure XP magnetic beads with two 80% ethanol 
washes followed by final elution in 20 μL 0.1X TE (1 mM Tris HCl pH 8.0 100 μM EDTA). Purified 
libraries from the same sample were pooled, quantified using the Qubit dsDNA High Sensitivity 
assay (ThermoFisher) then sequenced on a NextSeq 500 using 150 cycles for read 1 and 8 
cycles for each index. For barcoding experiments not requiring RNA FISH probe design, shorter 
reads (75 cycles) provided sufficient information to identify unique barcodes.   
 
To reduce PCR amplification bias, we determined the number of cycles (“N”) for each sample by 
first performing a separate qPCR reaction and selecting the number of cycles needed to achieve 
⅓ of the maximum fluorescence intensity. We included 0.25 μL 100X  SYBR Green I (10,000X 
diluted 1:100 in 10 mM Tris pH 8.0; Invitrogen S7563) per 25 μL qPCR reaction and, when 
possible, performed multiple reactions with serial dilutions of gDNA (1:4 and 1:16). For 
experiments with multiple similar samples (same MOI, same treatment) we performed qPCR on 




To test reproducibility of our barcode quantification, for a subset of samples we prepared 
duplicate libraries with separate indexes and compared barcode read counts between these 
technical replicates. As shown in Fig. 3.3, we found a high correlation (>95%) in barcode 
abundance between these technical replicates. 
 
A.2.9 Computational analyses of barcode sequencing data 
We recovered barcodes from sequencing data using custom Python scripts available at: 
https://github.com/arjunrajlaboratory/timemachine. These scripts search through each read to 
identify sequences complementary to our library preparation primers, and if these sequences 
pass a minimum length and Phred score cutoff, then the intervening barcode sequence is 
counted. In addition to counting total reads for each barcode, we also count the number of “UMIs” 
incorporated into the library preparation primers (see above). While we do not believe that these 
“UMIs” tag unique barcode DNA molecules, empirically they appeared to slightly improve the 
correlation in barcode abundance between replicate libraries and were therefore used for most 
subsequent analyses. Using the STARCODE software (available at 
https://github.com/gui11aume/starcode), we merged highly similar barcode sequences 
(Levenshtein distance ≤ 8), summing the counts and keeping only the more abundant barcode 
sequence.    
 
For selecting barcodes corresponding to resistant colonies, we ranked the barcode sequences by 
counts then converted the most abundant 100-200 barcodes sequences into fasta files for probe 
design as described below. Barcode sequences with ≥30 bases of homology to the vector 
backbone were excluded for concerns of generating non-specific FISH probes (we checked for 




We selected barcodes corresponding to resistant colonies that require DOT1L inhibition using the 
following criteria: 1. Among the most abundant 200 barcodes in DOT1L inhibitor pre-treated 
resistant cells, 2. not among the most abundant 500 barcodes in the DMSO pre-treated resistant 
cells and 3. greatest difference in abundance between DOT1L inhibitor pre-treated and DMSO 
pre-treated resistant cells among all barcodes passing criteria 1 and 2. For barcodes 
corresponding to resistant colonies not requiring DOT1L inhibition, we selected sequences that 
were: 1. in the top 200 barcodes in both the DOT1L inhibitor and DMSO pre-treated resistant 
cells and 2. which had relatively similar abundances across these two conditions (not among the 
500 barcodes with the largest difference in abundance).  
 
A.2.10 Barcode FISH probe design 
Using fasta files of selected barcodes, we design HCR probes using Rajlab ProbeDesignHD 
software(code freely available for non-commercial use here 
https://flintbox.com/public/project/50547/). For each barcode sequence, we designed 2 non-
overlapping 42mer probes with a target Gibbs free energy for binding of -55 (allowable Gibbs 
Free Energy [-65, -45]) . We excluded probes with complementarity to repetitive elements, 
pseudogenes or the vector backbone used to generate the barcode plasmid library. We then split 
each 42mer probe into 2 20mer sequences (removing the middle two nucleotides) and appended 
split-initiator HCR sequences using custom python scripts (sequences available on Dropbox at 
https://www.dropbox.com/s/9ec5hk3tzbmea6x/RewindSupplementaryTables_v2.xlsx?dl=0) 160. 
For each 20mer sequence, we measured the maximum complementarity to the vector backbone 
and other barcodes present in the sample in order to manually exclude probes with potential for 
non-specific hybridization. We ordered the final probe sequences synthesized from IDT in 
picomole scale 384 well plates. Finally, we resuspended barcode HCR probes to 50 μM in 
nuclease-free water then combined these probes into pools each containing 24 different barcode 




For ClampFISH we designed 30mer probes targeting select barcodes using Rajlab 
ProbeDesignHD software with a target Gibbs free energy of -40 (allowable Gibbs Free Energy [-
50, -30]). As above, we excluded probes with complementarity to repetitive elements, 
pseudogenes or the vector backbone. We then appended 10mer sequences to the 5’ and 3’ ends 
of each probe (used for subsequent ligation) and ordered the final probe sequences synthesized 
from IDT in picomole scale 384 well plates. We resuspended barcode ClampFISH probes to 100 
μM in nuclease-free water then combined these probes into pools each containing 30 different 
barcode probes. To these pools we ligated oligonucleotides (oligos) containing alkyne and azide 
modifications at their 5’ and 3’ ends, respectively (see 
https://www.dropbox.com/s/9ec5hk3tzbmea6x/RewindSupplementaryTables_v2.xlsx?dl=0 for 
oligo sequences). For this ligation, we first phosphorylated the 5’ ends of each probe set by 
combining 4 μL of the pooled oligos with 1 μL T4 PNK (NEB), 20 μL T7 DNA ligase reaction 
buffer (NEB), and 2 μL nuclease-free water then incubating at 37ºC overnight. Next, we added 
the alkyne and azide modified oligos along with complementary bridging 20mer oligos (3 μL each 
of 400 μM stocks) and heated the reactions to 95ºC for 5 minutes then cooled to 12º C at a rate 
of -0.1º C/second. After cooling, we added 1 μL T7 ligase (NEB) and incubated overnight at room 
temperature. We purified the ligated barcode ClampFISH probes using Monarch DNA cleanup 
columns (NEB) according to the manufacturer’s protocol. This protocol for generating barcode 
ClampFISH probes is also available online at https://www.protocols.io/view/invertedclampfish-
ligation-qxwdxpe. We prepared amplifier probes MM2B, MM2C, P9B and P9C as described 
previously 161.  
 
A.2.11 RNA FISH  
We designed oligonucleotide probe sets complementary to our genes of interest using custom 
probe design software written in MATLAB and ordered them with a primary amine group on the 3’ 




each gene, we pooled their complementary oligos and coupled the probe set to either Cy3 (GE 
Healthcare), AlexaFluor 594 (Life Technologies), or Atto647N (Atto-Tec)NHS ester dyes. We 
performed single-molecule RNA FISH as described in 162 and 5 for multiple cycles of hybridization. 
We aspirated media from adherent cells, washed the cells once with 1X PBS, then incubated the 
cells in fixation buffer (3.7% formaldehyde 1X PBS) for 10 minutes at room temperature. We next 
aspirated the fixation buffer, washed samples twice with 1X PBS, then added 70% ethanol and 
stored samples at 4º C. For hybridization, we first washed samples with washing buffer (10% 
formamide in 2X SSC) then applied the RNA FISH probes in hybridization buffer (10% formamide 
and 10% dextran sulfate in 2X SSC). We covered samples with coverslips then hybridized 
samples overnight in humidified containers at 37ºC. The following morning, we washed samples 
2 x 30 minutes with washing buffer at 37ºC, adding 50 ng/mL DAPI to the second wash to stain 
the nuclei. After these washes, we rinsed samples once with 2X SSC then added new 2X SSC 
and proceeded with imaging. To strip RNA FISH probes, we incubated samples in stripping buffer 
(60% formamide in 2X SSC) for 20 minutes on a hot plate at 37ºC, washed samples 3 x 15 
minutes with 1X PBS on a hot plate at 37ºC, then returned samples to 2X SSC. After stripping 
RNA FISH probes, we re-imaged all previous positions and excluded dyes with residual signal 
from subsequent hybridization.   
 
A.2.12 Barcode RNA ClampFISH  
For in situ Barcode FISH using ClampFISH, we adapted the protocol from Rouhanifard et al. 
2019 as follows161. We generated modified primary probes and amplifier probes as described 
above. For hybridization, we first washed fixed samples with washing buffer containing 40% 
formamide in 2X SSC then applied the primary ClampFISH probes in primary hybridization buffer 
containing 40% formamide, 10% dextran sulfate, 1 mg/mL yeast tRNA (Invitrogen 15401029) , 
0.02% BSA, and 100 μg/mL sonicated salmon sperm DNA (Agilent 201190-81) in 2X SSC. We 
included up to 180 ClampFISH probes targeting up to 60 different barcode RNA sequences per 
hybridization (total probe concentration 125 ng/μL - 250 ng/μL). We added coverslips to samples 
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then hybridized for 6-8 hours in humidified containers at 37ºC. After hybridization, we added wash 
buffer containing 40% formamide in 2X SSC to dislodge coverslips then replaced the wash buffer 
and incubated the samples for 20 minutes at 37ºC. We performed a second wash for 20 minutes 
at 37ºC using buffer containing 20% formamide and 2X SSC then performed the second round of 
hybridization with MM2B and MM2C amplifier probes in amplifier hybridization buffer (20% 
formamide, 10% dextran sulfate, 1 mg/mL yeast tRNA , 0.02% BSA, and in 2X SSC.; final probe 
concentration 10 ng/μL each). After the second hybridization we washed samples 2 x 20 minutes 
at 37ºC using buffer containing 20% formamide and 2X SSC then rinsed the sample with 2X 
SSC. We then performed the copper(I)-catalyzed azide-alkyne cycloaddition (“click” reaction) by 
adding a solution containing 150 μM BTTAA, 75 μM copper sulfate, 2.5 mM L-ascorbic acid and 
0.1% Triton-X 100 in 2X SSC to each sample and incubating at 37ºC for 15-20 minutes. To 
prepare this solution, we first combined the BTTAA and copper sulfate, add the 2X SSC 
containing 0.1% Triton-X, and lastly add freshly dissolved L-ascorbic acid (19-20mg of L-ascorbic 
acid sodium salt dissolved in 1mL nuclease-free water). Once the L-ascorbic acid is added, we 
immediately added the solution to our samples. Following the click reaction, we rinsed samples 
once with 2X SSC then washed 1 x 20 minutes at 37ºC with buffer containing 40% formamide in 
2X SSC. After this wash, we performed the third round of hybridization with P9B and P9C 
amplifier probes in amplifier hybridization buffer, followed by washes, click and post-click wash as 
described above. We continued with additional amplifier hybridizations (iterating between using 
MM2B+MM2C amplifier probes on even rounds and P9B+P9C amplifier probes on odd rounds) 
and washes, performing the click reaction during every odd round (3, 5, 7…).   
 
After the post-click wash for round 7 or round 9, we added RNA FISH hybridization buffer (10% 
formamide and 10% dextran sulfate in 2X SSC) containing probes targeting P9B and P9C and 
coupled to AlexaFluor594 and Atto647n, respectively (see 
https://www.dropbox.com/s/9ec5hk3tzbmea6x/RewindSupplementaryTables_v2.xlsx?dl=0 for 
sequences). We hybridized these probes overnight in humidified containers at 37ºC then washed 
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samples 2 x 30 minutes with washing buffer (10% formamide, 2X SSC) at 37ºC, adding DAPI to 
the second wash to stain the nuclei. After these washes, we rinsed samples once with 2X SSC 
then replaced the 2X SSC and proceeded with imaging. To remove ClampFISH signal, we 
stripped dye-coupled probes as described above for RNA FISH. 
 
A.2.13 Barcode RNA HCR:  
For in situ Barcode FISH using the Hybridization Chain Reaction (HCR) we adapted the protocol 
from Choi et al. as follows 160. We used 1.2 pmol each of up to 240 barcode FISH probes per 0.3 
mL hybridization buffer. Our primary hybridization buffer consisted of 30% formamide, 10% 
dextran sulfate, 9 mM citric acid pH 6.0, 50 μg/mL heparin, 1X Denhardt’s solution (Life 
Technologies 750018) and 0.1% tween-20 in 5X SSC. For primary hybridization, we used 100 μL 
hybridization buffer per well of a 6-well plate, covered the well with a glass coverslip, then 
incubated the samples in humidified containers at 37ºC for 6 hours. Following the primary probe 
hybridization, we washed samples 4 x 5 minutes at 37ºC with washing buffer containing 30% 
formamide, 9 mM citric acid pH 6.0, 50 μg/mL heparin, and 0.1% tween-20 in 5X SSC. We then 
washed the samples at room temperature 2 x 5 minutes with 5X SSCT (5X SSC + 0.1% Tween-
20), then incubated the samples at room temperature for 30 minutes in amplification buffer 
containing 10% dextran sulfate and 0.1% Tween-20 in 5X SSC. During this incubation, we snap-
cooled individual HCR hairpins (Molecular Instruments) conjugated to either AlexaFluor647, 
AlexaFluor594 or AlexaFluor546 by heating to 95ºC for 90 second then immediately transferring 
to room temperature to cool for 30 minutes concealed from light. After these 30 minutes, we 
resuspended and pooled the hairpin in amplification buffer to a final concentration of 6 nM each. 
We added the hairpin solution to samples along with a coverslip, then incubated samples at room 
temperature overnight (12-16 hours) concealed from light. The following morning, we washed 
samples 5 x 5 minutes with 5X SSCT containing 50ng/mL DAPI, added SlowFade antifade 
solution (Life Technologies S36940) and a coverslip then proceeded with imaging. To remove 
fluorescent signal for subsequent rounds of RNA FISH or immunofluorescence, we 
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photobleached samples on the microscope or stripped HCR hairpins as described above for RNA 
FISH probes.  
 
For performing HCR in suspension, we adapted the published protocol as follows. We fixed 
dissociated cells in suspension by washing the cells with 1X DPBS, resuspending the cell in ice 
cold 1X DPBS, adding equal volume of ice-cold fixation buffer (3.7% formaldehyde 1X PBS) then 
incubating with rotation at room temperature for 10 minutes. We next pelleted fixed cells by 
centrifugation at 800 x g for 3 minutes, washed twice with ice cold 1X PBS, then resuspended in 
70% ethanol and stored fixed cells at 4ºC. For primary probe hybridization we used 0.5 mL 
hybridization buffer containing 4 nM of each barcode RNA FISH probe and incubated samples 
using the same conditions as described above. After primary probe hybridization, we washed 
samples 4 x 10 minutes with 0.5 mL washing buffer then 2 x 10 minutes with 0.5 mL 5X SSCT.  
We next incubated samples for 30 minutes in amplification buffer and snap-cooled HCR hairpins 
as described above. For amplification, we used 15 nM final concentration of each HCR hairpin 
and incubated samples at room temperature overnight concealed from light. After amplification, 
we washed samples 6 times with 5X SSCT the proceeded with FACS. In between hybridizations 
and washes, we pelleted cells by centrifugation at 400 x g for 5 minutes and used low-molecular 
weight dextran sulfate (Sigma D4911) in hybridization and amplification buffers to improve 
pelleting.   
 
We note that the final hairpin concentrations used in these experiments is 4- to 10-fold lower than 
the manufacturer’s protocol, which we optimized to reduce nonspecific amplification while still 
enabling sensitive barcode RNA detection at 20x magnification. At the same time, we have 
noticed lot to lot variation in HCR hairpins purchased from Molecular Instruments with each lot 
requiring some testing and optimization for use with Rewind. Finally, we found that hybridization 
and wash buffers without citric acid, heparin, Denhardt’s solution or tween-20 (that is using only 
SSC, formamide and dextran sulfate) appeared to work as well as the manufacturer’s 
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recommended buffers for Barcode RNA HCR and we used these minimal buffers for barcode 
detection prior to immunofluorescence. 
 
A.2.14 Immunofluorescence  
We performed immunofluorescence using primary antibodies targeting total ERK (L34F12 Cell 
Signaling 4696) and phosphorylated ERK (p44/p42 ERK D12.14.4E Cell Signaling 4370). First, 
we rinsed cells 3 times with 5% BSA in PBS (5% BSA-PBS) then incubated at room temperature 
for 2 hours in 5% BSA-PBS containing 1:100 total ERK and 1:200 pERK antibodies. Next, we 
washed the cells 5 x 5 minutes with 5% BSA-PBS then incubated the cells at room temperature 
for 1 hour in 5% BSA-PBS containing 1:500 donkey anti-mouse secondary antibody conjugated 
to Cy3 (Jackson 715-165-150) and 1:500 goat anti-rabbit secondary antibody conjugated to 
AlexaFluor594 (Cell Signaling 8889). After the secondary incubation, we washed the cells 5 x 5 
minutes with 5% BSA-PBS containing 50 ng/mL DAPI, then replaced the wash buffer with 2X 
SSC and proceeded with imaging as described below.  
 
A.2.15 RNA FISH and Immunofluorescence imaging 
We imaged RNA FISH samples on an inverted Nikon TI-E microscope with a 20x Plan-Apo λ 
(Nikon MRD00205), 40x Plan-Fluor (MRH00401) or 60x Plan-Apo λ (MRD01605) objective using 
filter sets for DAPI, Cy3, Alexa594, and Atto647N. For barcode ClampFISH and barcode HCR, 
we first acquired tiled images in a single Z-plane (scan) at 20x or 40x magnification, then after 
identifying positions containing cells positive for resistant barcodes, we returned to those 
positions to acquire a Z-stack at 60x magnification. For subsequent rounds of single-molecule 
RNA FISH and ERK immunofluorescence we acquired Z-stacks at 60x magnification. For scans, 
we used a Nikon Perfect Focus system to maintain focus across the imaging area. 
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A.2.16 Image analysis  
To identify Barcode RNA FISH-positive and GFP-positive cells in Fig. 3.2., we used custom 
MATLAB scripts to first stitch together scanned images, then identify individual cells using the 
DAPI nuclear signal. Next, we used a custom graphical user interface (GUI) to zoom in on the 
stitched image, view the barcode RNA FISH (Alexa647) signal, and interactively select barcode 
RNA FISH positive cells. After selecting all barcode RNA FISH-positive cells, we repeated the 
same process with GFP signal to select all GFP-positive cells without knowledge of the cells’ 
barcode RNA FISH status. We then extracted the spatial coordinates, barcode RNA FISH status, 
and GFP status for all cells, and plotted the results using custom R scripts available on Dropbox 
(https://www.dropbox.com/s/jjxinl8vdx82n9o/inSituBarcodeFISHAccuracy.R?dl=0). MATLAB 
scripts for stitching and the custom GUI are available 
at  https://github.com/arjunrajlaboratory/timemachineimageanalysis. 
 
To identify Barcode FISH positive cells for Rewind, we used custom MATLAB scripts to stitch, 
contrast and compress scan images (scripts available at 
https://github.com/arjunrajlaboratory/timemachineimageanalysis) then manually reviewed these 
stitched images. This review yielded positions containing candidate Barcode FISH positive cells 
which we then re-imaged for verification at 60x magnification in multiple Z-planes. If we were 
uncertain about the fluorescence signal in a candidate cell (e.g. abnormal localization pattern, 
non-specific signal in multiple channels), we excluded the cell from imaging during subsequent 
rounds of RNA FISH or immunofluorescence.   
 
For quantification of RNA FISH images we used custom MATLAB software available at: 
https://github.com/arjunrajlaboratory/rajlabimagetools.  Briefly, the image analysis pipeline 
includes manual segmentation of cell boundaries, thresholding of each fluorescence channel in 
each cell to identify individual RNA FISH spots, and then extraction of spot counts for all channels 
and cells. After extracting spot counts, we analyzed RNA levels across single cells using custom 
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R scripts available at: 
https://www.dropbox.com/sh/eeu0o9f7bcghm7x/AAAropGHDhSZ7_TYxJsIV8DDa?dl=0/. In all 
figures, boxplots indicate the 25th, 50th and 75th percentiles with whiskers extending to 1.5 times 
the interquartile range. Notably, for some markers, we were not able to quantify expression in a 
few cells because of grossly abnormal or non-specific fluorescence signal (i.e. schmutz) or 
because we lost a cell during sequential hybridizations. We excluded data from these cells from 
analyses and as a result, some plots may contain slightly different numbers of points for different 
markers. For analyses involving dimensionality reduction (UMAP) or clustering, we only included 
cells with data for all assayed markers. 
 
For the UMAP visualizations we used the Seurat v3.2.0 package (the versions of all dependent 
packages are documented in the plotting scripts on Dropbox and at 
https://www.dropbox.com/s/vvrcdx5at2csd3z/RsessionInfo.txt?dl=0)163,164. For the analysis shown 
in Fig. 3.14, we ran the UMAP algorithm on scaled RNA FISH data using the first 5 principal 
components and setting n_neighbors = 30 and min_dist = 0.3 (default settings). For the analyses 
shown in Figs. 3.19 and 3.22, we used the first 6 principal components and set min_dist = 0.6 to 
better visualize the number of cells expressing high levels of DEPTOR.  
 
We adapted the RajLabImagetools pipeline for quantifying immunofluorescence images. After 
manually segmenting cells, we used custom MATLAB scripts to average fluorescence intensity 
within cell boundaries for each channel then took the maximum average fluorescence intensity 
across Z-planes. We additionally used DAPI signal to automate nuclei segmentation and 
separately quantified cytoplasmic and nuclear immunofluorescence intensity. We found similar 
results for both cytoplasmic and nuclear ERK immunofluorescence quantification.  
 
For quantification of cell and colony numbers following vemurafenib treatment, we used custom 
MATLAB software available at: https://github.com/arjunrajlaboratory/colonycounting_v2. The 
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analysis pipeline involves stitching the tiled DAPI images, manually segmenting individual wells 
and colonies, identifying individual cells based on DAPI signal, and then extraction of cell counts 
from the entire well and each colony.  We analyzed the extracted cell counts using custom R 
scripts available at: 
https://www.dropbox.com/sh/eeu0o9f7bcghm7x/AAAropGHDhSZ7_TYxJsIV8DDa?dl=0. We 
used a separate MATLAB script 
(https://www.dropbox.com/s/5tff7t0x86d80s1/countCellsTimeMachineScans.m?dl=0) to quantify 
the number of cells imaged in our Carbon Copies.  
 
To assign individual primed cells (marked by barcode RNA FISH signal) to subclones (Fig. 3.15), 
we first extracted the spatial position of each image in the whole-well scans containing at least 1 
primed cell. We then calculated the Euclidean distance between these images and used these 
distances to perform hierarchical clustering. Visual inspection of the clustering revealed a clear 
distance threshold of < 2mm for grouping subclones of closely related (and therefore neighboring) 
primed cells; thus, all primed cells within these groups were assigned to belong to the same 
subclone. To further check our subclone assignments, we manually inspected all barcode RNA 
FISH images and found that primed cells assigned to the same subclone had similar barcode 
RNA FISH signal intensity and intracellular patterns, while this signal similarity was not observed 
for primed cells assigned to different subclones. Most primed cells from different subclones were 
at least 7 mm apart, and for the few cases of primed cells located between 2 mm - 7 mm apart, 
we observed that these cells had distinct barcode RNA FISH signal patterns consistent with them 
belonging to separate subclones. This clear spatial separation gave us confidence in our ability to 
accurately assign individual cells to particular subclones. 
 
A.2.17 RNA sequencing and analyses 
We extracted RNA from fixed cells after barcode RNA FISH and sorting using the NucleoSpin 
total RNA FFPE XS kit (Takara). We performed cell lysis and reverse cross-linking at 50ºC for 90 
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minutes and otherwise followed the manufacturer’s protocol. After RNA extraction, we prepared 
sequencing libraries using the NEBNext single-cell/low-input RNA sequencing library preparation 
kit for Illumina (NEB) then performed paired-end sequencing of these libraries (38 cycles read 1 + 
37 cycles read 2) on a NextSeq 500 (Illumina). After sequencing, we aligned reads to the human 
genome (assembly 19; hg19) using STAR v2.5.2a and counted uniquely mapped reads with 
HTSeq v0.6.1.  
 
We performed differential expression analysis in R v3.6.0 using DESeq2 v1.22.2150 and with data 
from at least 2 biological replicates for each sample and condition. Biological replicates were 
sorted on separate days using distinct barcode RNA FISH probe sets. We considered a gene to 
be differentially expressed if the comparison between 2 conditions yielded a log2 fold change of 
≥1 or ≤ -1 and adjusted p-value of ≤0.1. For determining candidate markers for primed cells 
requiring DOT1L inhibition (Fig. 3.18) we compared primed and non-primed subpopulations 
sorted from both DOT1L inhibitor and vehicle control Carbon Copies and modelled the biological 
replicate and DOT1L inhibitor treatment as covariates in the design formula for DESeq2. We 
chose to include data from both DMSO- and DOT1L-inhibitor-treated Carbon Copies (2 replicates 
each) in the analysis and model DOT1L inhibitor treatment as a covariate due to the modest 
effects of DOT1L inhibitor treatment alone on gene expression (Fig. 3.18) and our particular 
interest in identifying gene expression markers that distinguish various subpopulations of primed 
cells. We performed hierarchical clustering and principal component analysis on log2 transformed 
tpm values using R v3.6.0. 
 
We tested for enrichment of differentially expressed genes among gene ontologies and pathways 
(KEGG, REACTOME, WikiPathway) using WebGestaltR. If a differentially expressed gene was 
included in one or more enriched GO term or pathway, we chose a consensus annotation (e.g. 
ECM organization and cell migration) for that gene. Otherwise, we assigned a gene annotation by 
137 
 
manual review. Our resulting gene annotation can be found at 
https://www.dropbox.com/s/9ec5hk3tzbmea6x/RewindSupplementaryTables_v2.xlsx?dl=0.  
 
A.2.18 Software and data availability 
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